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Abstract 
Coronary angioplasty is a commonly used therapy to remove stenoses in patients with 
chronic stable angina.  Although a successful procedure, there remain both the short-term 
(stent thrombosis and vessel injury) and long-term risks (late stent thrombosis and 
significant in-stent restenosis) such that indiscriminate use of stenting can be deleterious.  
A considerable body of evidence suggests clinical outcomes are improved when stenting is 
performed using invasive coronary physiology; if stenoses cause ischaemia 
revascularisation is preferential to deferment, while non-ischaemic stenoses may be treated 
with medical therapy and observation.  Successfully treated vessels are less likely to have 
major cardiovascular events and patient events are improved. 
However, there remains no good way of readily and practically predicting whether placing a 
stent will be successful with normalisation of abnormal coronary physiology.  Furthermore, 
there remains no good parameter to delineate the length of a stenoses and the amount of 
stenting required to achieve an optimal haemodynamic result.  The behaviour of coronary 
physiology after coronary intervention remains poorly described, particularly in the resting 
state.  Furthermore, human coronary disease is often complex with many coronary 
stenoses present.  This confounds our physiological assessment of a given stenosis and 
contributes to the poor utilisation of physiological technologies in the patients. 
In this thesis, I apply phasic assessment throughout the cardiac cycle to describe the 
behaviour of coronary physiology in humans who undergo assessment and intervention in 
the catheter laboratory.  The behaviour of coronary pressure, flow velocity and resistance 
will be assessed.  I will assess how these parameters change after coronary intervention to 
develop models of predicting the change in coronary flow and pressure.  I will then apply 
these models to a novel approach that allows assessment of physiological stenosis length, 
the identification of haemodynamic impact imposed by a single stenosis in diffusely 
diseased and tandem stenoses.  The aim is to produce a new clinical tool that can be 
readily used in the clinical assessment of challenging coronary disease.    
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1.1.1 Overview 
In this introduction, I will consider the management of coronary disease and the potential 
for coronary physiology to alter how this disease is managed.  I will place particular 
emphasis upon understanding the different physiological parameters in use in clinical 
practice, in particular how they relate to one another.  Specifically, I will discuss and 
critically evaluate hyperaemic measures such as FFR, HSR and CFR, as well as discussing 
the recent development of resting indices such as iFR and BSR.  This will then lead to an 
overview of how complex coronary disease involving tandem and diffuse disease is 
physiologically assessed and the challenges present.    
 
1.1.2 The Principles Of Coronary Revascularisation 
Coronary artery disease is a major contributor to global mortality and morbidity.1  Coronary 
stenoses create ischaemia that may be silent or manifest as chronic stable angina.  
Atherosclerotic plaque rupture may trigger thrombosis and the onset of acute coronary 
syndromes but this represents an apparently distinct pathological process from that 
present in stable disease.   
 
Coronary intervention in the form of percutaneous coronary intervention (PCI, also referred 
to as angioplasty) has proven benefits in the context of acute coronary syndromes.2,3  
However, the data has been less clear-cut in stable angina.  International guidelines have 
recognised that in the stable setting, the likelihood of reducing death or myocardial 
infarction are low.4,5  
 
Whilst pharmacological medical therapy has demonstrated excellent clinical outcomes 
within randomised controlled studies,6 it is common to perform invasive coronary 
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angiography to quantify the presence of epicardial coronary disease.  The principle driver to 
do so remains the potential to offer revascularisation with the belief that resolution of 
ischaemia will resolve symptoms and improve prognosis.7 
 
A common form of revascularisation has been coronary artery bypass surgery (CABG) - in 
which external venous or arterial conduits are attached to the aorta and to the coronary 
vessel distal to the site of obstruction.  Conceptually the entire distal vascular bed is 
supplied, achieving a good relief of ischaemia.  However, the longevity of grafted conduits 
is highly variable and the alteration of coronary haemodynamics by the presence of the 
graft is known to accelerate the atherosclerotic process in the native vessels.    
 
Percutaneous coronary intervention (PCI), also referred to as angioplasty or ‘stenting’ takes 
an alternative approach of balloon dilatation of the stenosis followed by placement of a 
metallic stent to counter acute recoil of the lesion.  The concept is that the lumen of the 
vessel is restored to that present within a reference segment of the vessel that should 
enable normal coronary flow.  A well-apposed stent should not impede coronary flow but 
residual disease within the vessel will continue to limit flow if not treated.  Stents create a 
new disease process in which in-stent atherosclerosis is very challenging to treat and 
uncovered stent struts act as a nidus for stent thrombosis at a later date with potentially 
fatal consequences.   
 
The relative simplicity of PCI compared to open-chest CABG has meant it has become the 
dominant form of revascularisation.  Refinement of techniques has meant even complex 
tandem stenoses and diffuse disease can be treated, as well bifurcations and vessel ostia.   
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The relative merits of the CABG and PCI, and the need for revascularisation versus medical 
therapy alone have long been debated.8  A recent network meta-analysis suggests CABG 
and modern generation drug-eluting stents improve outcomes compared to medical 
therapy.  The SYNTAX study suggested lower rates of death, myocardial infarction, stroke 
and repeat revascularisation with CABG9 in patients with complex and heavy burdens of 
disease.  In patients with unprotected left main stem disease, PCI was equivalent to CABG 
at both 1 year and 5 years in the relatively underpowered PRECOMBAT study.10,11 The 
same group demonstrated that PCI with modern “3rd generation” everolimus eluting stents 
was non-inferior to CABG at 2 years and 4 years in terms of death, myocardial infarction or 
stroke; however, there were higher rates of repeat revascularisation of non-target lesions in 
the PCI arm meaning that at four years, the main outcome was in favour of CABG.12  In 
contrast, the FREEDOM study found higher rates of myocardial infarction and death of any 
cause in patients with diabetes mellitus randomised to PCI compared to those having 
CABG.  
 
Furthermore, despite the relative merits of either revascularisation technique, patient 
preference plays a considerable factor in revascularisation decision making and not all 
patients weigh each component of the major adverse cardiovascular events in the same 
way.13 It therefore befalls on the Cardiology community to identify the factors that drive 
improvements in PCI to ensure good outcomes that also meet patients’ preferences. 
 
One factor remains that there are marked differences in the nature of the coronary disease 
being treated in patients selected for PCI or CABG.  Patients labelled with “three-vessel 
disease” could have straight forward stenoses than can be readily treated with PCI.  
Alternatively, even apparently single stenoses may exist within the confines of considerable 
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diffuse disease that limits coronary flow and relief of the stenosis would not resolve the 
ischaemia, while a CABG would.   
 
Methods of identifying such disease has been focused upon invasive coronary angiography 
but it is well established that coronary angiography has marked limitations in the 
assessment of stenoses since they are three-dimensional structures being assessed in a 
two-dimensional manner.   
 
Intravascular imaging by tools such as ultrasound (IVUS) or optical coherence tomography 
(OCT) provide considerably greater insight into the nature of coronary atheroma and 
structure of a given stenosis or diffuse disease.  However, neither IVUS nor OCT has clinical 
outcome data to suggest that they add sufficient additional value to the decision-making 
provided by angiography.  In contrast, invasive coronary physiology has a wealth of clinical 
data that suggests if PCI is performed in response to physiological parameters that suggest 
ischaemia, then outcomes are improved.  It stands to reason if PCI or CABG was 
performed only in vessels with the greatest ischaemia and therefore greatest need for 
revascularisation, then the greatest incremental clinical benefit can be accrued (Figure 1.1). 
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1.2 The Principles of Physiological Assessment of Coronary 
Disease 
 
1.2.1 The potential value of physiological assessment 
To better understand the contribution of coronary physiology, I have performed an overview 
of the literature and historical data. 
Physiological interrogation of coronary vessels and stenoses provides not only 
determination of flow limitation but stratification of risk and the potential value from 
revascularisation. Conceptually, physiological assessment should improve outcomes by 
focusing revascularisation where the gain is greatest. 
 
1.2.2 The impact of a stenosis upon coronary flow 
Animal-based research has established a basic understanding of the impact of a coronary 
stenosis.  
Every coronary stenosis imposes a degree of resistance to flow in the epicardial vessel.  
Coronary auto-regulation, working through a variety of paracrine and neural factors, 
responds by microcirculatory vasodilatation.  This maintains normal resting coronary flow 
up to a stenosis diameter of 85%, at the expense of distal coronary pressure.14  Resting 
flow is remarkably preserved despite worsening stenosis severity – up to 85% diameter 
stenosis by formal measurement.  Hyperemic flow starts falling when stenoses are 30% but 
falls significantly once stenoses are 50% (Figure 1.2 Adapted from Gould et al).14  Distal 
pressure falls due as a result in kinetic energy loss due to viscous friction, turbulence and 
flow separation across the stenosis (Figure 1.3) producing a resting trans-stenotic pressure 
gradient which increases with increasing stenosis severity (Figure 1.4)  The degree of 
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gradient at rest is therefore a marker of the physiological impact of the stenosis upon the 
microcirculation.   
Pressure wire technology began initial assessments predominantly at rest without 
hyperaemia.15,16 However, the catheters were bulky with low fidelity cycle averaged traces 
which made it challenging to assess all stenoses under rest.  This was particularly a 
problem as the catheters often occluded flow, while in less severe lesions, the damped 
pressure trace made it difficult detect pressure loss.   
As an alternative, vasodilatation and hyperaemia was sought, with the aim to increase flow 
and therefore increase the measurable gradient across a given stenosis to more easily 
distinguish mild, moderate and severe stenoses.15 
Typically, adenosine, ATP, papaverine or balloon occlusion can be used to induce varying 
degrees of hyperemia.17  This reduces microcirculatory resistance and increases coronary 
flow but does so in a non-uniform manner.  Trivial and mild stenoses demonstrate the 
greatest increase in flow in response to hyperemic stimulus.  With stenoses over 30% a 
reduction in hyperemic flow is observed which a more marked reduction evident at 
stenoses over 50% (Figure 1.2) 
Since stenoses cause natural microcirculatory vasodilatation, the vasodilator reserve, which 
is the capacity to respond to a hyperemic stimulus by increasing flow, falls with increasing 
stenosis severity.  It follows that severe stenoses that genuinely limit flow will have an 
impaired response to hyperemia and with increasing severity, there is less additional gain in 
the gradient observed above that evident at rest.  
The degree of pressure loss or gradient observed with these stenoses will be dependent 
upon the geometry of the stenosis; if turbulence is minimal, flow may escalate significantly 
with little pressure loss.  If turbulence predominates, pressure loss is exacerbated even if 
flow is increasing significantly and there is no true ‘flow limitation’.  In long lesions, a great 
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deal of resistance may cause considerable pressure loss alongside a failure to increase flow 
in response to hyperemia.  
For each stenosis, coronary flow and pressure have a curvilinear relationship in which curve 
steepness is directly related to stenosis severity (Figure 1.5) The greater stenosis severity, 
the greater the imposition on trans-stenotic flow and the larger the detectible pressure 
gradient.  In such stenoses, trivial increases in flow over the resting state are expected with 
a considerable resting pressure gradient.  In milder stenoses, resting gradients may be 
small but can become larger if the trans-stenotic flow can be increased considerably.  It 
follows that such stenoses are non-flow limiting despite the detectible pressure-gradient.  
The capacity to increase flow is a marker of microcirculatory function in the absence of 
epicardial disease, or a combined marker of epicardial and microcirculatory resistance 
when a stenosis is present.  If flow can be made to increase significantly across a stenosis, 
then it is likely that microcirculatory function must be intact even if not entirely normal.  
Microcirculatory vasodilatation will be related to size of the tissue bed and the demand 
placed.  If vasodilatation cannot compensate for the stenosis, distal flow diminishes and 
ischaemia under resting conditions would result.   
 
1.2.3 Disconnect between physiology and anatomical definition of disease 
A further important aspect to appreciate is that when considering the ‘severity’ of a 
stenosis, in reality in clinical practice we are intuitively discussing a gestalt of anatomical, 
physiological and clinical parameters.   
However, since anatomical assessment of vessels has been the mainstay of coronary 
disease assessment, then there have been natural efforts to relate physiological severity to 
anatomical findings.   
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All attempts demonstrate only a modest relationship with a relative disconnect between 
anatomical assessment of coronary anatomy and physiological findings.18–22 
This is likely because physiological parameters combine many different aspects of the 
coronary circulation.  For example, if the distal perfusing bed is large or is partially 
infarcted, it will be integrated into the physiological parameter.   
Differences between how the physiological parameters and anatomical findings can cause 
great interest as an academic exercise but in the clinical domain, where decisions are 
reliant upon the numbers computed, discordance can lead to considerable frustration or 
surprise.  For example, in studies in which FFR was systematically measured in all three 
coronary arteries, the discordance between FFR and angiography reached 35-40% of 
cases.18,23,24  Discordance can also exist between physiological parameters which can then 
become challenging to unpick unless an expert.25  In subsequent sections, I will discuss the 
different physiological parameters and why they may differ. 
 
1.2.4 What is the connection between ischaemia and outcomes 
The principle purpose of the physiological parameters is to detect ischaemia.  Ischaemia 
itself is felt to be linked to mortality based upon very large datasets from non-invasive 
testing such as SPECT.26  In this 10,627 patient study, patients with little or no ischaemia 
on SPECT had superior outcomes with medical therapy, while those with greater than 10-
15% ischaemia had better outcomes with revascularisation.  The absolute survival benefit 
was strongly associated with the degree of ischaemia and the speed for revascularisation.   
How ischaemia drives clinical events remains unclear.  Repeated ischaemic events may 
contribute to worsening left ventricular function with subsequent malignant arrhythmias.  
However, the likelihood of response to revascularisation was shown to be independent on 
left ventricular ejection fraction when there was sufficient ischaemia.27  
 34 
Alternatively, ischaemia on non-invasive testing may only reflect elevated resistance within 
epicardial arteries, such that the flow cannot elevate adequately during stress.28  The 
reduction in coronary pressure in response to elevated resistance to maintain resting flow 
may trigger altered coronary turbulence and shear stresses which could trigger plaque 
destabilisation and rupture.28  Although an attractive hypothesis, there is little evidence that 
clinical events are a result of this mechanism.  However, data from FAME-II and the large 
meta-analysis is compelling that hard clinical events only occur when pressure gradients 
are very high (and FFR values are very low, <0.60).29  
 
1.2.5 The change in coronary physiology after PCI 
Coronary intervention does not always restore coronary flow reserve (CFR) or FFR to 
normality.  This could be due to a number of reasons. 
Multiple moderate stenoses which cause pressure loss or a degree of flow limitation may 
be present.  Alternatively, more diffuse atheroma that can be underestimated 
angiographically can prevent normalisation. 
The coronary stent may be inadequately deployed and create turbulence with pressure 
loss.  Physiological parameters have been used to assess the adequacy of the coronary 
intervention; residual gradients suggest the need for further optimisation of the stent in the 
absence of other disease that could explain residual gradients. 
In some situations, coronary flow can rise considerably, for example four-fold higher than 
previously possible; in the presence of minor flow perturbation caused by the stent 
architecture or residual minor obstruction, then significant turbulence can be created.  This 
translates into a significant pressure loss under hyperaemic conditions, though in the 
presence of a high escalation of flow (that is, a false positive pressure gradient in the 
presence of flow that can rise significantly and therefore is ostensibly not flow limiting). 
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Physiological assessment of a stenosis is confounded by the presence of more proximal 
and distal disease.  Removing a given stenosis may reveal the importance of residual 
stenoses that was underestimated prior to the PCI.  A distal stenosis will always lead to 
underestimation of the proximal stenosis, while a distal stenosis will go underestimated in 
the presence of a significant proximal stenosis.  Even optimal PCI to a stenosis may simply 
increase hyperaemic flow in the vessel to reveal the physiological importance of the 
remaining stenoses.30  
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1.3 Fundamentals of practical physiological assessment 
 
Key components of physiological assessment are common to a variety of invasive 
techniques and it is worth considering these fundamental practical issues. 
 
1.3.1 Guiding catheters 
Physiological assessment requires the use of adequately sized guiding catheters to engage 
the vessel of interest.  Six French catheters are suitable although there are reports that 
readings can be made using five French guiding catheters.  Caution is required to ensure 
there is no damping of the pressure signal after engagement, since this will compromise all 
measurements. Catheters with side-holes should be avoided; although the side-hole can 
improve the appearance of the pressure trace, there remains a relative ostial obstruction 
such that the pressure trace on the screen does not represent the true proximal pressure.  
In the event of pressure damping or the presence of important ostial disease, it is 
appropriate to perform measurements with the guiding catheter disengaged.  This, 
however, obviates the possibility of using intracoronary vasodilators. 
In general, experts and local practice suggests that guiding catheters are used in 
preference over diagnostic catheters.  One practical reason is the for management of wire-
related complications.  Although infrequent, wire-relate complications such as wire-related 
coronary dissection or vessel occlusion can occur at the rate of 0.5-1.0%.24  These events 
would be more rapidly treated if a guiding catheter were utilised rather than a diagnostic 
catheter.  
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1.3.2 Anticoagulation 
Essential to all invasive coronary physiological assessment is the use of heparin to prevent 
thrombosis upon the wire; typically 70-100IU/kg is administered before any wires are 
placed.  Wire-related thrombosis may occur with under-dosing.   Although it is common 
practice to administer dual anti-platelet therapy because patients may undergo 
percutaneous revascularisation in the same procedure, there is no absolute need for anti-
platelets if adequate anticoagulation is given. 
 
1.3.3 Intracoronary nitrates 
A further essential step is to provide adequate intracoronary nitrates (200-300mcg).  
Nitrates are not used to create a long-lasting hyperemic effect but rather to stabilise the 
epicardial vessel. Adequate dosing of nitrates removes wire-related and guide-related 
vessel spasm and to ensure epicardial resistance is minimised without significant impact on 
the microvascular resistance.  This enables accurate physiological assessment; readings 
without nitrate should be repeated as even a small degree of distal wire spasm will raise 
distal coronary pressure while more proximal spasm will make distal assessment appear 
worse.  
 
1.3.4 Hyperaemia 
Hyperaemia is believed to occur in two stages. Agents primarily achieve maximal 
hyperemia through their vasodilator action on microvascular smooth muscle cells (an 
endothelium-independent response). The resultant increase in blood flow is thought to 
stimulate shear stress-induced endothelial nitric oxide release, which promotes further 
vasodilatation of the microcirculation (flow-mediated dilatation) and increase in blood flow 
(an endothelium-dependent response).  Therefore the response to hyperemic agents will 
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integrate a change in coronary blood flow and microvascular function but alone cannot 
distinguish between both components.   
 
Non-specific agents such as adenosine and papaverine are commonly used to induce 
maximal hyperemia for assessment of indices such as CFR, FFR and IMR.31  The dose of 
adenosine is accepted as 140mcg/kg/min when given as a central venous infusion (e.g. 
femoral vein);  ATP can be given as an alternative at the same dose17,32  
The hyperaemic effect is typically observed after 30-40 seconds and infusions should 
continue for 1-2 minutes to observe for stable hyperaemia.  Side-effects include relative 
hypotension, a central chest discomfort or burning, dyspnoea and bronchospasm.33  It 
should be avoided in patients with severe brittle asthma. Short-lived atrio-ventricular 
conduction delay is frequent and FFR values during such pauses should be discounted.  
It is common to seek peripheral veins to avoid additional femoral venous punctures; there is 
data to support this approach but hyperemia may become more variable with a longer time 
course.34,35 
 
For intracoronary dosing, clinical practice remains variable.36  Early validation work was all 
performed using considerably lower doses than found in clinical practice today.  Accepted 
intracoronary doses of adenosine or ATP are 80-120mcg in the left coronary system and 
40mcg in right coronary artery; these typically produce hyperemia lasting 5 to 10 
seconds.37,38 
 
With all intra-coronary hyperaemic agents, caution is required in ensuring pressure ports 
are closed to ensure appropriate pressure traces can be recorded and there is additional 
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skill in being able to administer the drug at sufficient speed, flush through the catheter and 
re-connect to pressure within an adequate time-frame for an adequate FFR reading. 
 
Papaverine is an alternative intracoronary agent that achieves a longer lasting hyperaemia 
between 30-60 seconds which may permit pullback assessments at the cost of transient 
QT prolongation and rare trigger ventricular tachycardia or torsades de pointes.38   It is 
typically used where adenosine is not available (15-20mg in the left coronary artery; 10-
12mg in the right coronary artery).38  
 
Newer alternatives include Regadenoson, a selective A2A receptor agonist that has been 
approved for use in myocardial perfusion imaging.  Given as a single bolus into a peripheral 
vein using a weight-unadjusted dose (400mcg over 10 seconds), Regadenoson achieves a 
peak flow velocity after a minute and declines thereafter.39  Favourable findings have been 
reported when compared to adenosine-mediated FFR measurements.40  However, the 
duration of hyperemia is very variable between patients making pullback and multi-vessel 
assessment unreliable and inconsistent.  Side effects include adenosine-like effects with 
hypotension, chest discomfort and flushing.  Third-degree heart block has also occurred 
suggesting that some of purported safety aspects of this drug remain undetermined.  Both 
adenosine and regadenoson have FDA ‘Black Box’ warnings that use may be associated 
with heart attack and death.  
 
Alternatives to achieve increase flow include the use of contrast – which in some settings 
can have a similar effect to that of other intracoronary hyperemic agents.17  Small studies 
have suggested favourable findings compared to adenosine-mediated FFR.41  Larger 
studies have been performed, but have not yet been formally reported (CONTRAST Study, 
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NCT02184117).  In the latter study, a variety of different contrast agents, doses, volumes 
and rates of injection were used.  It is unclear if they are all give the same results as the 
overall amalgamated results. 
 
Caution is required when using contrast as the hyperemic effect is variable between 
injections, very short-lived and can contribute to considerable contrast burden.  
Furthermore, it remains unclear what the threshold for treatment should be; small studies 
have limited power to determine cut-offs while larger ones are not helpful if different types 
and volumes of contrast are used.  Since the hyperemia is sub-maximal, changing volumes 
can lead to different pressure ratios and uncertainty.   
 
 
1.4 Fractional Flow Reserve (FFR) 
 
1.4.1 Calculation of FFR 
Fractional flow reserve (FFR) is a reference standard for coronary physiology in the catheter 
laboratory.  It is used routinely and widely in clinical practice and is supported by a large 
volume of research data.  FFR, as a concept, is defined as the maximum myocardial blood 
flow in the presence of an epicardial stenosis divided by the theoretical maximum flow in 
the absence of a stenosis (maximum flow when the vessel is normal) in given artery.42  
The central tenet of FFR is that the flow limitation imposed by a stenosis can be estimated 
by measuring only coronary pressure.43  Since pressure and flow are not linearly related 
across all pressure ranges, a direct relationship can only be inferred if coronary 
microcirculatory resistance is constant (and minimal) as is theoretically the case during 
maximal arteriolar vasodilatation.43  Hyperaemic agents such as adenosine, papaverine, 
 41 
ATP or regadenoson are used to reduce resistance and increase coronary flow, thereby 
magnifying a trans-stenotic pressure gradient that is often present at rest.43  Presented as a 
ratio of the distal and proximal coronary pressures (Pd/Pa) during hyperemia, FFR is 
defined as the maximal blood flow in a stenotic territory divided by the maximal blood flow 
expected in the same artery in absence of that stenosis.42,43  This was determined using 
external constrictors to act as stenoses in otherwise smooth animal vessels.42  
 
In common parlance, a vessel with FFR of 0.80 has 80% of the blood flow it should have if 
the stenosis was absent. Theoretically, if a stenosis was removed from that vessel, the FFR 
should be 1.0.  For FFR to be correct the resistance imposed by the microcirculation and 
any collaterals must be entirely stable and flow across the stenosis maximal.  If higher flow 
across the stenosis can be achieved, or if the microcirculation resistance can be lower, 
then the severity of the stenosis will be underestimated and the calculated value of FFR will 
be overestimated (e.g. 0.85 when it should be 0.76). 
 
1.4.2 Impact of venous pressure 
The original validation of FFR recognised that the outflow of blood from capillaries into the 
venous circulation contributed resistance;42 this was accounted for by Pd-Pv/Pa-Pv. To 
simplify FFR and its increase adoption, venous pressure is now assumed to be zero.  This 
was done to allow Pv to be removed from the equations calculating FFR.  However, typical 
venous pressures of 2-8mmHg are reported during hyperaemia.44  The implications are that 
stenosis severity may be underestimated, particularly if venous pressure is elevated.45  
Whilst the effects may be diluted in population samples, for individual patients the effects 
and the change in categorisation can be marked.  
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In our own dataset (presented at EuroPCR 15, not yet published), when FFR values are 
close to the threshold, not accounting for RAP can lead to misclassification.  Patients with 
pulmonary hypertension, heart failure or renal impairment requiring dialysis are more likely 
to have RAP values between 8 and 15mmHg.  Accounting for an RAP of 7mmg lead to a 
significant difference in the mean FFR value in a truly intermediate patient population - from 
a mean of 0.83±0.09 to 0.81±0.11 (p=0.04).  More importantly, the number of patients 
offered revascularisation increased significantly: assuming a mean of 10mmHg meant 9% 
additional PCI would have been appropriate.  
 
1.4.3 Stenosis specific assessment 
A further simplification has been considering FFRmyo (total flow through the myocardial 
bed, including collateral flow) and FFRcor (quantification of flow limitation due a stenosis) 
as the same.  FFRcor requires coronary wedge pressure (Pw) - measured during balloon 
occlusion of a stenosis, to estimate the flow contribution from collateral vessels.  
Accounting for Pw by using the equation: Pd-Pw/Pa-Pw gives a truer representation of the 
impact of stenosis on vessel flow than the simplified FFR equation.42  Without correction, 
FFRmyo underestimates the true FFR value of a stenosis.42,46  
 
There may be considerable advantage in computing FFRcor, since it is known that 
significant pressure loss can occur in the presence of large perfusion territories, even in the 
presence of a relatively small trivial lesion when flow is significantly elevated.  Equally, 
apparently negative stenoses may be ischaemia causing and go un-treated.  However, to 
determine FFRcor balloon inflation and occlusion of an otherwise intermediate stenosis is 
required, potentially causing vessel injury and worsening the stenosis.  Therefore, Pw is not 
routinely measured and FFRcor has been neglected.  The impact of this in clinical practice 
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is unclear because all the clinical trials have been performed utilizing the simplified FFR 
formulae.   
 
 
1.4.4 Thresholds for significance and evidence to support: DEFER and 0.75 cut-off 
A cut-off FFR value of <0.75 across an epicardial stenosis is accepted to be indicative of 
myocardial ischemia. There is a close correlation between FFR <0.75 and different non-
invasive indices of reversible myocardial ischemia.47  Whilst there may be discrepancy with 
individual functional tests, when multiple tests are performed, agreement is more likely; 
early work suggests FFR"0.75 detects 97% of ischaemia.47  Meta-analytical work suggests 
the match with non-invasive testing is typically 70%.48  The DEFER study demonstrated it 
was clinically safe to defer revascularisation with FFR values over 0.75, although the study 
was small, and the number of points in the intermediate range even smaller.49  
 
In DEFER, patients scheduled for coronary angioplasty for a stenosis of greater than 50% 
without proof of ischaemia were randomised to deferral or performance of PCI.49  In each 
arm, FFR was measured; stenoses with FFR <0.75 underwent PCI while those with 
FFR#0.75 either underwent PCI or no PCI depending upon their original randomization.  In 
total, 167 patients were randomised to deferral of PCI with an FFR#0.75.  At 5 years, 
patients who had been deferred had significantly lower rates of cardiac death and acute 
myocardial infarction compared to those with FFR<0.75 that underwent PCI (3.3% vs 
15.7%, p=0.002).  However there was no significant difference in cardiac death and acute 
MI in those who had FFR#0.75 but underwent PCI (3.3% vs 7.9%, p=0.21) suggesting that 
PCI could be performed relatively safely even in non-ischaemic lesions.  Follow-up was 
available in 92% of the patients to 15 years; mortality data was available in 97% of patients.  
 44 
There was no significant difference in death or revascularisation amongst the patients that 
had lesions deferred compared to those who were treated.  
!
1.4.5 FAME Study: establishing the 0.80 cut-off 
FFR values over 0.80 have over 90% sensitivity of excluding ischaemia.43  The FAME and 
FAME II studies both used a 0.80 threshold, ostensibly to ensure potentially ischaemic 
stenoses were not missed.   
FAME randomised patients to either FFR-guided revascularisation in multi-vessel disease 
or an angiographic approach where all stenoses #50% were stented; FFR reduced the 
number and length of stents placed and reduced the number of lesions considered 
significant (Figure 1.1).50 This led to an improvement in composite outcomes of death, 
myocardial infarction and repeat revascularisation.50  
FAME-II randomised those patients with confirmed FFR"0.80 to PCI with optimal medical 
therapy or optimal medical therapy alone.51,52  Two year follow-up suggested the composite 
of death, non-fatal MI and revascularisation was significantly lower with PCI than medical 
therapy when peri-procedural events were excluded, although the majority of the events 
were urgent revascularisation and the trial was stopped early which may overestimate the 
benefits.52 
Therefore it is typical for revascularisation to be offered when stenoses have FFR"0.75, 
while deferral is more likely when FFR>0.80.  For values in the ‘grey-zone’ (between 0.75-
0.80), clinical judgement is required, combining knowledge of the patient’s clinical 
presentation, other investigations and the impact of natural variability.53  
It is common practice to give additional doses of hyperaemic agent when values are close 
to the threshold: higher doses can give confidence that maximal hyperaemia has been 
achieved, but since flow is not being directly measured, caution is required since some 
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changes can result from the haemodynamic disturbance of higher doses.  Furthermore, 
there is a paradox whereby any additional pressure drop may be occurring in spite of 
increases in flow. 
 
 
1.4.6 FAME-II: the outcomes of FFR-guided revascularisation 
A key question for the open-label FAME-II study was to determine whether patients with 
ischaemia defined by FFR have improved outcomes if treated by PCI compared to optimal 
medical therapy alone. 1600 patients with stable coronary disease were due for FFR 
assessment of any angiographically visible stenoses (>50%).51,52  Those with an FFR "0.80 
were randomised to FFR-guided PCI with optimal medical therapy or to have medical 
therapy alone.  Those with FFR>0.80 were treated medically and followed in a registry.  The 
study was stopped early, after 888 patients had been randomised, due to an increased 
number of events in the medical therapy arm.  The primary end-point, a composite of 
death, non-fatal MI or urgent revascularisation within 2 years was significantly lower in 
those who underwent PCI rather than medical therapy (8.1% vs 19.5%, HR 0.39 [0.26-
0.56], p<0.001) (Figure 1.1).52  The major driver of events was urgent revascularisation, with 
18 patients (4%) in the PCI arm versus 72 (16.3%) needing PCI (HR 0.23, [0.14-0.38], 
p<0.001) but there was no difference in mortality (HR 0.74, [0.26-2.14], p=0.58) or MI (HR 
0.85, [0.50-1.45], p=0.56).51 Those patients who had been deferred with an FFR>0.80 had a 
low primary end-point of 3% at 7 months51 and 9% (15 patients) at 2 years.52  There was 
little difference between the deferred population (FFR>0.80) and those with FFR"0.80 who 
had undergone PCI (HR 0.90, [0.49-1.64], p=0.72].  
FAME-2 provides excellent contemporary data and learning points for future trials.  It can 
be seen that blinding patients and operators of the physiological value will have great 
importance.  As shown by RIPCORD24 and R3F23, the behaviour of physicians and the 
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management plan for patients is altered in knowledge of an FFR value.  It is natural then, 
that knowledge of the unblinded FFR value may have altered management of patients and 
accounted for some of the early revascularisation decisions.  Furthermore, it is unclear how 
patients react to the knowledge that they have a stenosis known to be causing ischaemia.  
It is noted that in the medical therapy (unstented) arm, there was a dramatic cumulative 
increase in class IV angina (pain at rest); this was particularly so in those with a change in 
reported symptoms and less so in those with objective markers such as ECG changes or 
troponin rise.  This suggests knowledge of stenosis significance may have influenced 
patients’ perception of symptoms.  Trials such as the DEFINE-FLAIR study (NCT 
02053038)54 which is enrolling 2500 patients into an outcomes-based iFR-FFR comparison 
will have patients and those conducting follow-up blinded to the physiological arm or 
values to minimise such bias. 
 
FAME-2 provided support for use of the 0.80 threshold, and supports those studies that 
have shown increased ischaemic-driven target-vessel revascularisation for those vessels 
deferred when FFR was 0.75-0.80.55,56  
 
FAME-2 furthermore confirmed the degree of ischaemia was related to the number of 
events.  An FFR value of 0.65 demonstrated significant interaction with the primary end-
point at the 7-month assessment (when FFR"0.65, events in the PCI arm were 7 vs 35, HR 
0.08 [0.03-0.26], when FFR>0.65, events were 12 vs 21, HR 0.46 [0.21-1.01], p=0.01 for 
interaction).51 At 2 years, however, the interaction only showed a trend towards significance 
(p=0.07).51  This signal is interesting since the mean FFR value in FAME-I in stenoses 
undergoing revascularisation was 0.60±0.14, that is the clinical benefit was accrued 
because stenoses stented were truly ischaemic rather than intermediate.   
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Further data to support this comes from a comprehensive meta-analysis of study (9,173 
lesions) and patient-level (6,961 lesions) data from studies reporting prognosis after FFR 
measurement.29  Clinical events increase as FFR decreases and revascularisation 
demonstrates the greatest benefit the lower the FFR value.  In an unadjusted Cox 
regression model from a patient-level meta-analysis of 6,961 stenoses, the optimal FFR 
threshold for a composite of death, MI and revascularisation was found to be 0.67.29 That 
is, revascularisation offered benefit over medical therapy for these outcomes when FFR 
values were below this threshold.   
Taken together, these findings suggest the real value of FFR is in the assessment of all 
stenosis severities rather than just intermediate stenoses. Since anatomical parameters 
poorly predict an FFR value, then limiting FFR to only ‘intermediate’ stenoses will poorly 
identify potential ischaemia; rather all stenoses should be assessed to maximise gain.  
Similarly, it suggests endpoints in trials will be predominantly driven by stenoses with very 
severe FFR values.  
 
1.4.7 FFR in acute coronary syndromes 
The value of FFR in the acute coronary syndrome setting has some limited data.57  Value 
may be added if non-culprit stenoses can be assessed at the time of catheterisation to 
avoid later investigation.  Concerns have regarded a possible sub-hyperemic response and 
underestimation of severity due to microvascular dysfunction leading to a sub-hyperaemic 
response to adenosine leading to under-estimation of stenosis severity. Repeating FFR 
values 6 weeks after MI (both STEMI and NSTEMI) show little change in the mean FFR 
value for the study group, though there can be significant change on a per-patient basis.58  
Certainly in STEMI, microvascular responsiveness changes over time giving a significant 
worsening of FFR in non-culprit vessels when repeated measurements are made 1 day after 
STEMI and more so at 6 months.59  
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FAMOUS-NSTEMI study was designed, but not powered, to assess the differences in 
health outcomes when both culprit and non-culprit vessels undergo FFR-guided treatment 
during NSTEMI.60  The investigators tackled the hypothesis that FFR would add clinical 
benefit compared to standard angiographic management in 350 NSTEMI patients with at 
least one stenosis greater than 30% severity amenable to revascularisation.  FFR was 
measured in 704 of 706 stenoses and patients were randomised to FFR-guided or 
angiographic-guided PCI (FFR was not disclosed).60  430 (61.1%) stenoses had FFR"0.80 
and 80% of each arm had at least one physiologically significant vessel.  In the FFR-guided 
arm, 22.7% patients were treated by medical therapy compared to 13.2% in the medical 
therapy arm (p=0.02).  Despite this, the number and length of stents was similar in both 
groups, and there was no difference in-hospital costs.60  
   
Although not powered for outcome, prospective follow-up noted no difference in clinical 
events at one year,60 with Kaplan-Meier plots showing convergence of a combination of 
death, MI or heart failure admission.  Since both arms had similar stent rates, stent-related 
complications could be responsible or alternatively patients with NSTEMI deferred from 
stenting may have had a catch-up of events (they were under-treated initially).  Breakdown 
of events according to culprit and non-culprit vessel would also help interpretation.  Larger 
studies with greater delineation of the drivers of events are required but FAMOUS clearly 
demonstrates it is technically feasible to make pressure wire assessments during cardiac 
catheterisation for NSTEMI.   
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1.4.8 FFR in other settings 
FFR has been widely assessed in a number of different settings to assist clinical decision-
making.  There are clinical studies utilising FFR for the assessment of left main stem 
disease,61,62 side-branch vessels and for guiding surgical graft placement.63  There remains 
limited data for the use of FFR within surgical grafts.64 FFR has been used in patients with 
acute coronary syndromes with reasonable reproducibility, despite concerns that the 
microvasculature is not optimally responsive to adenosine shortly after infarction.   
 
1.5 Changes in FFR with changing haemodynamics 
FFR is widely reported as being independent of changes in haemodynamics.  This has been 
based upon the original validation work in animals during which flow velocity and pressure-
based FFR values demonstrated good correlation in the presence of phenylephrine 
(hypertensive agent) or sodium nitroprusside (hypotensive agent).42  A further small study in 
13 patients demonstrated that FFR had a low coefficient of variation between pairs of 
values when measured before and after atrial pacing (to increase heart rate), reduction of 
blood pressure (with sodium nitroprusside) and after dobutamine infusion.65  
However, some have disputed whether FFR, a pressure-based index can be truly 
independent of factors that alter blood pressure (Figure 1.6).  Theoretical mathematical 
model suggest that FFR is affected by changes in haemodynamics.66  
Indeed, when the original animal data showing the pressure independence of FFR is 
reviewed using a Bland-Altman analysis,42 that the extremely close relationship between 
pressure-based FFR and true flow-based FFR is less close than originally reported (Figure 
1.7) 
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1.5.1 AFFECTS Study 
The AFFECTS study demonstrated that haemodynamic responses of proximal and distal 
coronary pressures to adenosine, take one of seven distinct patterns. These patterns 
depend on the changes in Pa and Pd during peak and stable hyperemia (Figure 1.6).67  
Centrally administered adenosine (140mcg/kg/min) typically gives an initial rise in systemic 
blood pressure, triggered by the passage of adenosine through the pulmonary circulation 
which triggers reflex peripheral vasoconstriction.68  Following this, adenosine increases 
large artery compliance causing a fall in peripheral resistance and a fall in aortic reservoir 
pressure.  This manifests as a fall in systemic BP and a fall in proximal pressure (Pa); 
AFFECTS showed a mean fall of 10.2±10.5mmHg in Pa.67 This fall in Pa, accounted for over 
half of the change in distal pressure (Pd) in response to centrally administered adenosine.67 
That is, much of the change in Pd, which is perceived to be due to a reduction in 
microcirculatory resistance, is in fact due to a reduction in the proximal driving pressure 
from the aorta.   This is self evident as under stable hyperaemia when pressure and flow are 
linearly related, then when pressure (Pa) is reduced that flow is reduced by the same 
proportion.  
 
Since FFR can be calculated during either initial peak or stable hyperemia and given that Pa 
and Pd can differ at these two time points according to the 7 possible responses, it is 
possible FFR values will differ at peak and stable hyperemia.  For example, for a given Pd, if 
in peak hyperemia, Pa is high then a low FFR may be calculated;  if Pa then falls during 
stable hyperemia, a higher FFR will result.  
 
The impact of this is seen clinically: Echavarria-Pinto et al. showed the lowest Pd/Pa ratio 
during hyperaemia occurred during peak hyperemia rather than stable hyperaemia in 
almost 20% of cases.69  In three cases out of 104 cases this produced FFR values that 
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suggested different revascularisation decisions at peak and stable hyperemia.69  This small 
number, from an expert centre, may be larger in a more unselected real-world cohort that 
did not specifically exclude poor quality traces.  Whilst some may use FFR as the lowest 
value recorded, it is important to remember the central tenet of FFR from which all the 
clinical outcome data is derived is that measurements are only made under conditions of 
maximal stable hyperemia. 
 
1.5.2 Hyperaemic agent impacts upon variability 
The choice of hyperemic agent will have a differential impact on haemodynamics.70 
Adenosine (both intravenous and intracoronary) reduced blood pressure significantly more 
than intracoronary nicorandil (a fall of 12.9±9.1mmHg vs 9.2±6.7mmHg, p<0.001).70  
Regadenoson reduced blood pressure even more than adenosine, but the values of change 
in the reported subset are smaller perhaps reflecting methodological differences (adenosine 
caused a rise in blood pressure 3.2±12.1 vs regadenoson -2.7±11.1, p<0.001).70  Although 
no relationship between the difference in FFR values between the two hyperaemic agents 
and the change in haemodynamics was found, this is perhaps because FFR was calculated 
only during ‘maximal hyperemia’ (likely to be the lowest ratio), with no actual comparison 
between peak and stable values.  Therefore the true impact of pressure changes on the 
ratio remains unexplored in that dataset.  
When Pa pressure falls considerably, paradoxical vasoconstriction of the microcirculatory 
bed can occur, in order to preserve tissue perfusion.  This can be observed as a 
paradoxical rise in Pd during intravenous adenosine infusion.71,72  This may be seen 
particularly with severe stenoses and long infusions of adenosine (although 1 minute is 
typical, many centres and studies use 4 minutes as originally validated, e.g. FUTURE 
(NCT01881555)73.  The implications are that when FFR is used widely as is increasingly 
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suggested, then a small number of lesions may be incorrectly classified as non-significant if 
the clinician is unaware for the potential for paradoxical vasoconstriction. 
 
1.5.3 Practical implications upon FFR measurement 
It is common for physicians to administer additional dose of hyperemic agent when FFR 
values are close to the threshold: this is to ensure resistance is at its lowest and ensure 
lower FFR values cannot be achieved.74  However, higher intravenous doses have been 
shown to adversely affect haemodynamics37 and higher doses have no validation in clinical 
outcome studies.  The current thresholds for treatment (whether 0.80 or 0.75) were derived 
at much lower doses of adenosine,17 and higher does may require different thresholds. As 
such, keeping to recommended doses helps standardise assessment and allows 
interpretation with the clinical outcome studies. 
 
The route of hyperemic agent administration varies between centres.  The majority of the 
landmark trials used intravenous infusion of adenosine but in practice, many use 
intracoronary adenosine boluses in the majority of cases.18  The reason for this are multi-
factorial including but not limited to the avoidance of the need for additional femoral 
punctures or infusion pumps, increased cost efficiencies and lower incidence of side-
effects.36  One added value is that intracoronary dosing may avoid haemodynamic 
confounding as central aortic pressure is less likely to change,37 and this appears preserved 
even if intracoronary infusions are used.75  Whilst classification agreement is good across a 
wide-spectrum of stenoses,36 in more clinical populations classification match between IC 
and IV dosing can fall to 78% around the 0.80 threshold.70  Therefore revascularisation 
decisions may be affected in truly intermediate stenoses.   
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Concerns over the prognostic impact of such changes in revascularisation decisions is 
unclear.  FAME-2 demonstrated that there were very few events that occurred when 
patients had FFR values close to the threshold of 0.80, either above or below it. Therefore, 
certainly in trial populations, changes in classification may lead to little difference in 
outcomes.   
 
1.6 Role of FFR in diagnostic angiography 
An area of great potential remains the use of FFR during routine clinical angiography rather 
than at the time of coronary intervention. Greater utility may be gained by performing multi-
vessel physiological assessment at the time of angiography to objectively delineate the 
clinical significance of any coronary atheroma.  Studies suggest there may significant 
changes in medical decision making with the additional information.23,24  
 
1.6.1 RIPCORD Study 
In the RIPCORD study 200 patients undergoing coronary angiography had a management 
plan first made based only upon angiographic findings.24 FFR was then measured in all 
vessels #2.25mm diameter and used to guide a second management plan.  A quarter of 
patients had a change in management plan upon disclosure of FFR data.24 9 out of 72 
patients (12.5%) in whom medical therapy had been recommended on the basis of 
angiography, were recommended for revascularisation once FFR was known.24  A quarter 
of patients of whom were recommended for revascularisation based on angiography, 
required medical therapy once FFR was known.24   In total, a third of vessels considered 
significant changed after FFR assessment.24 
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1.6.2 R3F Study 
The R3F study was a larger study with a similar design, enrolling over 1075 consecutive 
patients undergoing coronary angiography in 20 French centres.23  
Unlike RIPCORD, patients were only included if at least one ambiguous lesion was present,  
and FFR was performed only in the vessel of interest.  Whilst the overall proportion of 
medical therapy, PCI and CABG appeared similar with only a modest but statistically 
significant change, individual patients had a marked change in plan, with 464 (43%) 
patients having a different management plan made upon FFR disclosure.23  Importantly, 
from a safety perspective, the event rate after 1 year of follow-up was identical in the cohort 
of patients who were reclassified by FFR and those in which angiographic-guided plans 
were concordant with the FFR findings (11.2 vs 11.9% MACE rates, p=0.78).23  
 
Taken together, RIPCORD and R3F confirm the limited value of angiography-alone to guide 
treatment decisions, and strongly suggest that routine coronary physiology should be 
considered in all patients referred for diagnostic coronary angiography.  This is particularly 
important for complex tandem disease:  such disease may be medically managed based 
upon diagnostic angiography alone as the patient may not be referred on for the 
physiological assessment.  If physiology was performed at the diagnostic procedure, then it 
is possible that more patients could be treated with intervention. 
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1.7 Resting Physiology and iFR 
 
1.7.1 Development of resting physiological tools 
Coronary stenosis assessment at rest has been available since the dawn of coronary 
intervention,76  but was limited by bulky low-fidelity equipment.  Exogenous hyperaemic 
agents were settled upon aid discrimination between stenoses by increasing flow across 
them.  However, exogenous induction of hyperaemia does not increase flow uniformly 
across all stenosis severities. PET-derived quantification of blood flow shows that 
adenosine increased blood flow most in unobstructed vessels or those with <50% diameter 
stenosis.77  In those with >50% stenosis, namely those considered for suitable for 
revascularisation, there was no significant increase in flow.77  Resting blood flow was 
preserved across all stenosis severities, and this is likely occurs by compensatory 
microcirculatory vasodilatation in response to the stenosis at the expense of distal pressure 
which falls even at rest (Figure 1.4).  Since pressure falls at rest with stenosis severity, then 
a resting index should be sufficient to quantify severity provided there is sufficient flow 
velocity to distinguish between stenoses.  This thesis will assess this in large patient cohort. 
 
1.7.2 iFR - an alternative tool to assess stenosis significance 
The instantaneous wave-free ratio (iFR) is a resting index of stenosis severity, which 
provides a physiological quantification of the impact a stenosis upon the coronary 
circulation.  iFR is measured during a specific period of diastole known as the wave-free 
period, where flow is intrinsically at its highest compared to the whole cycle.78,79  By 
measuring during a higher flow velocity, the capacity to discriminate between stenosis 
severities at rest is amplified and maximal compared to any other phase of the cardiac 
cycle. 
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The wave-free period was originally isolated by application of wave-intensity analysis 
(WIA)80,81 Wave intensity demonstrates that throughout the cardiac cycle, forces 
propagating from the proximal vessel, the aorta, conflict with those travelling from the distal 
end, the microcirculation (Figure 1.8).82,83  Competing interaction between the waves occurs 
throughout systole and the largest microcirculatory wave occurs at the beginning of 
diastole to explain why coronary flow is predominantly diastolic.   
 
During diastole the waves are quiescent,78 and during this wave-free period, 
microcirculatory resistance is at its lowest and most stable compared to the rest of the 
cardiac cycle. During this time, pressure and flow velocity are linearly related and pressure 
ratios can asses the flow limitation imposed by a stenosis.78 The wave-free period exists as 
proportion of diastole changing with alterations of R-R interval. .  This means that iFR can 
be calculated during irregular rhythms (e.g. atrial fibrillation) and can be calculated for heart 
rates normally acceptable for physiological assessment (30-130 bpm).  It can be calculated 
prospectively or from any pressure trace used for FFR that contained a period of rest 
(Figure 1.9). 
 
1.7.3 The ADVISE Family of Studies 
The ADVISE study was the first-in man assessment of iFR.78 After describing the wave-free 
period using combined pressure and flow velocity measurements,  computer algorithms 
were developed to reliably identify the wave-free period using pressure-only technology.78   
The pressure-only iFR algorithm was compared to FFR in 157 stenoses with a good 
correlation (0.90) and receiver-operating characteristic area under curve of 93%.78   
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The ADVISE family of studies demonstrated that in, in 15-20% cases iFR, a resting index, 
was numerically lower than a hyperemic index.78,84  This observation may have been under-
reported in clinical practice since many would avoid hyperemia when the resting gradient 
was already significant.  Similar findings have been observed by Seto et al, and are 
explained by the AFFECTS study.67,85  This phenomenon is more frequent in severe 
stenoses in which vasodilator reserve is depleted and trans-stenotic flow is dependent 
upon the proximal driving pressure.  Even small haemodynamic perturbations can trigger 
compensatory microcirculatory vasoconstriction in an effort to preserve perfusion.  This is 
observed as an apparently rising Pd or FFR ratio with continued infusion.84  
 
In a small number of cases, a stenosis may have trivial resting gradient but have a large 
hyperemic gradient.  Without measurement of flow, this would suggest the resting gradient 
was ‘incorrect’.  However, CFR flow studies, whether by PET or invasive measurement, 
show these events are consistent with a considerable increase in flow across a mild 
stenosis that gives false-positive hyperemic pressure gradient (that is, not truly flow-limiting 
stenoses).25,86  When patients with stenoses such as this are deferred, prognosis appears to 
be excellent.87  These concepts are revisited in detail later.   
 
1.7.4 iFR assessed in clinical populations 
The ADVISE-Registry compared iFR and FFR in a routine clinical population and found a 
classification match of 80%.88  This is similar to the classification match between repeated 
measures of FFR in the DEFER study (85% match).88  Therefore, the capacity for iFR (or any 
other index trying to match FFR) to agree with FFR will be constrained by the intrinsic 
variability of FFR and it’s capacity to agree with itself. Adjusting for this, by taking maximal 
agreement as 85% (80/85) gives an agreement of 94%.   
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DEFER suggested FFR classification could change in 15% of cases when repeated 10 
minutes apart.53  Lesser change is noted if measurements are 2 minutes apart89; greater 
change when 6 weeks apart.58  Values closest to the cut-point have greatest propensity to 
change; datasets made up of data-points away from the cut-point will have less change.  
Datasets in which values around the cut-point appear to be absent have the least change.  
Since the ADVISE-Registry was unselected consecutive cases performed as part of routine 
care, the lesion distribution was unimodal with mean FFR of 0.81±0.09.  With the majority of 
data-points close to the cut-point, this maximised the chance that small changes in either 
iFR or FFR would give classification mismatch. Previous FFR validation studies differed: 
they demonstrated bimodal distributions with a paucity of values at the cut-point.53  This 
would aid validation against other parameters but not be representative of performance in 
clinical populations and lead to inadvertent bias.   
 
An independent study from South Korea demonstrated similarity to the ADVISE-Registry.90 
In this rigorously collected data, resting indices iFR and whole cycle resting Pd/Pa had 
excellent diagnostic accuracy compared with FFR, with iFR demonstrating greater 
discriminatory power than Pd/Pa.  Pd/Pa values are typically clustered around a narrow 
range, where even small artefact or drift will impact upon the diagnostic efficiency.  iFR 
values for the same dataset were more widely spread, with dispersion range similar to the 
FFR, meaning that iFR provided greater diagnostic stability over a wider range (Figure 1.10) 
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1.7.5 CLARIFY Study: assessing the impact of hyperemia on the wave-free period 
Given the limitations of iFR-FFR comparisons, where the upper limit of agreement will 
always be determined by the accuracy of the reference parameter, it is reasonable to 
compare iFR and FFR to third party parameters of ischaemia.  The CLARIFY study, 
compared iFR and FFR to the hyperaemic stenosis resistance (HSR) index.  HSR is a 
combined pressure and flow velocity index91–93 that essentially calculates the gradient of 
pressure-flow curve as originally described by Gould.15  Since it indexes trans-stenotic 
gradients by flow velocity it corrects for false positive pressure gradients - situations when 
high flow velocities under hyperaemic conditions generate apparently important gradients 
by turbulence alone without any true flow limitation.  In CLARIFY, both iFR and FFR had 
equal diagnostic efficiency to match an ischaemic classification with HSR (both 92%, with 
no significant difference between the two tests).79  
 
The CLARIFY study further addressed key questions brought by the community.  One was 
whether iFR would be lower in the presence of adenosine, and whether the administration 
of adenosine over the wave-free period with further improve diagnostic categorisation.   
 
CLARIFY confirmed that iFR could be numerically lower when measured during adenosine-
mediated hyperemia (referred to as iFRa) often far lower than that of FFR.79  During iFRa, 
microvascular resistance was consistently lower than achievable by adenosine alone over 
the whole cardiac cycle; that is resistance is lower than that measured during FFR.79  
Therefore, for those who wish to always make measurements at the lowest resistance 
possible, then iFRa is the most ideal parameter.  However, despite the marked additional 
reduction in resistance and lower values, iFRa was not diagnostically superior to iFR.  There 
was no statistical difference between iFRa, FFR and iFR in diagnosing ischaemia when 
compared to a third-party hyperemic ischaemia parameter, HSR (hyperaemic stenosis 
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resistance).  The optimal threshold for ischaemia for iFRa was 0.66, corresponding to its 
much lower values. The implication is that while it is certainly possible to elicit lower 
numbers by combining hyperaemia with the wave-free period, there is no diagnostic 
advantage in doing so.  
 
CLARIFY confirmed the findings of PET studies which show that adenosine increased flow 
most in mild stenoses: in CLARIFY, invasive assessment of microvascular resistance 
showed that mild stenoses had the greatest response to adenosine, with limited impact in 
significant stenoses.79  In contrast, the wave-free period had a more consistent reduction in 
microvascular resistance across all severities.  In stenoses classed as ischaemic by HSR, 
there was no difference in the resistance reduction offered by adenosine and the wave-free 
period.79  In non-significant stenoses, adenosine hyperemia produced a greater reduction in 
resistance than offered by the wave-free period but without any additional diagnostic 
advantage as classification match was identical between parameters.79  This suggests that 
the wave-free period provides sufficient information for diagnostic classification of stenosis 
severity and that the addition of hyperemia adds little.  
 
1.8 iFR comparative studies with other markers of ischaemia 
During the validation of FFR, it was evaluated against non-invasive parameters of ischaemia 
such as exercise testing 94 and PET44 (Figure 1.12). In many cases, these non-invasive 
parameters were themselves validated by their capacity to detect anatomical coronary 
disease.95 To avoid circular arguments, third party assessments provide an alternative 
arbiter of ischaemia.  iFR has now been compared to other parameters of ischaemia in a 
number of studies.  Each demonstrates that a resting index has the capacity to provide as 
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much information as a hyperemic index, even when compared to a reference standard that 
requires hyperemic stress. 
 
1.8.1 Comparison with HSR 
The CLARIFY study has already been discussed, and demonstrated equivalent capacity of 
iFR and FFR to assess ischaemia classified by HSR.79  A second study larger study similarly 
assessed iFR and FFR against HSR in 120 stenoses.96  In this study, iFR was found to have 
a significant higher classification match than FFR (89% vs 82%, p<0.01).96 
 
1.8.2 Comparison with Myocardial Perfusion Scanning 
A third study assessed iFR, FFR and the basal stenosis resistance (BSR) index97 against a 
comprehensive combined ischaemic reference of myocardial perfusion scintigraphy (MPS) 
and HSR.98  Stenoses were considered ischaemic if both the MPS and HSR were positive 
which is pertinent as it confirms both a perfusion maldistribution (MPS) as well as an 
epicardial stenosis (HSR) as the source of the perfusion defect.  No significant difference 
was found between each indices,98 and the results were consistent with other non-selective 
cohorts using MPS.99 
 
1.8.3 Comparison with Positron Emission Tomography 
A fourth study compared iFR and FFR against positron emission tomography (PET), which 
is recognised as the gold standard for quantifying myocardial blood flow.100  De Waard et al. 
performed ([15O]H2O) PET imaging in 34 patients with 49 intermediate coronary artery 
disease followed by invasive pressure wire assessment. Both iFR and FFR had a 76% 
classification agreement with PET, and both had similar AUC for ROC analysis (0.85 for FFR 
and 0.86 for iFR, p=0.71).100 Both iFR and FFR had an identical pattern of agreement and 
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disagreement with PET MBF.  This is a remarkable finding and is akin to the finding that 
FFR was related to MBF on PET imaging in 22 patients which validated FFR as a test for 
ischaemia.44  
 
1.8.4 Comparison with Coronary Flow Reserve 
Finally, iFR and FFR have been compared to invasive Coronary Flow Reserve (CFR).101  
Calculated using a Doppler flow velocity wire and presented as a ratio of resting flow-
velocity to hyperaemic flow-velocity, CFR is a strongly prognostic index.102  CFR >2 are 
non-flow limiting while those below suggest a significant stenosis.  When iFR, FFR and CFR 
were measured in 216 stenoses, iFR had closer agreement with CFR than FFR with a 
statistically significant higher AUROC (iFR 0.82 vs FFR 0.72, p<0.001).101  Even when 
constraining to the physiological range of 0.60-0.90, iFR maintained a stronger association 
with CFR than FFR (AUROC 0.78 vs 0.59, p<0.001).101  
 
This suggests iFR has a closer association with hyperaemic flow velocity and CFR than 
FFR.  This is understood when it is appreciated that significant FFR values can occur in the 
presence of high flow velocity across mild but not flow-limiting stenosis.  This mechanism, 
may account for discrepancies between iFR and FFR.  In the JUSTIFY-CFR cohort, when 
iFR was negative and FFR was positive, it could be noted that the CFR was above 2 in 97% 
of cases.  These findings suggest that when iFR and FFR appear to disagree, iFR provides 
a greater degree of information about the state of coronary flow than FFR.   
 
These findings support the concerns many physiologists have expressed for some time - 
that FFR has only a modest agreement with CFR.25 Johnson et al (2012) studied 438 
stenoses and found FFR and CFR matched only 60%.25 There are two areas of discrepancy 
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to consider - when FFR is positive ("0.80) but the CFR is normal (>2.0), and secondly when 
FFR is negative (>0.80) but the CFR is abnormal (<2.0).  The first situation is vexing, as the 
pressure-based index suggests revascularisation while the flow-based index shows the 
flow can increase sufficiently without intervention.  
 
One possible explanation of discrepancies between FFR and CFR has been that of 
inadequate hyperemia.  Since both indices require maximal hyperemia, in the same manner 
that FFR is impacted by inadequate hyperemia, CFR readings may underestimate true flow 
values.  This has been suggested as many of studies have used lower doses of IC 
adenosine than currently used in practice. However, giving further vasodilator to increase 
hyperemic flow would mean both indices move even further in opposite directions:  FFR 
would become more positive (FFR<0.80) while CFR would be become more negative 
(CFR>2.0).  Therefore the discrepancy cannot be resolved by higher doses.  Furthermore, 
higher doses could mean assessments that are congruent could become incongruent: an 
FFR value close to 0.80 with a CFR >2.0 with higher doses could have an FFR that dips 
below 0.80 while CFR will only rise.   
 
Whilst FFR has outcome data such discrepancies are under-described in the FFR trials.  
Van de Hoef et al reported 10-year follow-up data of patients with discrepant pressure and 
flow measurements who were deferred from PCI.  In those with a positive FFR ("0.80) but 
normal CFR (>2.0), MACE rates were no different from those patients with a negative FFR 
(>0.80) and a normal CFR (>2.0).87  That is, managing these patients according to their 
normal flow value achieved the same result regardless of the FFR.87  Those with negative 
FFRs (>0.80) but abnormal CFRs (<2.0) had very high MACE rates, suggesting this pool of 
patients are not getting appropriate revascularisation.  This finding may account for the 
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highly variable event rate (2.5-11% at one year) reported after deferring stenoses with 
FFR>0.80.103  
 
By combining iFR and FFR it is possible to more closely attain an estimate of hyperaemic 
flow.  If the iFR is negative and FFR is positive, the data suggests these stenoses are likely 
to represent those with high probability (97%) of CFR>2.0 where clinical outcomes are 
identical between PCI and deferral.101  Whereas, if the iFR is positive and the FFR negative, 
this suggests a low CFR.87,101  In such cases it may be prudent to revascularise where 
anatomically feasible; further studies assessing the value of this are underway. 
 
 
1.9 Clinical application of iFR 
 
1.9.1 The iFR-FFR Hybrid approach 
While awaiting outcome data, a prudent application of iFR in the clinical setting is to apply 
the Hybrid iFR-FFR strategy (Figure 1.11).104 The aim is to achieve a high diagnostic 
agreement with FFR that has outcome data, whilst reducing the need to administer 
adenosine. iFR is measured in all patients; if the value found is within a narrow range then is 
adenosine administered to calculate FFR.  Multiple different Hybrid iFR-FFR approaches 
are possible according to classification match sought:  a match of 95% requires adenosine 
if iFR values are between 0.86-0.93, sparing almost 60%-70% of patients adenosine.104  
 
External validity of the iFR-FFR hybrid approach has been provided by ADVISE-II and the 
ADVISE-In-Practice studies.  ADVISE-II was a prospective global double-blind multi-centre 
study of 690 truly intermediate stenoses (mean FFR 0.83±0.11).105  Nearly 70% of stenoses 
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could avoid adenosine using the Hybrid approach whilst maintaining 94% overall 
classification match with an FFR-only approach.   
 
ADVISE-in-practice was the first study to employ the commercially available iFR console.106  
In this international, multi centre study of 392 stenoses in 313 patients, iFR had a high 
classification match with FFR (80% using the FFR 0.80 cut-point; 88% with ischaemic 
threshold of 0.75 and 92% if the FFR gray-zone was accounted for).106 Using the Hybrid 
approach 61% of the patients could be spared from adenosine with a 94% classification 
match with FFR.106 
 
The Hybrid approach has been adopted in routine clinical practice and is being used in 
SYNTAX-II (NCT 02015832)107 in which three vessel disease on angiography will undergo 
revascularisation according to physiological findings on iFR-FFR assessment.  Since 
physiological assessment can convert angiographic three-vessel disease to lesser 
severities,23,108 SYNTAX-II may show rapid assessment with iFR-FFR can assist in focusing 
revascularisation to functionally important stenoses in cases otherwise treated surgically.  
 
Clinicians experienced in using iFR are increasingly using it alone as a single physiological 
parameter, with a single threshold of significance (an iFR <0.90 is treated with 
revascularisation, while iFR#0.90 are deferred).  These thresholds were determined against 
an FFR threshold of 0.80 in the large and independent RESOLVE study which combined 
many different datasets.109 The validity and safety of such approach is being assessed in 
two international studies, DEFINE-FLAIR54 and the iFR-SWEDEHEART110.  
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1.9.2 iFR in Acute Coronary Syndromes 
At present, iFR has very limited data in the setting of ACS.  The FORECAST study is an 
independent study, using offline iFR calculation, which demonstrated it is feasible to make 
iFR measurements in non-culprit vessels in ACS.111  In 123 stenoses in 82 patients with 
ACS and stable disease, an iFR threshold of 0.92 best matched an FFR of 0.80 with a 
diagnostic concordance with FFR of 81.3%.111  No difference in diagnostic efficiency 
between ACS patients and those with stable disease was found and all apparent 
discrepancies were within the FFR 0.75-0.80 gray-zone.111  Furthermore, when using a 
Hybrid iFR-FFR approach, they found 68% of patients would be spared adenosine.  Further 
data will come from the DEFINE-FLAIR study, which is including patients with ACS.  
 
1.9.3 On-going outcome studies with iFR 
Clinical outcomes studies are underway to determine the safety of using an iFR-only 
approach to guide revascularisation.   
 
DEFINE-FLAIR is a multi-centre international, double-blind outcome study, which will be the 
largest physiology study performed to date (Figure 1.13). 2500 patients with intermediate 
stenoses, will be randomised to either an iFR-guided approach (treatment threshold 
iFR<0.90) or an FFR-guided approach (treatment threshold FFR"0.80).54  Both stable 
patients and those with acute coronary syndromes (non-culprit vessels) are included.  The 
study is powered to test major adverse cardiovascular events at 1 year for non-inferiority 
between iFR and FFR.  FLAIR is unique because not only will the patient be blinded to the 
physiological parameter used, but those performing patient follow-up will also be blinded.  
Other endpoints include the cost efficiencies between iFR and FFR. 
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The iFR-SWEDEHEART (NCT 02166736) study is simultaneously being performed in 
Sweden as part of the pioneering Swedeheart registry.110  In this study, 2000 patients will 
be randomised to either iFR or FFR and have follow-up within the Registry system.  Since 
clinical outcomes and study design have been harmonised with DEFINE-FLAIR, combined 
both studies will provide data on 4500 patients and approximately 7500 coronary stenoses. 
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1.10 Flow based parameters of ischaemia 
 
1.10.1 Coronary flow reserve (CFR) and relative CFR (rCFR) 
The concept of coronary flow reserve is to compare the flow at rest with that measured 
under hyperaemia.  CFR is derived from the ratio of steady state maximal hyperemic flow to 
resting flow in a given artery.112 Conceptually elegant, CFR can be measured invasively 
using intracoronary wires capable of measuring coronary flow velocity (using a piezo-
electric Doppler or thermodilution principles (using wires with a thermistor).  It can also be 
measured during non-invasive testing using PET-derived quantification of regional 
myocardial blood flow or by transthoracic echocardiographic assessment of coronary 
blood flow. Compared to non-invasive functional imaging techniques has shown that a CFR 
<2.0 strongly correlates with ischaemia in the subtended territory.113 Extensive prognostic 
data that strongly suggest that events are low if flow can elevate greater than twice that 
measurable at rest.102  
 
Relative CFR (rCFR) indexes the CFR value of the interrogated vessel by that of a normal 
unobstructed reference vessel in the same patient, provided that at least one vessel is 
available.112  Accordingly, a normal rCFR may be between 0.65 to 1.0.  An important 
limitation is that of potential collateralisation between coronary territories in the presence of 
a severe stenosis may alter the values.  Since vasodilators cause indiscriminate 
microcirculatory vasodilatation, then flow in the reference vessel may be significantly higher 
than if the stenosis in the neighbouring territory was absent.  Consequently the CFR in the 
reference vessel may be supra-normal, causing over-estimation of the significance of the 
stenosed territory.  Alternatively, an inadequate hyperaemic response in the ‘reference’ 
territory would lead to under-estimation of the importance of the stenosed vessel.   
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1.10.2 Practical approaches to measuring CFR 
CFR is calculated using either Doppler flow velocity, or thermodilution.  Doppler flow 
velocity traces are acquired using a piezo-electric tipped guide-wire to elicit spectral traces;   
average peak flow velocity (APV) is determined by digital tracking and CFR is computed 
using the ratio of APV at rest and hyperaemia.  Epicardial resistance must be stabilised 
using intracoronary nitrates, ensuring a constant surface area which allows flow velocity to 
be directly proportional to flow. 
Added care and attention is required to ensure the flow sensor is co-axial within the vessel.  
Not only must the Doppler signal be dense, but the automated digital tracing around the 
Doppler flow velocity signal must also be fully optimised.  Inadequate tracking will impair 
CFR calculation and any phasic analysis. When stenoses are highly obstructive, acquisition 
of high quality traces is challenging. 
The principle of thermodilution is based upon the concept that transit time of an intra-
coronary injectate, derived from a thermodilution curve, is inversely proportional to flow [2]. 
CFR can therefore be derived as the ratio of the mean transit time of an intra-coronary 
injectate at baseline and maximal hyperemia.  Dedicated pressure wires with a temperature 
sensor can detect the transit time of a hand held 3–4ml intra-coronary injectate of room 
temperature saline. The shaft of this wire, on which the temperature-dependent electrical 
resistance is monitored, acts as a proximal thermistor. The distal pressure sensor also 
allows simultaneous high-fidelity temperature measurements. Multiple injectants are 
typically performed to take an averaged thermodilution curve.  Thermodilution techniques 
require for a standardised volume of injectant, given at a standard speed and force, 
followed by a standard flush time.  Changing these parameters can lead to subtle changes 
in the thermodilution patterns observed.  The need to inject means intravenous hyperemia 
is required. 
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1.10.3 Clinical interpretation of CFR 
The CFR values has been linked to events.  When the global CFR is reduced <1.6 the risk 
of cardiac events rises considerably114  For patients with a CFR#2.0, the risk of future 
adverse events is much low. There are intermediate risk for those patients with CFRs 
between 1.6 and 2.0.115  
 
Across multiple different techniques to assess CFR, including PET and doppler flow 
velocity an average global CFR of 4.2 has been observed in young patients with smooth 
arteries and without any obstruction.116  For patients undergoing angiography or those with 
risk factors, the average CFR is 2.8.116  Those with established coronary disease, the 
average CFR is 2.0.   
 
In the absence of an epicardial stenosis, CFR is a measure of microvascular reserve and 
the capacity to respond to an exogenous vasodilator.  In the presence of an epicardial 
stenosis, CFR provides a marker of flow obstruction; values below 2 are considered flow 
limiting. When used alone, CFR cannot estimate the relative contribution of microvascular 
dysfunction and epicardial stenosis since it inherently combines both.  CFR may be used 
alongside another hyperemic index such as fractional flow reserve (FFR); however, there 
may be similar concern that inadequate hyperemia may lead to misclassification of stenosis 
significance.  Discrepancy between FFR and CFR can occur in 30-60% of cases.  Typically, 
the pressure-based index has been considered correct because the availability of FAME 
study data, although alternative explanations should be considered since pressure is being 
used to estimate flow.   
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When CFR may be low, and FFR is above the treatment threshold, it may be interpreted 
that that there is a non-flow limiting stenosis with microvascular dysfunction.  However, 
since FFR is reliant upon achieving adequate hyperemia, then a non-significant value may 
not be accurate.  In this case, alternative hyperemic approaches may be sought: 
papaverine may overcome resistance to adenosine.  Alternatively, a resting index such as 
the instantaneous wave-free ratio (iFR) may help.  Since the resting index relies upon the 
natural response of the circulation to the stenosis it is not reliant on the response to the 
exogenous agent.  A truly significant stenosis will cause resting pressure loss even if the 
response to a hyperemic agent is incomplete.  If the iFR is positive, then it suggests, 
together with the low CFR that the flow limitation is genuine and that a high FFR is due to a 
lack of microcirculatory response to adenosine.  If iFR is negative, it suggests that the 
epicardial resistance offered by the stenosis is small and predominantly microvascular 
disease is present.  
 
An alternative discrepancy is that CFR may be high, suggesting there is no difficulty in 
escalating flow when required, while FFR may be strongly significant, suggesting a flow 
limitation.  This situation can occurs because high flow velocities across even trivial 
stenoses can generate turbulence and energy loss that is detectible as pressure loss, 
despite the capacity to increase flow.  Should a resting index such as iFR be negative, it 
suggests little impact of the epicardial stenosis.  Alternatively, a combined pressure and 
flow velocity parameter such as the hyperemic stenosis resistance (HSR) may help.   
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1.10.4 Hyperemic (HSR) Stenosis Resistance and Basal Stenosis 
The pressure-flow velocity relationships of a stenosis can be described by the gradient of 
the curve and this is encapsulated by HSR and BSR.  Both measures use the trans-lesional 
pressure gradient and index it by the flow velocity distal to the stenosis (Pa-Pd / flow 
velocity).117  HSR is measured under hyperemic conditions, while BSR is measured at rest; 
application of both enable elucidation of the relative contributions of epicardial and 
microvascular resistance to impaired coronary flow.  Both are accurate surrogates for 
myocardial ischaemia.91,97,117 Stenoses with hyperemic resistance over 0.80mmHg/cm/s or 
resting resistance over 0.66mmHg/cm/s are likely to be causing ischaemia.91,97  
Since both HSR and BSR include both pressure and flow measurements, the difficulties 
posed by CFR or FFR measurement are resolved.  High flow situations causing pressure 
loss due to Bernoulli’s principle are readily detected; similarly microvascular disease limiting 
flow increases without epicardial limitation can be determined.  
The specific value of both these parameters is that they remove the likelihood of false-
positive pressure gradients that can occur when coronary flow increases significantly 
across an otherwise mild non-flow limiting stenosis.  As predicted by the curvilinear 
relationship between pressure and flow, even a trivial narrowing can generate a 
considerable pressure gradient if the flow increases dramatically and this may occur, 
particularly in proximal lesions in vessels subtending a large territory (such as the LAD) with 
a microcirculation that is particularly responsive to exogenous vasodilators (Figure 1.5). 
Firstly, the large response to a vasodilator suggests there is considerable vasodilatory 
reserve within the microcirculation that has not had to adapt to flow-limiting stenosis.  
Secondly, the fact that flow can elevate significantly across the stenosis suggests it cannot 
be flow limiting. Using a pressure-only index, under conditions of hyperaemia, a large 
gradient manifest in this manner (‘false positive’) would be indistinguishable from a ‘true 
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positive’ value.  By measuring both the gradient and the actual flow, both HSR and BSR 
resolve this difficulty and give a highly accurate representation of the significance of a 
stenosis.  
In modern clinical practice, HSR and BSR can be acquired using a combined pressure and 
flow velocity guidewire that features both a pressure sensor and a piezo electric crystal 
capable of measuring Doppler flow velocity.  As with CFR, optimised flow signals are 
required and familiarity with wire handling.  Advances in the commercially available 
consoles may facilitate use of these parameters, but until then, HSR and BSR remain in the 
research domain.    
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1.11 Physiological assessment of tandem and diffuse disease 
 
1.11.1 Physiological assessment of diffuse and tandem disease 
At present, FFR is the principle physiological parameter used routinely clinically in patient 
management and its application is supported by guidelines.118  However, FFR was 
principally validated in a cohort of patients with very discrete lesions and the basic 
equations of FFR do not distinguish between focal and diffuse disease.  Therefore the final 
FFR number does not tease apart what the dominant contributing factors are.  To date, 
therefore, FFR can be used as a tool to detect ischaemia to the level of a particular vessel 
but cannot detect which specific stenosis is driving that ischaemia.  Therefore, FFR may be 
used as a ‘go or no go’ tool to demonstrate that PCI is required but the choice of the site of 
intervention is left with the angiographic appearance and the judgment of the operator. 
An individual stenosis may not contribute significantly to the pressure loss observed within 
vessel; instead much of the pressure loss may be due to diffuse disease elsewhere within 
the vessel.  Alternatively, a number of complex lesions within a vessel may contribute little 
ischaemia, while another, more innocuous appearing segment of disease may be 
responsible for the patient's on-going angina.  Knowing this in advance will significantly 
help in selecting appropriate stenoses for revascularisation and would be an important 
advancement in clinical practice in the catheter laboratory. 
Deferring intervention when the vessel is not ischaemic appears to be safe in cohorts with 
focal stenoses.119 Taken at face value, this data could be applied to vessels with diffuse and 
tandem disease - applying that concept that if the entire vessel even in the presence of 
diffuse disease is above the threshold for intervention, then deferral would be safe.  This is 
how the majority of clinical decisions are made at present but unfortunately may not be 
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valid in the presence of diffuse or tandem lesions.  CFR studies suggest this group is at 
elevated risk of events and there may be discrepancy with FFR.116  FFR values are 
dependent upon achieving maximal hyperaemia and it is acknowledged that hyperaemia is 
limited in the presence of multiple stenoses.120  
What follows is a review of the literature to date of the physiological assessment of tandem 
and diffuse disease.   
 
1.11.2 Coronary stenoses are frequently part of more significant disease 
Coronary stenoses are rarely isolated.  It is common for stenoses to be part of a larger 
burden of diffuse atheroma, or to have sequential stenoses within a single vessel.  This can 
be true within a single vessel, but also true within multiple vessels in the same patient.  The 
result being that myocardial ischaemia is dependent upon the sum total of the stenoses. 
Even angiographically unobstructed vessels are likely to have significant plaque burden or 
under-appreciated stenoses simply due to the limitations of coronary angiography.  Early 
IVUS studies demonstrated angiographic lumen assessment considerably underestimated 
the presence of important atheroma.121 This is important to recognise since even 
angiographically normal vessels may have a pressure loss it.  Secondly, it suggests that 
even apparently discrete stenoses with apparently disease-free coronary segments may 
have considerable atheroma meaning that there is overall a visual underestimation of the 
degree of coronary disease present.   
Diffuse disease which impairs CFR is strongly associated with a high rates of clinically 
adverse events.114,115  When PCI is performed in such vessels, residual diffuse disease may 
mitigate against any benefit observed by removing a more focal area of disease.  Therefore 
understanding the physiological impact of diffuse disease is essential if these vessels are to 
be treated by coronary intervention.  
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1.11.3 Flow interaction occurs when more than one stenosis is present 
Hyperaemic parameters such as FFR and CFR were developed based around the concept 
of assessing the importance of a single stenosis within an otherwise unobstructed vessel.  
The majority of the validation work was performed in such vessels: in particular, the animal 
work was performed in young animals without diffuse atheroma and stenoses modelled by 
external constrictors placed around the vessel.  When more than one stenosis is present, 
any assessment with the wire sensor placed in the distal vessel will summate the overall 
physiological impact of all the stenoses in the vessel.  As such they are a representation of 
vessel ischaemia or flow limitation but not of the impact of an individual stenosis.    
 
The assessment of a single stenosis when there is other disease present represents a 
significant challenge.  Under hyperaemic conditions there is considerable interaction of the 
flow dynamics between multiple sequential stenoses.  The flow under hyperaemic 
conditions between two tandem stenoses cannot, nor would not, be the same as the flow 
proximal to the first stenosis or that distal to the second stenosis.   
 
This is important in particular for FFR that aims to be specific to stenoses and is used 
clinically in that way.  When there is a single stenosis, maximum hyperaemia will generate a 
maximal trans-stenotic pressure gradient that is applicable to the single stenosis present.  
Removing that stenosis should normalise the vessel.  When a second stenosis is present, 
flow through one stenosis will be sub-maximal due to the second stenosis, even under 
maximal vasodiltation.30  The degree of interaction and influence between the stenosis is 
unpredictable and will change according to treatment of one or other of the stenoses.  This 
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means that the FFR for each stenosis is not the ratio of pressure proximal and distal to 
each individual stenosis.30   
 
Furthermore, hyperaemic flow falls with all degrees of disease means that distal stenoses 
are exposed to lower flow rates than passing through proximal stenoses.  This creates a 
degree of interaction between all stenoses.  The degree of interaction will be dependent 
upon the true underlying severity of the stenosis (which is challenging, if not impossible, to 
describe in a single parameter).  Changes in trans-stenotic flow will alter the trans-stenotic 
pressure gradient; since the two are related in a curvilinear fashion, then even small 
changes in flow velocity may lead to considerable pressure changes.   
 
A significant proximal stenosis will mean distal stenoses have a low trans-stenotic flow and 
therefore low trans-stenotic pressure gradients.  The pressure gradient observed in the 
vessel with the sensor distal will be mostly made up of the proximal stenosis with less 
relative contribution by the distal stenosis.  However, removing the proximal stenosis would 
mean increased flow to the distal vessel, with a new trans-stenotic pressure gradient 
detectible across the distal stenosis.  This gradient may well be significant on its own and it 
was under appreciated prior to PCI of the proximal stenosis. 
 
Similarly, an important distal stenosis may limit the increase in flow velocity across a 
proximal stenosis under hyperaemia; therefore a distal stenosis may mean the proximal 
stenosis is under appreciated. 
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Wedge occlusion of an individual stenosis could help in giving a more stenosis-specific 
assessment but comes at the expense of committing to intervention of the stenosis that is 
temporarily occluded.   
 
Figure 1.14 summarises how interaction can occur between two discrete stenoses.  This 
will be amplified as the number of stenoses increases. 
 
This interaction can be observed even in vessels that have considered angiographically 
normal during quantitive flow assessment using PET.  In patients with no overt obstruction, 
hyperaemic flow was quantified longitudinally and shown to fall significantly from the base 
of the heart to the apex.122  This reduction was more than 2 standard deviations from what 
was observed from normal volunteers.  This suggests, that in even when there is trivial 
angiographic disease, there is considerable impact on hyperaemic flow.  This may well be 
due to plaque disease but IVUS data has not been co-reported alongside PET 
measurements. 
 
 
1.11.4 Animal models that confirm that there is a flow interaction 
All degrees of disease are likely to contribute in some way.  Whilst flow interaction is 
typically considered when two very discrete lesions are visible, it is possible that even mild, 
angiographically normal segments of the vessel are causing a flow interaction because 
even trivial disease may alter hyperemic flow velocity.  Whilst this has been tested in animal 
models,123 it has not in humans.  
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In animal experiments in 10 dogs, the presence of a proximal stenosis reduced the capacity 
for hyperaemia to increase coronary flow across a distal stenosis significantly.123  The 
presence of two 75% stenoses had a greater reduction in coronary flow reserve than a 
single 75% stenosis.  When proximal lesions were worse (88% in the original paper by 
Gould and colleagues), the capacity to increase flow across the distal lesion was removed 
entirely.  This suggests that the proximal stenoses significantly impairs the capacity to 
assess additional pressure gradients in a distal stenosis.123 
 
1.11.5 Clinical implications of flow interaction 
The clinical importance of this interaction is that clinicians would like to know which of the 
stenoses present should undergo coronary intervention and know in advance whether the 
residual stenoses would require intervention to achieve a haemodynamically optimal result.  
Ideally, an interventionalist would like to know the importance of all the stenoses, since the 
PCI strategy may be governed by the importance of some of the stenoses.  If it can be 
known that only one stenosis requires PCI, then a more selective approach could be 
undertaken.  However, since under hyperaemic conditions, performing PCI to one lesion 
will alter the flow dynamic relationships for the residual disease, then pressure gradients 
calculated pre-PCI for the other stenoses would not hold true after PCI.   
 
1.11.6 FFR assessment of Sequential Stenoses 
Animal modelling has been used to delineate the impact of sequential stenoses under 
hyperaemic conditions.  Using the conceptual model shown in Figure 1.16 an animal model 
was used to assess whether theoretical formulae could predict the FFR after intervention to 
one of the stenoses.30 
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The findings demonstrated that in the presence of a worsening proximal stenosis, the 
apparent FFR value calculated between the two stenoses, under-estimated the severity of 
the proximal stenosis.  The distal FFR value was essentially unchanged - but the value 
between the two stenoses became progressively less significant.30  
 
In the presence of a worsening distal stenosis, the apparent FFR value between the 
proximal and distal stenosis becomes non-significant  - this is despite the proximal stenosis 
being physiologically important prior to the creation of the distal stenosis. 
 
Bland Altman analysis demonstrates significant bias between apparent and true FFR values 
between two stenoses (Figure 1.16). In particular, when proximal stenoses have low FFR 
values (e.g. Below 0.80), the apparent FFR between the proximal and distal stenosis could 
be between 0 and 0.50 FFR units difference from the true FFR.  The apparent FFR over-
estimates the true FFR for the proximal stenosis significantly with an inverse correlation 
between the overestimation and the true FFR for the proximal stenosis (r -0.62, p<0.01). 
 
Similar findings were observed with significant distal stenoses.30  The apparent FFR when 
there was a distal stenosis was present systematically and significantly underestimates the 
true FFR of the proximal stenosis (r -0.39, p<0.01).   
 
For a fixed proximal stenosis, the error in FFR calculation was >0.10 in 45% of the apparent 
measurements for the proximal lesion.  For a fixed distal stenosis, the error was >0.10 in 
22% of the apparent measurements.  The error in calculating an FFR for a stenosis is 
significantly larger in the presence of a second more proximal stenosis than for a second 
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more distal stenosis.  The greatest error was found for mild distal stenoses, when the 
proximal stenosis was more severe.30  
 
This work is important:  it is the simplified FFR equation used in clinical practice, and while 
few interventionalists refer to the measurement as FFR(apparent), the presence of even mild 
distal disease beyond the sensor location means that any FFR being measured, is in fact 
FFR(apparent).   
 
Whilst hyperaemic pullbacks are recommended as a means of circumventing the issue, the 
FFR values measured at any location are in fact FFR(apparent) values, if there is any 
proximal or distal disease at all.   This means that all assessments performed under 
hyperaemic pullback conditions will systematically underestimate the significance of true 
FFR of any stenosis proximal to the location of the sensor.  Therefore, all clinical decisions 
made to treat on this basis will be exposed to a systematic error due to the flow interaction 
between stenoses.  This is inevitable as there will always be a degree of distal disease, 
perhaps in the small vessels that cannot be reached.   
 
 
 
1.11.7 Mathematical correction of FFR in sequential stenoses 
It is possible to overcome the limitations of interaction between stenoses by using the a 
series of equations developed from basic FFR theory.30  
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When applying these equations, it was possible to calculate the true FFR of a stenosis in 
the presence of another stenosis without significant over or under-estimation.30  This was 
true for whether there was a fixed proximal stenosis and varying distal, or if there was a 
varying proximal and fixed distal stenosis (Figure 1.15). 
 
These equations require careful calculation of the different components of pressure and 
importantly also require the determination of wedge pressure (Pw).  This means an 
intracoronary balloon must be inflated in the stenosis in question - which if it is being 
assessed with a view to avoid coronary intervention is an undesirable step in clinical 
practice.  Although Pw may be achieved by fairly low-pressure balloon inflation - any 
disruption of the endothelium by the balloon will pose the risk of disease acceleration or 
neo-atherosclerosis.  Alternatively, there may be sufficient clinical justification to perform 
balloon occlusion if the vessel FFR is truly ischaemic and therefore intervention was to be 
performed anyway.  However, if the aim was to minimise stenting of unnecessary lesions, 
then the calculation of Pw may counter a key principle of the clinical application of FFR.  
 
Wedge pressure varies widely between patients and cannot be easily estimated.  It 
depends upon the degree of collaterals and is measure of this.  When there is balloon 
occlusion of the vessel, the residual distal pressure will be mostly attributable due to flow 
from collaterals entering distal to the occlusion.  Furthermore, the calculations are 
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cumbersome and not readily performed in clinical practice by physicians during a case.  
Small degrees of drift will have significant effects upon the Pw and Pm values between 
stenoses, which will then impact upon the FFR(apparent) and FFR(true) values calculated.   
 
1.11.8 Limitations of Sequential Lesion FFR research in Animals 
The experimental protocol used highlights the difficulties of performing this research in 
large animals such as pigs: severe stenoses had to be created to generate large 
hyperaemic pressure gradients and when gradients were small, they were excluded.  This 
introduces bias, since apparently moderate or severe lesions may naturally only produce a 
trivial gradient in some circumstances, as is found clinically.  By excluding them, the 
investigators in fact enforced a bias that anatomical severity had to match physiological 
severity.  Furthermore, not all animals responds to the hyperaemic agents uniformly, with 
several requiring additional boluses and one requiring a dobutamine infusion, which itself 
alters the haemodynamic conditions and may generate additional ischaemia.  Furthermore, 
it remains unusual that the dogs had no change in blood pressure or heart rate in response 
to hyperaemic agents, while humans do change both.   
 
A further limitation of animal models of sequential stenoses is that constrictors were placed 
without a major arterial branch between the stenoses.  In theory, a major branch would act 
as a source for steal for flow under hyperaemic conditions, which means that distal 
stenoses would have sub maximal flow.  With many branches along a vessel, it is 
conceivable that hyperaemic flow will decline as flow moves from proximal to distal.   
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1.11.9 Assessment of serial stenoses in humans 
Pijls et al (2000) described an experiments performed in humans with tandem stenoses 
undergoing coronary intervention.120   
 
FFR was calculated in the distal vessel and then a slow hyperaemic pullback was 
performed.  This data was then used to compute the apparent FFR values for the proximal 
and distal stenoses.  The stenosis with the largest hyperaemic pressure gradient was 
stented first, on the pressure wire, which enabled measurement of wedge pressure (Pw) 
and therefore the determination of the true FFR as well as calculation of the predicted FFR 
using the mathematical formulae that correct for flow interaction.   
 
As seen in the animal work, the presence of a second stenosis means that the apparent 
FFR(app) was an underestimate of the true FFR.  Again, it was observed that the influence 
of a distal stenosis on the haemodynamic significance of the a proximal lesion was larger 
than that of a proximal lesion on a distal one.120  
 
In this study, however, it was concluded that despite the significant risk of underestimation 
of stenosis significance, that hyperaemic pullback using apparent FFR was the appropriate 
treatment approach.  The recommendation to overcome the limitation of error was to repeat 
the hyperaemic pullback after balloon inflation of the stenosis in question, to enable 
reassessment of residual gradients.    
 
1.11.10 How are serial stenoses assessed in clinical practice? 
Koo and colleagues have presented the largest clinical dataset of patients undergoing 
management according to a FFR-Pullback approach.124   
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In 131 patients with multiple intermediate lesions, (141 vessels and 298 lesions) FFR was 
performed and a pressure wire pullback under steady state hyperaemia.  FFR had a very 
significant relationship with diameter stenosis of the worst lesion (r = -0.28, p<0.001).  The 
stenosis causing the largest pressure step-up (largest delta in pressure gradient) was 
treated first.  FFR was then repeated to assess the need for further intervention.  The 
apparent FFR of the residual disease was calculated using the pressure wire data from the 
initial pullback; this was compared to the FFR found after the first PCI - with the implication 
that angioplasty result was perfect and the residual FFR was due to the remaining 
intermediate lesions.124 
 
In this detailed assessment in humans, a similar finding as shown in animals with external 
constrictors was found.  When treating the stenosis with the largest pressure gradient, the 
pressure gradient for the remaining stenosis increased significantly (from 7.7±5.9mmHg to 
10.9±7.8mmHg, p=0.01).124  This suggests that one stenosis was limiting the capacity to 
measure a trans-stenotic gradient.  Furthermore, the apparent FFR underestimated the True 
FFR for the second stenosis. 
 
In keeping with the finding that a distal stenosis was more likely to alter the FFR value of a 
proximal lesion, Koo and colleagues found that stenting a distal stenosis lead to a large 
incremental rise in FFR (proximal stenoses produced a 21.7% increment (0.69±0.08 to 
0.84±0.08), while distal stenoses gave a 31.8% increment (0.66±0.10 to 0.87±0.05)).  This 
implies that the distal stenosis were causing an overestimate of the proximal stenosis 
severity.124 
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The graph presented in the Kim et al paper enables digitisation of the data and re-analysis. 
Figure 1.17 demonstrates a Bland-Altman which confirms that the apparent FFR value has 
systematic bias in predicting the true FFR.   
 
The presented scatter plot shows that in only 3 cases did the apparent FFR suggest the 
residual stenosis had a significant FFR ("0.80). In these three cases, the true FFR was also 
below 0.80, but often a much lower numerical value suggesting the apparent FFR had 
underestimated the stenosis severity.  Using the graph to estimate the difference, an 
average of 0.0966 unit underestimation of significant stenoses is observed. 
 
In 15 cases, the apparent FFR was non-significant but the true FFR was significant, further 
confirming under-estimation of the severity residual stenoses.  In these cases, the FFR 
pullback was unable to determine that the second stenosis required intervention prior to 
PCI to the first stenosis.  This significantly reduces the clinical applicability of the technique, 
since physiological assessment and pullback must be performed each time a stenosis is 
treated. 
 
Following these findings, this work flow has been suggested in the use of hyperaemic 
pressure wire assessment of tandem stenoses125: 
1. Insert a pressure guidewire past the most distal stenosis.  
2. Measure the FFR of all stenoses together under maximal hyperaemia. 
3. If FFR is insignificant (FFR > 0.80), defer revascularisation in the serial stenotic 
lesions and treat with optimal medical therapy. 
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4. If FFR is significant (FFR " 0.80), perform a pressure pullback tracing under maximal 
hyperaemia. 
5. Perform PCI in the lesion with the largest pressure step-up first. Do not miss 
anatomical considerations around the target lesion. 
6. Repeat a pressure pullback tracing past the most distal stenosis. 
7. Repeat the decision-making process for each stenosis in the series.  
 
The need to make repeated assessments and to alter decisions regarding interventions 
therefore represents an unmet need in coronary intervention.    
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1.12 Introduction Figures 
 
Figure 1.1 Results of FAME and FAME-II Studies!
!
!
FAME randomized patients with multi-vessel disease to a FFR or angiographic guided 
approach; stenoses with FFR>0.80 were deferred.  FAME II randomized patients with a 
stenosis found to have an FFR "0.80 to PCI with optimal medical therapy (OMT) or to OMT 
alone.  Adapted from Tonino et al 2009 and De Bruyne et al 2014.50,52 
!
!
!
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Figure 1.2 Conceptual model of coronary flow based upon the findings in animals 
with external constrictors placed around vessels to mimic stenoses 
 
Resting flow is remarkably preserved despite worsening stenosis severity – up to 85% 
diameter stenosis by formal measurement.  Hyperemic flow starts falling when stenoses are 
30% but falls significantly once stenoses are 50%.   Adapted from Gould et al 1974.123   
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Figure 1.3 Graphical representation of coronary flow and pressure changes across 
a coronary stenosis.   
!
!
!
 
Pressure gradients across stenoses are due to both viscous and separation losses. 
Pressure is lost owing to viscous friction along the stenosis (Poiseuille’s law).  Flow also 
accelerates as it passes through the narrowed segment, causing pressure loss as pressure 
is converted into kinetic energy (Bernoulli’s law).  Flow separation and the formation of 
eddies prevent complete pressure recovery at the exit of the stenosis. Measurement of 
intracoronary haemodynamics includes proximal perfusion pressure (Pa), coronary pressure 
and flow velocity distal to the stenosis (Pd and Vd, respectively), and the venous pressure 
(Pv), which is typically assumed to be negligible. $P is the difference between Pd and Pa. 
Normal diameter (Dn), stenosis diameter (Ds), proximal velocity (Vn), and stenosis velocity 
(Vs) are indicated.  From van de Hoef et al (2013).
126 
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Figure 1.4 Conceptual model of coronary physiology in the presence of a stenosis 
with worsening severity 
 
 
As stenosis severity increases, there is increasing dilatation of the microcirculation at rest 
which theoretically should maintain resting flow at the expense of distal pressure which 
falls.   
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Figure 1.5 Pressure-gradient and flow velocity relationships for differing stenosis 
severities 
 
The gradient of the curve signifies the severity of the stenosis.  Pressure drop across a 
stenosis is determined by $P = Fv + Sv2 (where F is friction losses and S is separation 
losses).  This produces curvilinear relationship unique to any stenosis; the steepness of the 
curve reflects the severity of the lesion (e.g. Reference vessel, stenosis A, B, C).  Increasing 
the flow velocity across a stenosis will alter the pressure gradient observed.  In stenosis A, 
there is a large resting pressure gradient that is accentuated during hyperemia with little 
increase in flow.  In stenosis B, increasing the concentration of hyperemic agent (depicted 
as arrows) will increase flow velocity to generate a larger gradient; since resting flow is 
unchanged, CFR and FFR will move in opposite directions.  In even milder stenoses, such 
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as A, large escalations of flow velocity from a relatively low resting value could create a 
large pressure gradient; in these situations, pressure does not reflect the change in flow.  
A very steep curve, such as in Stenosis C is a physiologically more significant stenosis than 
Stenosis A.  Reference vessels, without any obstruction will have a pressure loss when flow 
velocities are very high.  In each stenosis, it can be seen in this hypothetical model that 
basal flow velocity is similar despite differences in stenosis significance.  They can be 
distinguished by the pressure gradient.  In the presence of hyperaemia, the degree of 
pressure gradient will increase.  In the most severe stenoses, the pressure gradient 
increases least.  In more moderate  stenoses, such as stenosis B then subtle variation in 
the degree of hyperaemia achieved will alter the pressure gradient observed.  The impact of 
this is demonstrated with green shading.  Assuming a mean arterial pressure of 100mmHg, 
then a trans-stenotic gradient of 15mmHg under hyperaemia would represent a FFR of 
0.85.  If the flow velocity increases from 32cm/s to 41cm/s then the FFR would be 0.75.  In 
itself, this represents a paradox since flow velocity is increasing to generate this pressure 
drop and lower FFR.  Plotting this as a CFR (lower part of graphic) it can seen that for this 
change to occur, a CFR of 2.7 is present.  This value is normal and a frequent finding in 
unobstructed vessels;  in common language, it means that the flow velocity can increase 
2.7 times its normal level when resistance is minimised.  This demonstrates the paradoxical 
nature of CFR and FFR mismatch in moderate stenoses. 
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Figure 1.6 The seven different hemodynamic responses to adenosine infusion 
 
 
 
Both proximal (Pa - Red) and distal (Pd - blue) pressures change during adenosine infusion 
– with differential behaviours during peak and stable hyperemia. This will affect the ratios of 
Pd/Pa calculated at peak and stable hyperemia. Reproduced with permission from Tarkin 
JM, et al.67 
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Figure 1.7 Bland-Altman graphs of Qs/Qn with FFR 
 
 
 
The original validation work for FFR measured a true FFR by directly measuring flow 
velocity in the presence and absence of a stenosis (Qs/Qn). This was compared with FFR, 
and when plotted with different hemodynamic states had high correlation and R2 values. 
However, re-plotting the data of the 5 dogs presented in the published paper as a Bland-
Altman plot shows that the Qs/Qn values are less tightly associated as may be suggested 
by correlations.  Data extracted from Pijls et al 1993.42 
 96 
Figure 1.8 Wave intensity analysis and the wave-free period 
 
 
A.  Wave-Intensity analysis figure.  Panel A is adapted from Sen et al (2012).78  Wave-
intensity analysis (upper most panel) demonstrates the proximal and microcirculatory 
(distal) originating waves generated during the cardiac cycle. A wave-free period can be 
seen in diastole when no new waves are generated (shaded green). This corresponds to a 
time period in which there is minimal microcirculatory (distal)–originating pressure (second 
panel), minimal and constant resistance (third panel), and a nearly constant rate of change 
in flow velocity (fourth panel).  B.  Multiple heart beats are shown, including systole and 
diastole.  The green shaded areas shows the wave-free period is reproducible from beat-
to-beat.  Resistance is constant while flow velocity is higher than over the whole cycle.  
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Figure 1.9 iFR is a pressure only index calculated during rest 
 
On the left, resting intracoronary pressure is shown with Proximal aortic pressure (Pa) in red 
and Distal coronary pressure (Pd) in green.  The wave-free period requires at least a single 
heart beat to calculate.  On the right, hyperemia has been induced causing a change in Pa 
and Pd.   
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Figure 1.10 Sensitivity of iFR and Pd/Pa 
 
Left Panel: Sensitivity of the instantaneous wave-free ratio (iFR) and Pd/Pa to detect a 
stenosis considered significant by fractional flow reserve (FFR). iFR has greater sensitivity 
over Pd/Pa even in a clinical distribution. Right Panel:  Schematic representation of the 
spread of values provided by Pd/Pa, iFR and FFR. The greater spread of iFR and FFR 
afford it greater sensitivity to detect significant stenoses, whereas because all Pd/Pa values 
are constrained within a very narrow range, the effect of technical variability such as 
pressure-wire drift or noise on diagnostic accuracy is much higher. Pa, proximal pressure; 
Pd, distal pressure. Left panel reproduced with permission from Park et al 2013.90   
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Figure 1.11 The iFR-FFR Hybrid approach 
 
In this clinical approach, the desire is to match an FFR based classification of lesions while 
reducing the number of patients who are given adenosine.  IFR is measured first, and if the 
value is within a range over which match with FFR is moderate, adenosine is given to 
measure FFR.  Using this approach, a variable match with FFR and number of patients free 
of adenosine can be achieved depending upon the desired degree of classification match.   
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Figure 1.12 iFR and FFR compared to ischaemic parameters 
 
 
 
Adenosine-free instantaneous wave-free ratio (iFR) has equivalent diagnostic accuracy 
to adenosine-mediated fractional flow reserve (FFR). In multiple studies where both 
parameters are compared to a third-party parameter of ischaemia, including the gold 
standard of positron emission tomography (PET), there is no difference in the accuracy of 
either pressure index to detect ischaemia.   
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Figure 1.13 DEFINE-FLAIR study protocol 
 
 
ACS, acute coronary syndrome; FFR, fractional flow reserve; iFR, instantaneous wave-free 
ratio; PCI, percutaneous coronary intervention. Reproduced with permission from Petraco 
R, et al.106 
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Figure 1.14 Interaction between stenoses in a vessel 
 
 
The presence of two or more stenoses creates complex interaction of flow and thereby 
impacts upon pressure measurements.  Formulae are available to estimate the FFR of a 
given stenosis without the impact of another but requires balloon occlusion of the stenosis 
in question (Pw).  Used with permission from Nijjer et al (2014).127  
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Figure 1.15 FFR true and apparent in stenoses created in human models 
 
  
Figure reproduced from: Pijls et al (2000).120 
 
Left Panel A.  The apparent and true FFRs in animal models of stenoses 
Right Panel B.  Application of the correction formulae to predict the FFR using wedge 
occlusion of a stenosis. 
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Figure 1.16 FFR true and apparent in the presence of variable proximal and distal 
stenoses 
 
 
The left panel A&B.  FFR(apparent) over-estimates the true FFR of a distal stenosis when a 
proximal stenosis is present. 
The left panel C&D.  The apparent FFR of a proximal stenosis over-estimates the true FFR 
when a distal stenosis is present. 
Right panel E-H.  Using the Pw occlusion formulae it is possible to predict the true FFR of 
either the proximal (E and F) or distal stenosis (G and H).  
Adapted from: De Bruyne et al 2000.120 
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Figure 1.17 Bland-Altman Analysis of Apparent and True FFR in tandem stenoses 
 
 
 
Figure 3 from Kim et al 124 (upper panel) was digitised using WebPlotDigitiser 
(http://arohatgi.info/WebPlotDigitizer/index.html) and analysed in Stata v11 using the 
Batplot algorithms. The bias was 0.09146±0.07718 (95% CI -0.05982 to 0.2427).   
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Aims of this thesis 
The aim of this thesis is to understand the behaviour of resting physiology across stenosis 
severity and after coronary intervention to assist in the development of a resting tool to map 
the severity of lesions within a vessel. 
In the introduction I have discussed the role of coronary physiology, in particular what is 
established and what physiological parameters are available for clinical use.  The 
subsequent chapters will focus on upon experiments that explore coronary pressure and 
flow velocity in human patients. 
First, I will seek to understand and define the behaviour of basic physiological parameters 
in patients undergoing coronary catheterisation. This will be done using the largest pressure 
and flow velocity dataset published to date. 
Secondly, I will determine the reproducibility of resting parameters over the short term and 
over a much longer period (6-12 months). 
Thirdly, I will then aim to understand how pressure based indices change after coronary 
intervention in the form of angioplasty. Since coronary pressure can mask a host of other 
physiological changes, I will then seek to determine how coronary flow velocity and 
microvascular resistance change with intervention.  This information will enable models that 
predict the change in coronary haemodynamics based upon  
Finally, this information will be utilised to develop a resting pullback approach that can 
measure the severity of individual stenoses and predict the change in resting 
haemodynamics before coronary intervention is performed.  
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2 Methods 
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2.1.1 Patient Recruitment and Ethical Approval 
All participants recruited into the studies performed as part of this PhD were patients 
undergoing electively planned routine coronary angiography and angioplasty for clinical 
reasons.  The Appendix lists the entry and exclusion criteria. 
 
The majority of the patients were recruited from Imperial College Healthcare NHS Trust at 
the Hammersmith Hospital.  A number of additional patients were recruited from 
collaborating sites, including the John Radcliffe Hospital (Oxford, UK), the Amsterdam 
Medical Center (Amsterdam, The Netherlands), WellStar Cardiology Department, North 
Fulton Hospital (Roswell, Georgia, USA), and the Cardiovascular Institute, Hospital Clínico 
San Carlos (Madrid, Spain).  Details for the involvement of these centres is provided in the 
relevant chapters.   
 
Patients were asked to be involved in the studies according to criteria set-out in the study 
protocols approved by local and national ethics committees (NRES ref: 09/H0712/102 
NCT01118481 and 09/H0712/102-amended August 2011;  NRES ref: 11/LO/1454).  Patients 
were provided with sufficient time to decide over involvement in the studies.  There was no 
specific follow-up of patients required and no specific additional risk posed.  All treatment 
decisions were made clinically and not according to data acquired as part of the research 
protocols. 
 
2.1.2 Cardiac Catherisation, Equipment and Data Acquisition 
2.1.2.1 Cardiac catheterization  
Cardiac catheterization was performed according to standard clinical practice. The majority 
of the studies were performed through the right femoral route via a six French sheath.  A 
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smaller number were performed through the transradial route.  There are no expected 
differences in the physiological information gained via either route as the same catheters 
care utilised.  Unfractionated intravenous heparin was prior to the insertion of any 
intracoronary wires (70-100 IU per kg); additional doses were given to maintain an activated 
clotting time of 250 seconds throughout the case.  Routine diagnostic images were 
acquired by the performing Cardiologist before beginning the study protocol.   
 
Intra-coronary nitrates (300mcg-600mcg) were used prior to the insertion of any 
intracoronary wire and to ensure that the diagnostic images were of the best quality and 
free of catheter-induced spasm.  The nitrates stabilise epicardial resistance and minimise 
changes in the epicardial artery diameter.  Additional doses of nitrate were given at frequent 
intervals as per normal practice during prolonged physiological assessment.   
 
2.1.2.2 Coronary Catheters 
All aortic recordings were made via a 6 French guiding catheter: for the left coronary 
system EBU3.5 or 3.0; for the right coronary artery, JR4-guide.   
 
2.1.2.3 Aortic pressure measurement 
It is typical to measure aortic pressure (Pa) continuously throughout intracoronary 
procedures utilising the fluid-filled hollow guide catheters.  Pressure is transmitted through 
the column of fluid from the tip of the guiding catheter through a connecting tube to a 
pressure transducer integrated into the catheter laboratory haemodynamic system.  The 
height of transducer system was adjusted according to the patient size and position on the 
catheter table, typically 5cm below the sternum and then fixed for each case.  This position 
estimates the location of the aortic root.  The transducer system and the console were 
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simultaneously zeroed by opening the ports to air at the beginning of every case and during 
the case when adjustments to patient position or a new pressure wire was required.   All the 
tubing and manifold system was flushed and kept clear of any bubbles that may interfere 
with pressure tracings.   
 
2.1.2.4 Coronary guidewires, balloons and stents 
The Cardiologist performing the assessments and treatment to coronary stenoses was 
given full discretion to select the coronary guidewires, balloons and stents.  In all cases, 
modern devices, accepted in routine clinical practice, were used.  Drug-eluting stents were 
used in almost all cases. 
 
2.1.2.5 Hyperaemia  
All patients performed at the Hammersmith Hospital had hyperaemia induced using 
centrally administered adenosine (140mcg/kg/min); in all cases this was through a 5 or 6 
French right femoral vein sheath.  In patients recruited from Amsterdam Medical Centre, 
adenosine was administered via a rapid intra-coronary bolus (typically in boluses of 60mcg 
to a total of 120-180mcg of adenosine).   
 
2.2 Specialist equipment utilised for data acquisition 
2.2.1 ComboMap system (model 6800) 
The ComboMap system ((Figure 2.2) processes the information it receives from the 
guidewire (ComboWire), pressure transducer (from the catheter table) and other external 
inputs.  The guidewire connected to the machine via a mobile Pimette which could be 
placed close to the patient during the invasive study but avoid contact with fluids (Figure 
2.3).   
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The console is connected directly to the transducer which receives patient aortic pressure 
from the guiding catheter (Figure 2.4). This is then sent to the catheter laboratory 
haemodynamic system to enable clinical recording and documentation of patient blood 
pressures.  The console also receives analogue ECG data from the patient; this should be 
optimised to ensure the R-wave is the largest point rather than a T-wave.  The R-wave is 
used to determine the cardiac cycle during data processing. 
 
Intravascular blood pressure and/or blood flow velocity measured by the sensors present 
upon the Combowire XT are show in real time on the touch-screen display. Recording is 
selected manually and can only be made prospectively.  Recordings can be ‘book-marked’ 
but separate rigorous notes of the what the data represents and the location in the vessel it 
was recorded must be made.   
 
2.2.1.1 The ComboWire XT  
The ComboWire XT combines both pressure and flow velocity sensors at the tip of a 
steerable 0.014” guide wire (Figure 2.8).  Wire activation required flushing with heparinised 
saline while the wire remained in its housing.  The two connectors (RJ45 type for pressure 
and multi-pin for flow velocity) are connected to the pimmette.  When this is done, the 
console system will activate the wire and start a calibration system.  The best results are 
achieved if the wire is resting flat on the table.  Only once this was completed was the wire 
removed and used; problems reported by the console at this stage meant a new wire was 
chosen.  
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The wire tip is not pre-shaped and caution is required during wire-shaping to avoid the 
sensors housed at the very end of the wire.  In all cases the shaping was performed away 
from the sensors to prevent damage.  Shaping is mandatory to enable the wire to be 
passed into the target coronary artery. 
 
The pressure sensor contains resistors that change their resistance in response to changes 
in blood pressure.  The change in resistance alters the electrical signal sent to the wire and 
which is interpreted by the ComboMap console to generate a blood pressure reading.   
 
The Doppler sensor uses piezoelectric crystals which change shape in response to an 
electric current.  This elicits outward travelling sound waves while inward travelling sound or 
pressure waves causes the crystals to emit electrical currents.  This property enables 
piezoelectric crystals to transmit and receive ultrasound signals.  The system employs a 
pulsed-wave Doppler method to determine blood flow velocity.   
 
2.2.1.2 Acquiring flow velocity data 
The ComboWire must be normalised at the vessel ostium prior to usage (see section below 
on normalisation for details; Figure 2.1).  In short, the purpose of normalisation is to ensure 
that the distal pressure signal derived from the wire and that of the aortic pressure trace 
from the guide catheter are overlapped in both phase and value (starting Pd/Pa ratio of 1.0).   
 
Once ready, the wire must be manipulated to the location of interest - for example, 
proximal and distal to the coronary stenosis of interest.  Appropriate shaping of the wire-tip 
facilitates passage.  On occasions, a more manoeuvrable wire may be placed in the distal 
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vessel first, as a guide for the Combowire.  The other wire was removed prior to 
measurements. 
 
Once in position, careful manipulation of the wire is required to achieve an adequate flow 
velocity trace.  The piezo-electric crystal emits a Doppler signal that elicits a pulsed wave 
velocity signal 4mm from the tip of the wire with a sampling volume of 45 degrees.  Slow 
and careful rotational movements are required while observing the spectral trace on the 
ComboMap system: the aim is to elicit the highest velocity trace possible with the most 
dense spectral trace (Figure 2.5 and Figure 2.6).  For all the recordings made, we also 
sought the complete cardiac cycle to be adequate visualized.  Additionally the sensor 
should be coaxial within the lumen of the vessel, as deflection close to a wall or a branch 
could alter the signal.  Considerable experience and patience is required to elicit optimal 
tracings - this was facilitated at the Hammersmith Hospital where Consultant Cardiologist 
colleagues had almost 10 years of experience of acquiring flow velocity data. 
 
2.2.1.3 Optimising IPV tracking signal 
Once an optimal signal has been elicited, significant effort was made to optimise the digital 
tracking of the spectral trace.  The digital tracking trace (Figure 2.7) represents the 
instantaneous peak flow velocity (IPV).  Only this is available for analysis when the data is 
recorded and later optimisation is not readily available.  Therefore live adjustment of the IPV 
threshold is necessary to elicit the optimal dataset.  Unoptimised signal can contain high 
peaks or entirely flat traces.  Furthermore, it was possible to have tracings that were 
adequate only for part of the cardiac cycle.  We found the best method of achieving optimal 
tracking this was to alter the scale of the spectral trace such that it was small and dense; 
then the IPV threshold would be adjusted (0-3) until the tracing matched closely.  Once this 
was performed, the scale could be expanded again and the tracking would typically remain 
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good.  Once a good trace had been achieved, a recording of at least 10 beats was made.  
In the majority of cases, longer recordings were made (30-60 seconds).  
 
2.2.1.4 Data export and processing 
Data exported by the ComboMap system onto CD or USB for analysis includes the time 
since recording was started, electrocardiogram (ECG), the proximal aortic pressure (Pa), the 
distal coronary pressure (Pd) and the instantaneous peak flow velocity (IPV) and the 
average peak flow velocity (APV). Data is written to a proprietary ‘SDY’ file format at a 
sampling frequency of 200Hz.  SDY files can be read by the Study Manager software 
(Amsterdam Medical Centre, Amsterdam, The Netherlands) or the ComboMap emulator 
software (Volcano Corporation, California, USA).  This can be used to generate text files 
containing the segments of the recording for further analysis in a bespoke Matlab 
environment.   
 
2.2.2 Pressure-Only systems 
2.2.2.1 S5 and Core Console 
The S5 console and Core Console process information from Prestige and Verrata 
Guidewires connected via pimmette.  The console is identical to the ComboMap console 
with the omission of the capacity to record flow velocity.  All other connections to the 
laboratory haemodynamic systems remain the same, as does the recording format and 
export methods.   
 
2.2.2.2 Verrata and Prestige Guidewires 
The Verrata and Prestige (and PrestigePlus) Guidewires measure intracoronary pressure 
using a sensor placed 3cm proximal to the tip of a steerable 0.014” guide wire.  Since the 
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sensor is away from the tip, wire shaping is readily performed without concern.  However, 
its location requires the wire is placed more distally in the vessel.  For both these wires and 
the ComboWires, it was routine to ensure the sensor was at least 6 diameters away from 
the lesion of interest.   
 
2.2.2.3 Aortic pressure measurement 
It is typical to measure aortic pressure (Pa) continuously throughout intracoronary 
procedures utilising the fluid-filled hollow guide catheters.  Pressure is transmitted through 
the column of fluid from the tip of the guiding catheter through a connecting tube to a 
pressure transducer integrated into the catheter laboratory haemodynamic system.  The 
height of transducer system was adjusted according to the patient size and position on the 
catheter table, typically 5cm below the sternum and then fixed for each case.  This position 
estimates the location of the aortic root.  The transducer system and the console were 
simultaneously zeroed by opening the ports to air at the beginning of every case and during 
the case when adjustments to patient position or a new pressure wire was required.   All the 
tubing and manifold system was flushed and kept clear of any bubbles that may interfere 
with pressure tracings.   
 
2.2.2.4 Pressure signal recording 
Live continuous recordings of the Pa and Pd pressure are presented on the console 
systems.  To make a Pressures can be recorded at any time, provided the introducer 
needle was removed and the Y-connector was firmly closed.  No specific manipulation of 
the wire is required to achieve high quality pressure recordings.  
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2.2.2.5 Challenges in optimising pressure recordings: 
 
1. Transducer Height:  Transducer height must be at the of the aorta, since when it is 
above the heart, the aortic pressure trace will be below that of the coronary pressure trace.  
This is readily recognised.  If, however, the transducer is below the heart, then the aortic 
pressure trace is above the distal coronary pressure and can generate an apparent trans-
stenotic pressure gradient.  This can be more challenging to recognise and was sought by 
ensuring both aortic and distal pressure traces had an identical zero.  
2. Normalisation of the pressure traces:  this is particularly important for phasic analysis 
since both pressures and phases must be aligned.  This was performed before the wire was 
introduced distally into any vessel. 
3. Pressure signal drift:  An established problem with the use of pressure wires is that of 
pressure signal drift.  This can be identified at the end of the distal pressure recording when 
the sensor is returned to the ostium.  Provided there is no drift, the Pd/Pa ratio should 
remain at 1.0.  If the value differs from 1.0, then drift has occurred - a result of electrical 
charge developing on the pressure sensor.  Drift may also be identified when the wire is 
distal to a stenosis since the pressure wave-form may take on the appearance of the aortic 
trace.  Measurements were repeated if drift exceeded 2mmHg in cases where passing the 
wire was challenging and in all cases when wire passage was uncomplicated.  The wire 
was normalised before repeating the measurements.  In cases where repeated drift was 
observed, a new wire was obtained.  Drift is a dynamic problem and most drift was 
observed if the wire was used immediately after activation.  To counter this, we pursued 
early activation of the wire by heparinised saline and a long period of the wire resting on the 
table prior to use.  
4. Guide Catheter damping:  The guiding catheter produces a degree of ostial stenosis for 
the vessel; this is particularly problematic for 8Fr and 7Fr.  This is visualised as damping of 
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the aortic signal with loss of the dicrotic notch.   To avoid this, 6Fr guiding catheters were 
used for all the procedures.  Caution was also taken during adenosine infusion since this 
can cause increased intracoronary flow and altered aortic haemodynamics such that the 
guiding catheter is drawn into the vessel: this will cause damping with a reduction of flow 
and under-estimation of distal stenosis significance.  Catheters with side-holes were not 
used since although they appear to generate a normal aortic pressure wave-form, the 
catheter pressure is not truly representative of aortic pressure.   
5. Whipping artefact:  whipping may be observed if the pressure sensor is against the 
vessel wall or is repeatedly striking it.  This can be over-come by withdrawing the wire 
slightly and traces with whipping were not used for analysis. 
6. Erroneous console determination of indices:  the ComboMap, S5 and Core consoles 
also use simple algorithms to calculate the indices of stenosis significance.  In particularly, 
FFR is typically calculated at the points when the ratio is at its lowest.  However, FFR 
should be calculated when there is stable hyperemia which may not represent the lowest 
ratio.  This is particularly problematic with intracoronary adenosine injections where 
continuous recording during the injection phase can give an arterfactual aortic pressure 
trace and therefore an erroneous FFR value.  To counter this issue all traces were 
measured offline using bespoke software in a MatLab environment and the values 
produced by the machine were treated only as a guide.   
 
2.2.3 3N's approach for making resting measurements 
When making physiological assessment at rest, a rigorous standardized approach is 
required to avoid confounding; this is particularly pertinent as resting gradients may be 
smaller than those present during hyperemia.  The approach is encapsulated by the ‘3Ns’: 
Nitrates, Normalise and No Touch. 
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2.2.3.1 Nitrates for epicardial stability 
Intracoronary nitrates should be used liberally and routinely.  Nitrates are used to stabilize 
epicardial resistance which is necessary for all physiological parameters since the 
introduction of the pressure wire will cause a highly variable degree of spasm.  This is 
typically not be visible upon angiography but can significantly alter the distal pressure 
recording.  In absence of nitrates, proximal wire spasm can artificially make a stenosis 
appear more significant while more distal spasm will reduce significance.  This is true for 
hyperemic measurements also. 
 
Typically 300-600mcg of intracoronary glyceryl trinitrate was given prior to all recordings 
and administer this as soon as the guiding catheter is engaged, before the pressure wire is 
passed into the vessel.  If time has elapsed between the last administration and a 
recording, nitrates were re-administered.  
 
The degree of hyperaemia induced by Intracoronary nitrates was formally assessed. Using 
simultaneous pressure and flow velocity measurements, it can be observed that shortly 
after giving nitrates followed by a rapid bolus of saline as a flush, there is 15-20 second 
period of increased flow velocity.  There is then an immediate return to the basal state.  In 
practical terms, since nitrates are administered before the sensor-based wire is introduced 
then by the time the wire is passed and normalized, then any residual flow increase has 
returned to basal levels.   
 
Intracoronary nitrates can reduce systematic blood pressure.  Caution was applied during 
the administration of intracoronary nitrates to limit aortic spill-over.  In routine physiological 
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assessment of the coronary vessels, systemic blood pressure should be maintained with in 
mean arterial pressure of between 60-100mmHg;  below this, auto-regulatory mechanisms 
may fail which will compromise all physiological measurements - both at rest and during 
hyperemia.  Any patients with a marked reduction of blood pressure required intravenous 
fluid resuscitation prior to continuing. 
 
2.2.3.2 Active, Phasic Normalisation 
Second, we ensured that all pressure wires were 'normalised' at the ostium of the vessel 
prior to insertion into the vessel.  This was to mitigate the effect of both drift but also time 
delay between Pa and Pd pressure traces.  When the wire sensor was introduced into the 
ostium of the vessel (e.g. left main stem), the introducer needle was removed and the Y-
connector port is firmly closed.  If the Y-connector is not closed, then blood leak means the 
aortic pressure trace is underestimated.  This step is essential to avoid erroneous 
recordings.   
 
Then time was taken to ensure that the baseline ratio of Pd and Pa be 1.0, but also there 
was no time shift between the traces (Figure 2.1). That is, both Pa and Pd should be entirely 
overlaid throughout the cardiac cycle.  This is critical for the determination of phasic indices 
such as iFR, and if not performed will give an entirely erroneous value.  
 
2.2.3.3 No Touch 
Thirdly, once the wire has been positioned in the location for measurement, effort was 
made to avoid any further touching of the pressure wire.  For optimal resting assessment, 
additional contrast injections were avoided just prior to measurement of the index.  If a 
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contrast injection was necessary, at least 20 seconds were waited before another recording 
was made to allow the impact of submaximal hyperemia to subside. 
 
In the post-PCI state, either after ballooning or stenting, data acquired using a Combowire 
demonstrated that immediately after intervention, residual hyperemia induced by balloon 
occlusion subsides by the time the balloon is withdrawn and the catheters have been 
flushed.  Since both steps are necessary before a repeat assessment is possible for all 
physiological indices, then we observed no significant impact on making measurements in 
the post-PCI state. 
 
2.2.3.4 Special conditions to achieve resting state 
Some have expressed concern that the resting state was challenging to recreate in the 
catheter laboratory.  We did not observe wide fluctuations in the resting gradients if wire 
spasm and movement of the pressure transducer have been excluded.  
Concerns that patients anxiety will affect iFR-FFR relationships can are mitigated as iFR 
measurements in the ADVISE family of studies was performed in typical catheter laboratory 
patients without a specific protocol for sedation. All the iFR measurements to date have 
been made without special preparation of the patient.  This increases the applicability of the 
technology and avoids concerns regarding sedation and recovery times.  
 
2.2.4 Approach for Hyperaemic measurements 
Hyperaemia was produced in a standardised manner using intravenous adenosine 
(140mcg/kg/min) administered via a central vein or by direct intracoronary bolus (120mcg 
IC).  Baseline recordings were made prior administration of hyperaemic agent.  Hyperaemia 
was administered for at least 60-90 seconds.  Recordings were continued throughout 
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administration of the agent and terminated once the haemodynamic state had returned to 
baseline. 
 
Haemodynamic changes in response to hyperaemia lead to at least seven different patterns 
elicited from a routine catheter laboratory population undergoing pressure wire 
assessment.67  This has lead to confusion as when to make hyperaemic calculations which, 
can alter the value determined.69  To avoid differing methodologies, the same approach 
reported by the validation papers for FFR was employed.  Measurements were made during 
a period of stability during the hyperaemic phase. 
 
2.2.5 Calculation of flow velocity-based indices 
Equation 2.1 demonstrates the indices assessed and how the analysis was calculated. 
Lesions were categorized by CFR, calculated by the ratio of whole cycle resting flow 
velocity to hyperemic flow velocity;128 values below 2 and 1.7 have been considered 
abnormal previously and both thresholds were tested.  The hyperemic stenosis resistance 
(HSR) was calculated using the hyperemic trans-stenotic gradient indexed by the 
hyperemic flow velocity; values over 0.80 mmHg/cm.s are abnormal.91  The basal stenosis 
resistance (BSR) was similarly calculated, but utilizes resting trans-stenotic gradient and 
resting flow velocity; values over 0.66 mmHg/cm.s are abnormal.97  
 
2.2.6 Calculation of pressure only indices 
iFR was calculated as a ratio of the distal coronary pressure to proximal coronary pressure 
at rest, using automated algorithms acting over the diastolic wave-free period as previously 
described in ADVISE78 and validated in RESOLVE.109 iFR is measured using intracoronary 
pressure-only, at baseline, without adenosine administration; its clinical cut-point is 0.90 
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while has an ischaemic cut-point of 0.86.79  Stenoses with an iFR "0.89 are likely to have an 
FFR of "0.80 and can be treated with revascularisation while those with iFR values >0.90 
could be deferred.  
IFR can also be calculated during vasodilator-induced hyperemia and is referred to as iFRa 
(iFR with adenosine).  This has a cut-point for ischaemia, 0.66, is based upon the findings of 
CLARIFY study.79   
FFR measurements were performed using a standard technique,129 using the ratio of distal 
coronary pressure to proximal pressure during stable hyperaemia; the clinical cut-point is 
0.80 and has an ischaemic cut-point of 0.75.47 
 
2.2.7 Phasic analysis over the whole cycle and the wave-free period 
Flow velocity, trans-stenotic gradient and microvascular resistance can be assessed over 
the  entire cardiac cycle (e.g. Flowwhole-cycle, TGwhole-cycle , and Rest MVRwhole-cycle ) and over the 
specific diastolic wave-free period during which iFR is calculated (Flowwave free period).  These 
parameters can be assessed during resting basal conditions and also during adenosine-
mediated hyperemia (Figure 2.9).  Microvascular resistance was calculated as shown in 
Equation 2.2.  
 
2.2.8 Pressure Wire Pullbacks 
2.2.8.1 Mechanised pullback  
Prestige PrimeWire Plus and Combowire XT wires were used to perform pressure wire 
pullbacks.  These were performed at rest in a mechanized manner using a Volcano Pullback 
device (R100, Volcano Corporation, San Diego, California; Figure 2.10).  Pullback speed 
was 0.5mm/sec and continued until the pressure sensor reached the left main stem ostium 
or right coronary ostium.  If pullbacks were made with the needle introducer left insitu, then 
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all normalisation and other measurements were also similarly made.  If the needle 
introducer was removed, then the haemostatic valve on the guiding catheter was opened 
sufficient to allow the wire to move without altering the pressure wave-form.  
 
During the pressure wire pullback, regular fluoroscopic recordings of the wire position were 
made, together with time stamps linking angiographic and pressure wire systems.  This was 
used to co-register the pressure wire data with the angiographic location during the off-line 
analysis.  The origin of the pullback and the end of the pullback were used as fixed points 
for the co-registration alignment.  At least four other co-registration points were taken. 
 
If the patient and the haemodynamics could tolerate a long-infusion of adenosine then 
mechanised pullbacks were performed under conditions of adenosine-mediated 
hyperaemia.  The physical set-up of the pullback was identical to the resting pullback.  
 
2.2.8.2 Manual pressure wire pullbacks 
Where possible, manual pressure wire pullbacks were also performed.  The wire was slowly 
withdrawn from the distal vessel by pulling back by hand: this was performed over 20-30 
seconds.  Pressure-wire to angiographic co-registration was performed at the beginning of 
the pullback, once in the mid-point in the vessel and at the ostium.   
 
Pullback analysis was performed as shown in Equation 2.3.  Additional detail is provided in 
the dedicated chapter. 
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2.2.9 Anatomical lesion measurement 
Coronary stenoses length and severity was measured using quantitative coronary 
angiography (QCA; McKesson, San Francisco) using the contrast-filled catheter for 
calibration.  Lesion lengths and severity were measured three times in a blinded fashion, by 
at least two trained QCA operators.  Lengths were then averaged.   
 
2.2.10 Coronary angioplasty methods 
Coronary stenoses were treated by the Interventional Cardiologist at their discretion 
according to clinical factors integrating patient presentation, symptoms and findings of 
other investigations including stress testing.  Physiological parameters collected as part of 
the study were available to the physicians but were not used exclusively to guide coronary 
intervention.  
Coronary intervention was performed by experienced Consultant Cardiologists and 
involved preparation of the lesion with balloon dilatation.  Stent length sizing was performed 
either angiographically, typically using balloon lengths to support sizing, or by optical 
coherence tomography (OCT).  Drug eluting stents were used in the majority of patients, 
with post-dilatation performed in the majority using non-compliant balloons sized according 
to the reference vessel diameter.  Angiographic findings were used as a guide for 
identifying the need for further optimisation, except in those patients in whom OCT had 
been used pre-PCI.  In those patients, OCT was used post-PCI to ensure adequate stent 
deployment and apposition. 
 
When coronary physiological parameters were measured after PCI, care was taken to 
ensure the measuring sensor was placed in the same location after the intervention.  
Intracoronary nitrates were repeated prior to any post-PCI measurements.   
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Equation 2.1 Calculation of pressure and flow based indices 
 
 
 
 
The formulae show the indices of stenosis severity calculated for analysis.  CFR = coronary 
flow reserve.  HSR = hyperaemic stenosis resistance; BSR = basal stenosis resistance; iFR 
= instantaneous wave-free ratio;  iFRa = instantaneous wave-free ratio with adenosine;  FFR 
= fractional flow reserve.   
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Equation 2.2 Calculation of microvascular resistance and transtenotic gradient. 
 
 
These equations can be used at rest or during hyperaemia.  They can be constrained to 
wave-free period or the whole cycle.   
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Equation 2.3 Calculations performed upon pullback data 
 
 
The instantaneous wave-free ratio (iFR) was calculated per heart beat during the pullback.  
The transtenotic gradient over the wave-free period - the time period in the cardiac cycle 
during which iFR is measured, was also measured on a per beat basis. 
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Figure 2.1 Active and Phasic Normalisation 
 
A.  The pressure wire sensor should be normalised at the ostium of the vessel.  In this 
example, a pressure-only wire is being used; the sensor is placed the at the junction 
between the radio-opaque marker and the rest of wire (3 cm proximal to the end of the 
wire).  In combined pressure and flow velocity wires (e.g. Combowire), the sensor is placed 
at the distal tip.  In this example the sensor is at the ostium, this will not affect the 
normalisation process.   
B.  There was initial phase delay between proximal aortic pressure (Pa, red) and distal wire 
pressure (Pd, yellow); while the Pd/Pa ratio over the whole cycle is 1.0, during the wave-
free period in diastole, the ratio is an erroneous 1.08 at the ostium.  Therefore any 
measurements taken would be erroneous.   
C.  After activating the formal normalisation process on the console, the distal pressure 
trace (Pd) is aligned with the aortic trace (Pa) in terms of both pressure values and also in 
phase throughout the cardiac cycle.    
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(Figure 2.2 ComboMap console 
 
 
 
Cartoon of ComboMap console used in the catheter laboratory to collect simultaneous flow 
velocity and pressure data.  Data could be archived using a CD-drive or via raw extraction 
using USB drives.  The data produced by the printer is not sufficient for analysis. Source: 
ComboMap Operators Manual Version 2.1, Volcano Corporation. 
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Figure 2.3 Pimette to connect to pressure-only or pressure and flow velocity wires 
 
 
The ComboMap connected to the guidewire via a mobile Pimette.  This delicate structure 
has two connectors; RJ45-style connection for the pressure wire and a 9 pin connector for 
the flow velocity signal.  A common error leading to failure to acquire data was to allow it 
even small quantities of fluid to enter the connector components.   Adapted from: 
ComboMap Operators Manual Version 2.1, Volcano Corporation.  
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Figure 2.4 ComboMap Connector Panel 
 
 
 
Array of connectors on the ComboMap console.  The aortic transducer receives directly 
from the patient and returns a signal to the catheter laboratory haemodynamic system.  An 
analogue ECG signal was also received.  USB ports could be used for data extraction and 
archiving.   
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Figure 2.5 Example of simultaneous intracoronary pressure and flow velocity 
recording from a Combowire 
 
 
 
 
Three distinct panels are visible.  Upper panel: White line - electrocardiogram reading.  
Middle panel:  Red line - proximal aortic pressure trace;  Yellow line - distal coronary 
pressure trace.  Lower panel: Doppler spectral trace is in the lower panel; flow velocity is 
predominantly diastolic.  The digital blue tracking trace that superimposes over the spectral 
trace has been optimised during data acquisition; this key step is critical to avoid noisy flow 
data which confounds phasic analysis.  On the left-hand side parameters are shown if 
traces have been properly bookmarked during the recording process.  
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Figure 2.6 An example of flow velocity measured at rest and during hyperaemia 
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Figure 2.7 Poor flow velocity tracking on ComboMap 
 
 
Despite good quality spectral trace, the digital tracking can be poor which will significantly 
impair data quality.  Large spikes in the instantaneous peak velocity (IPV) as shown, will 
produce unrealistic flow velocity values. Alternatively, the tracking line may grossly 
underestimate flow velocity.  Optimisation is required at the time of data acquisition since 
post-data processing is challenging if long recordings have not been performed.   
Adapted from: ComboMap Operators Manual Version 2.1. 
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Figure 2.8 Combowire XT 
 
 
Schematic figure demonstrating the features of the ComboWire XT used for simultaneous 
pressure and flow velocity recordings.  Both sensors are at the tip of the wire, rather than 
the more proximally seen in more typical pressure-only wires.  Adapted from: ComboMap 
Operators Manual Version 2.1. 
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Figure 2.9 Flow velocity measurements over the wave-free period and the whole 
cardiac cycle 
 
Simultaneous trans-stenotic pressure and flow velocity measurements permit assessment 
of haemodynamic change before and after PCI.  Flow velocity can be measured during 
adenosine-mediated hyperemia over the entire cardiac cycle (Hyperemic Flowwhole cycle).  It 
can also be measured under basal conditions, over the whole cardiac cycle (Rest Flowwhole 
cycle) or over the specific part in diastole known as the wave-free period (Rest Flowwave-free 
period).  
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Figure 2.10 Volcano R100 Pullback Device 
 
Pressure wire pullback was performed at rest in a mechanized manner using a Volcano 
Pullback device (R100, Volcano Corporation, San Diego, California).  Pullback speed was 
0.5mm/sec. The metal gripper can be used to firmly hold a pressure wire or an IVUS 
catheter.  
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3.1 Abstract 
Background: 
Our understanding of human coronary physiological behaviour is derived from animal 
models. We sought to describe physiological behaviour across a large collection of invasive 
pressure and flow velocity, to provide a better understanding of the relationships between 
these physiological parameters and to evaluate the rationale for resting stenosis 
assessment.  
 
Methods 
567 simultaneous intracoronary pressure and flow velocity assessments from 301 patients 
were analysed for coronary flow velocity, transtenotic-gradient (TG) and microvascular 
resistance (MVR). Measurements were made during baseline and hyperaemic conditions. 
The whole cardiac cycle and the resting diastolic wave-free period were assessed. 
Stenoses were assessed according to fractional flow reserve (FFR) and quantitative 
coronary angiography diameter stenosis percentage.  
!
Results  
With progressive worsening of stenoses, from unobstructed angiographic normal vessels to 
those with FFR"0.50, hyperemic flow falls significantly from 45 to 19 cm/s, (ptrend<0.001) 
in a curvilinear pattern. Resting flow was unaffected by stenosis severity and was 
consistent across all strata of stenosis (ptrend=non-significant). TG rose with stenosis 
severity for both rest and hyperemic measures (ptrend<0.001 for both). MVR declines with 
stenosis severity under resting conditions (ptrend<0.001), but was unchanged at hyperemia 
(2.3±1.1; ptrend=0.19). 
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Conclusions 
With progressive stenosis severity, TG increases. However, while hyperaemic flow falls 
significantly, resting coronary flow is maintained by compensatory reduction of MVR, 
demonstrating coronary auto-regulation. This data supports the notion that resting coronary 
indices provide a stenosis specific assessment of the physiological response of the 
coronary vasculature to the presence of a stenosis.   
 
3.2 Introduction 
The physiological behaviour of human coronary stenoses has been inferred from animal 
experiments that studied changes of flow velocity and pressure in the presence of 
artificially created stenoses.14,130,131  These experiments determined that stenoses created 
by external constriction or ligation had a non-linear relationship between the degree of 
coronary narrowing and trans-stenotic flow velocity and pressure gradient.131   Early 
attempts to replicate this across patients with coronary artery disease were unsuccessful, 
presumably due to the effect of atherosclerosis and cardiovascular risk factors on other 
domains of the coronary circulation.132,133   
 
Since plotting pressure-flow relationships can be challenging in clinical practice, indices 
have been formulated to describe the importance of stenoses.91,134  Those involving both 
pressure and flow velocity measurement have predominantly been used in a research 
setting.71,79,91,135  Pressure-only measurements, being easier to perform, have gained more 
common clinical application. Fractional Flow Reserve (FFR) a pressure-only hyperemic 
measure is treated as a simplified surrogate for flow based upon assessments in animals. It 
has compelling outcome data and is widely advocated to guide coronary assessment. 
Another newer pressure-only index, instantaneous wave-free ratio (iFR) is measured under 
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resting conditions, obviating the need for hyperemic vasodilators such as adenosine.78 
While the rationale for the hyperemic physiological assessment of coronary artery stenoses 
has been extensively validated, resting stenosis assessment has been less extensively 
explored. 
 
The aim of this study is to investigate the coronary pressure-flow relationship in patients 
with and without angiographic evidence of obstructive atherosclerosis under resting and 
hyperemic conditions. The IDEAL dataset is used to analyse 567 human coronary artery 
intracoronary pressure and flow velocity recordings to revisit pressure-flow relationships in 
a large clinical cohort of patients with stable coronary artery disease, representative of the 
clinical ‘real world’.  
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3.3 Methods 
3.3.1 Study population 
This study incorporates the data prospectively collected data from a total of 567 combined 
pressure and Doppler flow velocity measurements in 301 patients scheduled for elective 
coronary angiography at the Amsterdam Medical Centre Amsterdam, The Netherlands 
(n=161), Imperial College London, UK (n=160), the Hospital Clínico San Carlos, Madrid, 
Spain (n=21) and the VU University Medical Centre, Amsterdam, The Netherlands (n=225). 
All the patients recruited were scheduled for physiological assessment and/or coronary 
intervention for the investigation and treatment of stable angina. All subjects gave written 
informed consent for the acquisition of physiological data for study purposes. 
 
Exclusion criteria were significant valvular heart disease, weight >200 kg (determined by the 
catheter laboratory table capacity), angiographically identifiable myocardial bridging or 
collateral arteries and previous coronary artery bypass surgery. Patients with acute ST 
elevation myocardial infarction or non-ST elevation myocardial infarction within 48 hours 
were not included. Measurements were not taken from vessels with infarcted territories 
found on other imaging modalities.  Individual centre recruitment criteria are shown in the 
Appendix.  
 
 
3.3.2 Coronary catheterization 
Coronary angiography and pressure-flow assessments of coronary stenoses were 
performed using conventional approaches via either the femoral or radial artery. 
Intracoronary nitrates (200-300 mcg) were administered in all cases prior to the introduction 
of coronary wires. Contemporary combined pressure and Doppler flow velocity wires 
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(Combowire XT, Volcano Corporation, San Diego, California) were used and the distal 
pressure sensor was equalized with the aortic guiding pressure at the coronary ostia before 
distal passing of the wire. Measurements were made distal to the stenosis at a location of 
at least 3 vessel diameters from the stenosis to minimize the effect of flow turbulence. 
Adenosine was administered by intravenous infusion in 234 vessels and by intracoronary 
bolus injection in 333 vessels (doses 60-150 mcg) as recommended by the American Heart 
Association.38  
 
Doppler signals were optimized carefully to ensure adequate tracking profiles were 
observed. The electrocardiogram (ECG), pressures and flow velocity signals were directly 
extracted from the digital archive of the device console (ComboMap, Volcano Corporation). 
At the end of each recording the pressure sensor was returned to the catheter tip to assess 
the potential of pressure drift. If pressure drift was identified (greater than 2 mmHg) 
measurements were repeated or corrected for upon analysis. Data were analysed off-line, 
using a custom software package designed with Matlab (Mathworks, Inc, Natick, Mass). 
Tracings were only included if adequate flow velocity envelopes were identified. Resting 
indices were calculated at a time of stability, without any preceding injection of contrast or 
saline. Hyperemic indices were calculated during stable hyperemia, excluding ectopy and 
conduction delay. 
 
3.3.3 Coronary Arteries and Stratification 
Stenosed and reference vessels 
567 coronary assessments were made. 366 vessels had an angiographically visible 
stenosis. 201 vessels had no angiographic obstruction as determined by the physician 
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performing the procedure and confirmed by two observers (SN, GW). These 201 vessels 
were used as reference vessels. 
 
Stenosis stratification 
Both FFR and diameter stenosis assessed by quantitative angiography (QCA) were used to 
stratify stenosis severity. Myocardial FFR measurements were performed by using a 
standard technique, using the ratio of distal coronary pressure to proximal pressure during 
stable hyperemia.(Kern et al. 2006) QCA was calculated using a dedicated workstations 
(CAAS II, Pie Medical, Maastricht, The Netherlands; or McKesson, San Francisco, USA), 
which performed automated contour analysis with manual correction limited to situations 
causing artefacts or very tight stenoses. 
 
3.3.4 Calculation of haemodynamic parameters 
Flow velocity was assessed over four periods; first, flow velocity at rest over the entire 
cardiac cycle and secondly over the specific diastolic wave-free period (during which iFR is 
calculated), which was detected using the ECG signals. Flow velocity was also assessed 
during adenosine-mediated hyperaemia over the whole cardiac cycle and the wave-free 
period. The same two time periods in the cardiac cycle, both at rest and hyperemia, were 
used to derive measures of microvascular resistance (MVR) and trans-stenotic gradient 
(TG).  Figure 3.1 shows an example of simultaneous pressure and flow velocity 
measurements, together with the cardiac phases assessed. 
MVR (mmHg cm-1 s-1) is calculated by the dividing distal pressure (Pd, mmHg) by flow 
velocity (cm/s). When calculated for the whole cardiac cycle, values of pressure and flow 
velocity were averaged over an entire heart beat; typically measurements were made as an 
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average over 5 beats. When calculated over the wave-free period, pressure and flow 
velocity data was constrained to that averaged over the diastolic wave-free period.  
Instantaneous wave-free ratio (iFR) was defined as the ratio between distal and aortic 
pressure under resting conditions during the wave-free period specifically. 
For all measurements, computation of the parameters was performed by a single analyst 
blinded to the coronary angiograms or patient specific factors, using an automated MatLab 
script (MathWorks, Natick, MA, USA) with built-in wave-free algorithm (proprietary to 
Volcano Corp, San Diego, CA, USA), as previously described.(Sen et al. 2012) 
 
3.3.5 Statistical analysis 
Categorical data are presented as numbers and percentages, while continuous data are 
presented as mean ± standard deviation. Regression analysis was performed between 
quantitative values to determine the coefficient of determination. Curve fitting was achieved 
by applying 2nd and 3rd order and fractional polynomials. Association between flow 
velocity, trans (dependent variable) and strata of stenosis severity were assessed by 
analysis of variance (ANOVA) with correction for repeated measures followed by post-hoc 
pairwise methods, including Bonferroni, Sidak and Scheffe; this was followed by Tukey 
HSD testing where appropriate. Findings were confirmed using the Kruskal-Wallis testing to 
avoid assumptions of normality. Trends across the strata were assessed with regression 
and a non-parametric extension of the Wilcoxon signed-rank test (nptrend, Stata) and also 
with generalized estimating equations; in all analyses, the findings were the same 
suggesting a robust analysis. The analysis was repeated for TG or MVR as dependent 
variables. A p-value of <0.05 was considered statistically significant. All statistical analyses 
were performed using Stata 11.2 (StataCorp, Texas, USA).    
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3.4 Results 
3.4.1 Patient and vessel characteristics 
567 coronary assessments were derived from 301 patients (age 53.5±22.3 years old, 59% 
male, Table 3.1). No patients had hypertrophic cardiomyopathy or gross hypertrophy 
secondary to hypertension.  
 
Characteristics of the patients and vessels is shown per participating centre in Table 3.2. 
366 (65%) were from vessels with a visible stenosis on coronary angiography, with 85 post 
percutaneous coronary intervention (PCI) measurements. 201 (35%) measurements were 
from vessels free from angiographic disease and which served as reference vessels. For the 
366 vessels with a stenosis, the FFR ranged from 0.28 to 1.07; in 4 stenosed vessels the 
FFR was over 1.0 (1.01, 1.02, 1.03 and 1.07) due to hydrostatic consequences of a vessel 
above the position of the transducer.  
 
The distribution of stenoses was consistent with those typically found in clinical practice 
with mean FFR 0.81±0.16 and mean QCA diameter stenosis % of 46%±21, indicating the 
overall majority was of intermediate stenosis severity (Figure 3.2).  
 
3.4.2 Physiological assessment of reference vessels 
In the 201 reference vessels without angiographic evident stenoses, FFR ranged from 0.85 
to 1.08 with a mean FFR of 0.96±0.04. Overall these findings confirmed the angiographic 
diagnosis of an absence of obstructive epicardial disease. In 23 (11%) of the reference 
cases an FFR >0.80 and " 0.90 was documented, suggesting the existence of abnormal 
epicardial conductance.  
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CFR was measured in all the vessels.  Mean CFR in reference vessels was 2.64±0.76 
(95%CI 2.53±2.74); this was significantly higher than observed in stenosed vessels (CFR 
2.11±0.86), p<0.001.  Stratifying across all the FFR groups in the reference vessels reveals 
a consistent CFR (Figure 3.3), with no significant difference across the subgroups 
(p=0.103).  This confirms there was no obstruction to flow in these vessels.   
 
Overall there was no significant evidence of impaired microcirculatory responsiveness in 
the reference vessels.  Reference vessels responded to adenosine with a 2.93±0.85 fold 
reduction in microvascular resistance.  There was a borderline significant difference 
between the groups using ANOVA but no significant difference between groups was found 
using pothoc testing with pairwise comparisons using side, Bonferroni and Scheffe 
approaches.  The highest reductions in microvascular resistance was observed in reference 
vessels with FFR values of #1.0 (3.15±0.88). 
 
 
3.4.3 Relationship between physiology and anatomical assessment 
In stenosed vessels, the relationship between FFR and anatomical diameter stenosis 
percentage demonstrated significant scatter (R%=0.23, p<0.01;Figure 3.4). Similar findings 
were noted when plotting FFR and anatomical minimal luminal diameter (R%=0.19, p<0.001; 
Figure 3.5).   
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3.4.4 Whole cycle pressure-flow velocity relationships 
A given stenosis has a unique curvilinear relationship between the flow velocity and the TG 
across the stenosis. The pressure-flow velocity relationships over the whole cardiac cycle 
were calculated both during resting and hyperemic conditions, and averaged for each 
stratum of stenosis severity. The mean pressure-flow velocity relationships were stratified 
according to diameter stenosis by formal quantitative coronary angiography (Figure 3.7., 
left panel), and according to FFR classification (Figure 3.7.  right panel). A markedly 
increased dispersion of TG values can be appreciated, when stratified according to 
anatomical severity compared to physiological categorization. 
 
3.4.5 Diastolic pressure and flow velocity relationships 
Pressure-flow velocity relationships were calculated over the wave-free period specifically, 
both at rest and hyperemia. For each stratification, these relationships closely fit the 
pressure-flow velocity curves derived from whole-cycle physiology; curves including the 
wave-free period are shown in Figure 3.6.  
 
Resting wave-free period flow velocity was significantly higher than whole cycle resting 
conditions (p<0.05 for each FFR or QCA stratum), and consistently produced a higher TG, 
both at rest and during hyperemia (p<0.05 for each FFR or QCA stratum). The only 
exception was the TG in reference vessels or with FFR >0.91 under resting conditions, 
where TG was equivalent for whole cycle and wave-free period (1.5±0.2 vs. 1.6±0.2 mmHg 
respectively; p=0.53, and 1.1±0.1 vs. 1.3±0.1 mmHg; p=0.08), where there was no stenosis 
sufficient to cause diastolic pressure separation. Under hyperemic conditions, both a 
consistently higher flow velocity and TG were found during the wave-free period than 
during whole cycle (p<0.05 for each FFR or QCA stratum). 
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3.4.6 Influence of stenosis severity on coronary flow velocity 
Resting coronary flow velocity stratified according to angiographic and FFR strata, is 
depicted in Figure 3.7, upper panel. The numerical relationships between stenosis severity 
and the analysed parameters, as well as the physiological indices, are shown in Table 3.3 
and Table 3.4. Resting coronary flow velocity has no significant relationship with stenosis 
severity whether assessed by FFR or anatomical severity (Ptrend=0.16). Hyperemic flow 
velocity, over the whole cycle and the wave-free period shows a strong statistical 
association and trend to decline with incremental stenosis severity (p<0.001 for all 
assessments).  
 
MVR (Figure 3.7 middle panel) measured at rest showed highly significant trends to fall with 
increasing stenosis severity, during both whole cycle and wave-free period specifically 
(Ptrend <0.001). Hyperemic MVR over the whole cycle was low for all stenosis severities, but 
showed a trend to increase in the most severe strata of stenosis severity (Ptrend =0.01). This 
trend was not observed during the wave-free period under hyperemic conditions, which 
remained consistent across all strata of stenosis severity (Ptrend =0.89 for FFR, and Ptrend 
=0.82 for the anatomical stratification). The trend toward higher values of hyperemic MVR 
over the whole cycle but not during the wave-free period, arises from an increasing MVR 
under the systole specifically (Figure 3.9A). In turn, the higher whole cycle than wave-free 
period MVR in the severe stenoses, is driven by a relative increase in distal systolic 
pressure as compared to wave-free period pressure (Figure 3.9B). 
 
In contrast, TG (Figure 3.7, lower panel) whether measured at rest or hyperemia had strong 
and significant relationships with stenosis severity and followed identical trends, also for the 
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wave-free period (p<0.001 for all assessments). Hyperemic TG was strongly related to FFR 
(R% 0.95, p<0.001) and wave-free period TG was strongly related to iFR (R% 0.97, p<0.001). 
 
A natural incremental hierarchy exists between the physiological states assessed: resting 
whole cycle, the resting wave-free period, hyperemic whole cycle and hyperemic wave-free 
period physiology. This was true for flow velocity and TG (p<0.001 for both); for MVR the 
same hierarchy exists in reverse (p<0.001). When stenoses had diameter stenosis >90% or 
FFR"0.50, the hierarchy was no longer valid with resting flow velocity exceeding hyperemic 
and MVR being lower at rest than during hyperemia suggesting exhaustion of vasodilatory 
reserve. 
 
Identical findings are also found when iFR is used to categorise stenoses (Figure 3.8). The 
findings are also maintained when the post-PCI measurements are excluded or when only 
the post-PCI measurements are analysed (Figure 3.16).  
 
3.4.7 Anatomical stenosis severity and the changes in flow velocity 
When analysed according to the area stenosed or minimal luminal diameter the same 
physiological outcomes for flow, MVR and TG were observed (Table 3.4) as when analysed 
according to FFR or DS%.  
 
When data were analysed according to lesion length, resting flow decreased numerically 
slightly but statistically significantly with increasing stenosis length (Figure 3.10).  Very long 
lesion lengths were the main contributor to the trend.  In stenoses up to 40mm long, resting 
wave-free flow velocity was preserved at 24.1±12.6cm/s;  in stenoses over 40mm in length, 
flow was 19.1±7.9, creating a significant trend (p=0.01) although not a significant difference 
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in mean values by ANOVA (p=0.62) or T-test (p=0.15).  The same was true for whole cycle 
resting flow (18.3±8.7cm/s vs 15.4±1.9cm/s, p=0.23). Hyperemic flow velocity similarly 
diminished from 39.4±22.4cm/s to 26.7±18.8cm/s, demonstrating a strong trend as well as 
a significant difference values.  MVR appeared to be unrelated to lesion length, with no 
significant trends noted for rest or hyperemia.  In contrast, trans-stenotic gradient was 
strongly related to length for all four physiological states (Ptrend <0.001 for all).  All other 
parameters, such as minimal lumen diameter (Figure 3.11) and area (Figure 3.12), were in 
keeping with the results as stratified according to DS% or FFR. 
 
The overall trends and relationships observed remain unchanged when the data is stratified 
according to the presence of diffuse and focal disease (Figure 3.13) or according to singular 
or serial stenosis (Figure 3.14). 
 
 
3.4.8 Relationship between stenosis location and changes to flow velocity 
Conceptually more proximal stenoses impact upon a larger myocardial mass and therefore 
proximal lesions may demonstrate a different pattern of physiological behaviour.  This was 
investigated by assessing the location of the stenosis.  First analysis was performed using 
FFR (Figure 3.19).  The trend analysis shows that overall trends are broadly similar to the 
main cohort (Table 3.7).  
 
Since it is known that FFR values can be influenced by the presence of other disease that 
may be under-appreciated, the relationship was also assessed by anatomical stenosis 
severity as an alternative assessment tool.  In general the same trends were found (Figure 
3.20) and Table 3.8.    
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There appeared to be a significant trend between rest flow and stenosis severity in proximal 
stenoses.  However, analysis by ANOVA revealed no significant difference in mean resting 
flow values across stenosis severities (p=0.204 for both whole cycle resting flow velocity 
and wave-free period flow velocity).  
 
Microvascular resistance at rest showed the most significant relationship with stenosis 
severity when in the mid-vessel.  However, all other assessments of microvascular 
resistance showed no significant relationship with severity. 
 
3.4.9 Adenosine administration route 
Stratification of the data by the administration route of adenosine according to FFR, 
showed findings in keeping with the overall dataset for flow and TG (ptrend<0.001 for all 
phases) (Figure 3.15). Hyperemic whole cycle MVR significantly increased with progressive 
stenosis severity for the intracoronary administration route (ptrend=0.04), but remained 
consistent for the intravenous administration route (ptrend=0.35). During the wave-free 
period, hyperemic MVR was consistent for the intracoronary route (ptrend=0.17) but 
showed a trend to being lower with progressive stenosis severity during intravenous 
adenosine (ptrend=0.03).   
 
3.4.10 Diffuse disease 
Diffuse disease can cause pressure loss or diminish flow velocity.  The presence of 
angiographic diffuse or predominantly focal disease was determined by two independent 
reviewers.  When stratified according to the presence of diffuse disease the same trends 
were observed as seen in the main dataset (Figure 3.13).   
 153 
 
3.4.11 Results according to recruiting institution  
Since there are baseline differences in the risk profiles of the recruiting institutions, an 
attempt to find differences on the results was sought.  The data was analysed according to 
the recruiting institution.  The overall findings were consistent with those of the combined 
dataset (Figure 3.18) 
 
3.4.12 Relationship between coronary vessels 
There are known differences between the coronary arteries.  To investigate this in detail, 
analysis was performed according to the vessel investigated (Figure 3.17).  The same 
trends and statistical behaviours observed in the main analysis was observed on a per 
vessel basis (Table 3.6).  Resting flow was preserved across stenosis severities in all three 
vessels (p>0.6 for LAD and RCA; p=0.10 for LCx), while hyperaemic flow falls with 
worsening stenosis severity (p<0.001 for all).  Resting microvascular resistance falls with 
worsening stenosis severity while hyperaemic resistance remains flat or rises significantly.  
Trans-stenotic gradient is strongly associated with lesion severity (p<0.001 for all).   
 
3.4.13 Relationship between resting indices and FFR  
IFR, measured at rest, was compared to FFR, measured over the whole cardiac cycle 
during stable hyperaemia.  A curvilinear relationship was noted (Figure 3.21) with a highly 
significant correlation (r 0.89, p<0.001) and coefficient of determination (R% 0.79, p<0.001).   
 
The relationship between Pd/Pa with FFR was similarly significant, (r 0.89, p<0.001;  R% 
0.79, p<0.001) (Figure 3.22).  iFR and Pd/Pa were also strongly related, (r 0.98, R% 0.97 
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p<0.001) (Figure 3.23); however, paired analysis demonstrated there was a significant 
difference between the two resting indices (p<0.00001).   
 
Assessment of the difference between iFR and Pd/Pa reveals that iFR is consistently lower 
than Pd/Pa and this size of the difference increases with increase stenosis severity (Figure 
3.23B-D). 
 
Conceptually, giving adenosine should reduce the value of a resting index.  The change in 
the index after the addition of adenosine was compared was assessed in relation to the 
severity of the stenosis (Figure 3.24).  Resting Pd/Pa was lower than FFR in 41 vessels; 30 
reference vessels (mean FFR 1.0±1.03) and 11 stenoses (mean FFR 0.86±0.21).  It was 
lower by a mean of 0.02±0.01 overall.  Pd/Pa was the same as FFR in 22 vessels;  20 of 
these vessels were reference vessels without any obstruction, the remaining two vessels 
had moderate stenoses with negative FFR values. 
 
In 123 stenoses (21.7% of the IDEAL dataset), iFR was numerically the same or lower than 
FFR.  IFR was lower than FFR in 83 vessels; 49 were stenoses (with a mean FFR of 
0.64±0.22) and 34 were reference vessels (mean FFR 1.0±0.02).  In the stenoses, iFR was 
0.09±0.07 units lower than FFR while in reference vessels if was 0.01±0.01 units lower.  IFR 
was the same as FFR in 40 further vessels; 14 were stenoses with a mean FFR of 
0.87±0.13, 26 were reference vessels with a mean FFR of 0.98±0.02. 
 
The flow response of vessels with an FFR the same or higher than the resting index was 
investigated.  In reference vessels, there was no difference in CFR between those with an 
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FFR that was lower than iFR and those in which the resting index was lower (2.62±0.70 vs 
2.68±0.90 respectively, p=0.61). 
 
In stenoses, when the iFR is lower than FFR the CFR was also significantly lower than when 
FFR was lower than iFR (CFR 1.39±0.63 vs 2.26±0.82, p<0.001).  This suggests there may 
be microcirculatory disorder that fails to respond to adenosine to give a falsely negative 
FFR, while the resting index suggests flow limitation. 
 
In 34 stenoses, the iFR value was positive (iFR "0.89) but the FFR was negative (FFR 
>0.80).  In 85% of these, the CFR was abnormal (CFR<2.0); the overall mean CFR was 
1.55±0.39.   
 
3.4.14 Diagnostic classification match between indices 
The diagnostic classification match of the indices was assessed.  Since the classification 
match will be dependent upon the distribution of the stenoses, a V-Test analysis was 
performed to identify areas of discrepancy (Figure 3.25). 
 
IFR matched FFR diagnostic classification 100% for stenoses with FFR values of >0.95 and 
<0.65.  The nadir of classification match, 60%, was when stenoses were closest to the FFR 
cut-point of 0.80.  This compared favourably to HSR, considered a gold standard of 
stenosis significance - which matched with FFR only 20% at the FFR threshold.  BSR 
mimicked HSR.  CFR showed low diagnostic match throughout.  
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ROC Analysis 
Receiver operating curves were plotted using FFR and HSR as the gold standards.  IFRa, 
BSR and FFR produced the highest AUC to match ischaemia classified by HSR (Figure 
3.26), and Table 3.9 and Table 3.10.  This remained true when only moderate stenoses, 
either defined by FFR (0.6-0.90) or by diameter stenosis (50-70%).   
 
3.4.15 Pressure derived CFR measurements 
Reports have suggested it is possible to compute CFR using pressure only 
measurement.136  In our cohort, we sought to compare pressure-derived CFR with flow 
velocity derived CFR.  The scatter plot showed only a weak but significant correlation 
coefficient (r) of 0.11 (p=0.02).  The R% was very low at 0.01 but statistically significant 
(p=0.02). 
 
The correlation was improved if only vessels with angiographic stenosis were separated 
from reference vessels (Figure 3.27).  In vessels with angiographic stenosis, the r was 0.22 
p<0.001, while in reference vessels it was r =-0.038, p=0.65.  The R% for stenoses was 0.05 
(p<0.001). 
 
3.4.16 Total Vessel Resistance 
The total resistance in the vessel was computed by adding microvascular resistance with 
stenosis resistance for each physiological state assessed, at both rest and hyperaemia.   
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Under resting conditions, when stenoses are stratified by anatomical significance (Figure 
3.28), there is no significant difference in total vessel resistance across categories.  This 
was true for both whole cycle (p=0.06) and wave-free period physiology (p=0.07, both 
confirmed to be non-significant on Tukey-HSD posthoc testing.   
 
When stratified according to FFR (Figure 3.29), stable TVR is noted across all FFR strata 
until FFR values fall below 0.60; in these vessels there is a significant increase in TVR 
(p<0.001) which is true whether the whole cycle or the wave-free period is assessed.   
 
Although TVR is shown to be stable across the majority of the stenoses, it can be seen that 
this is achieved by falling microvascular resistance while stenosis resistance rises with 
stenosis severity (for both FFR and diameter stenosis classifications).   
 
There is no significant difference between resting stenosis resistance whether calculated 
over the whole cycle (essentially BSR) or the wave-free period (iSR) (p=0.24, paired analysis 
across the whole cohort;  all p-values non-significant (p>0.07) when assessed per FFR 
strata and p>0.23 when assessed per Diameter stenosis Strata).  
 
However, paired analysis shows that total vessel resistance measured over the wave-free 
period was significantly lower than TVR calculated over the whole cycle (4.44±2.0 vs 
6.31±2.72, p<0.001).  This is because microvascular resistance over the wave-free period is 
significantly lower, across the entire cohort (3.99±1.94 vs 5.84±2.54, p<0.001) and per 
strata (p<0.0001 for all strata of FFR).   
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Under conditions of hyperaemia, across the whole cohort total vessel resistance is lower 
than resting TVR whether measured over the whole cycle or the wave-free period.  
However, there is a significant increase in TVR with increasing stenosis severity whether 
assessed by FFR (p<0.0001) or by diameter stenosis (p<0.0001).  In the most severe 
stenoses, in which vessels have FFR"0.60, the TVR observed during hyperaemia over the 
whole cycle was not different from that observed at rest (hyperaemia 6.05±3.17 vs 
5.54±2.42, p=0.10).  This was also true for stenoses with diameter stenoses #60% 
(5.26±3.85 vs 4.78±2.71, p=0.37).   
 
Stenosis resistance is increased by the induction of hyperaemia - hyperaemic stenosis 
resistance (HSR) was statistically higher than basal stenosis resistance (BSR) in all strata of 
lesion severity, except when FFR"0.60 (p=0.23 and p=0.90 for the lowest two FFR strata; 
p=0.08 for FFR"0.60).  This was also true for anatomical definitions of coronary disease, 
where there was no difference between HSR and BSR when diameter stenosis exceeded 
70% (p=0.97).  
 
Microvascular resistance during hyperaemia was lower than resting MVR during the wave-
free period for all strata with FFR>0.60; when FFR"0.60, there was no significant difference 
in resistance (wave-free period MVR 2.59±1.38 vs hyperaemic whole cycle MVR 2.80±1.36, 
p=0.40).   
 
TVR during hyperaemia over the wave-free period was significantly lower than over the 
whole cycle for all strata of anatomical and FFR classified disease.  Stenosis resistance 
calculated over the hyperaemic wave-free period was higher than HSR when stenoses were 
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non-significant - that is FFR>0.80.  When FFR"0.80, there was no significant difference 
(p=0.32).   
 
Microvascular resistance was significantly lower for all strata compared to the whole cycle 
(p<0.001 for all stratifications).  
 
Overall, these findings suggest that under the resting state, total vessel resistance is stable 
regardless of the presence of a stenosis.  Resting microvascular resistance declines in 
direct proportion to increases in stenosis severity. 
 
 
3.4.17 Assessment of the reduction in microvascular resistance 
The wave-free period reduces resistance during the whole cardiac cycle by focusing 
assessment during diastole.  Adenosine reduces resistance by altering the entire cardiac 
cycle.  Previously the CLARIFY study had suggested the wave-free period had a more 
consistent reduction in resistance than offered by adenosine, which had a wider scatter.79 
However, the CLARIFY study was a small study and we sought to replicate the results in 
the larger international dataset. 
Analysis was performed to assessed the magnitude of reduction achieved by adenosine or 
by application of the wave-free period (Figure 3.30). 
Considerable scatter was noted during hyperemia; the mean reduction in resistance for 
vessels with an anatomical stenosis evident was 2.6±0.99 fold compared to the resting 
whole cycle.  In reference vessels, the resistance was reduced by 2.9±0.90 fold which was 
significantly higher than in stenoses (p<0.001).   
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During the wave-free period, resistance was reduced 1.59±0.37 fold in stenoses, and 
1.44±0.19 in reference vessels;  stenoses produced a greater reduction in resistance 
(p<0.001), with the most severe stenoses showing the most reduction.  Scatter was less 
marked than over the whole cycle.   
 
Measuring the resistance reduction offered by the wave-free period measured during 
adenosine infusion, a marked scatter was produced.   
 
When the gain in resistance reduction is compared, using HSR as an independent arbiter, 
there is no significant difference between whole cycle with adenosine and resting wave-free 
period.  In HSR positive stenoses (99 stenoses in total) , MVR was reduced by 1.83±0.55 
fold by the resting wave-free period, while it was reduced by 1.99±0.76 (p=0.16).   
 
In 271 HSR negative stenoses, there was a greater reduction in resistance offered by 
adenosine-induced hyperaemia than the wave-free period (2.82±0.97 vs 1.50±0.22, 
p<0.001).   
 
3.4.18 Why does Hyperaemic Microvascular resistance increase in severe stenoses? 
To determine why hyperaemic microvascular resistance rises with increasing stenosis 
severity, analysis was performed during hyperaemia, over the whole cycle, during systole 
and during the diastolic wave-free period.  Analysis was performed using FFR as the 
stratification for stenosis severity (Figure 3.9)  
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Since hyperaemia can alter stenosis classification, further analysis was performed using iFR 
(Figure 3.31).  Using a resting diastolic classification of stenoses, the rise of systolic 
resistance with worsening stenosis severity is amplified.  
 
Since stenosis classification by pressure-alone can falsely identify non-flow limiting 
stenoses as being significant, HSR stratification was also performed (Figure 3.32).   
 
Overall the same consistent trends were observed.  At extreme stenosis diastolic distal 
pressure rises under hyperaemia while flow continues to fall.  Systolic pressure falls linearly 
as does flow (Figure 3.33).   
 
The findings suggest that under hyperaemia, in extreme stenoses, there is destabilisation of 
the normal physiological patterns that exist normally in milder and moderate stenoses. 
 
One explanation for the observed rise in MVR when using hyperemic whole cycle 
measurements can be attributed to the impact of the collateral circulation in severe 
stenoses.  Because collaterals connect with the receiving vessel distal to the position of the 
Combowire, flow supplied by the collaterals will not be detected, while collateral pressure is 
transmitted through the vessels and can be detected by the wire.  
 
As microvascular resistance is calculated as the ratio of distal pressure which is elevated by 
collateral supply, and the flow velocity of the obstructed vessel (which will not detect the 
impact of collaterals) then the calculated MVR may be observed to rise accordingly.  
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When using whole cycle pressure values, the contribution of the elevated pressures is 
higher than when using the lower diastolic pressure values.  Prior work suggested collateral 
pressure is elevated mainly during systole and much less so during diastole. In the graphs 
above, it can be seen that systolic Pd pressure is significantly higher than diastolic/wfp Pd 
– which would fit with the previous work.137  
 
Overall, it seems plausible that collateral pressure contributes and elevates MVR during 
systole (and thus whole cycle measurements), but not during diastole or wave-free period. 
Further work to assess the collateral flow or pressure during diastole is required to 
understand this in detail. 
 
3.4.19 Predicting physiology based upon anatomical factors 
Several attempts have been made to predict FFR using anatomical parameters.  A 
multivariate model consisting of percentage diameter stenosis, percentage area stenosed, 
minimal lumen diameter and length of stenosis.  The model predicted the variance in FFR 
with an R% of 0.35 (p<0.001).  All components were significant predictors (p<0.001) with the 
exception of stenosis area (p=0.07).  However, with multivariate logistic regression, only 
lesion length was a significant predictor of a positive FFR with an OR of 1.05 (95% CI 1.02 - 
1.08), p<0.001.  The most optimal predictor of a negative FFR was stenosis diameter (AUC 
0.75, 95% CI 0.69-0.81), which was significantly higher than the AUCs achieved by the 
other anatomical factors (QCA AUC 0.25 95%CI 0.19-0.31;  length 0.34 95% CI 0.27-0.41;  
percentage area 0.23 95% CI 0.17-0.29).  
 
Work with CT-Coronary angiography have suggested that lesion length / MLD4 is a good 
predictor of positive FFR.138 In this cohort there was a poor relationship between this 
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parameter and FFR, with an R% of 0.18 (p<0.001); AUC for a positive FFR was 0.78 
(p<0.001).  However, it was not a significant predictor of FFR on logistic multivariate 
regression (OR 1.00, (95% CI 0.99-1.01).  
 
Predicting the hyperaemic flow based upon anatomical and physiological parameters 
Using multiple regression, with a model that included FFR, trans-stenotic gradient, 
microvascular resistance, % diameter stenosis, lesion length, percentage area of vessel 
stenosed, area of the stenosis, length of the analysed segment, the presence of serial and 
diffuse lesions was able to describe 60% of the variance in hyperaemic whole cycle flow (R% 
0.60, p<0.001).  The strongest predictors were, as anticipated FFR, trans-stenotic gradient 
and microvascular resistance (p<0.004).  The presence of diffuse disease was also 
significant factor that reduced hyperaemic flow with a coefficient of 7.1±3.1 (p=0.02).   
 
In contrast, for resting flow over the wave-free period, the only significant factor was the 
reduction in microvascular resistance (coefficient -7.1±0.55, P<0.0001).  
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3.5 Discussion 
In this study we describe the relationship between flow velocity, pressure and 
microvascular resistance, estimated from measurements obtained over the whole cardiac 
cycle or selectively within the wave-free period under resting and hyperemic conditions. 
 
Firstly, we show that non-hyperemic coronary flow velocity remains constant across the full 
spectrum of stenosis severities. Secondly, we show that this preservation of flow is 
mediated by a reduction in resting microvascular resistance in response to increasing 
stenosis resistance. Thirdly, we show despite the maintenance of resting flow velocity it 
occurs at the expense of distal coronary pressure, which falls with widening TG with 
increasing stenosis severity. The capacity for resting gradients to increase while preserving 
flow velocity lends support to the clinical use of invasive resting coronary pressure 
assessment to establish functional stenosis significance. 
 
Finally, we provide reference values stratified according to angiographic diameter stenosis, 
of parameters used in physiological assessment of the coronary circulation (Table 3.4). 
 
 
3.5.1 Auto-regulation ensures that resting myocardial blood 
The maintenance of resting coronary flow velocity is regulated by endogenous adenosine 
release, changes in intrinsic myogenic tone, endothelial cell signalling, and neurohumoral 
control which combine to produce continuous auto-regulatory adaption of arteriolar vessel 
diameter.139,140  In this study, we use invasively measured coronary flow velocity as a 
surrogate for volumetric flow assessment, and found that this was stable in human 
coronary arteries across a wide range of stenosis severities. Whilst the resistance imposed 
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by a stenosis rises according to the Hagen-Poiseuille equation,126 we observe a reduction in 
microvascular resistance to compensate (Figure 3.7). This reduction is closely related to 
stenosis severity keeping resting flow stable and therefore, for the majority of truly 
moderate stenoses, a vasodilator reserve should be expected. This is observed by a 
reduction in resistance in presence of a hyperemic agent, such as adenosine used in this 
study.  
For stenoses with very little physiological impact, a large vasodilatory reserve is present 
meaning a large potential increase in flow during hyperemia. This has been observed in 
positron emission tomography (PET) studies where myocardial flow rises most when 
stenoses are trivial.77  In more significant stenoses however, vasodilatory reserve will 
become progressively exhausted, with limited increase in flow response to an exogenous 
vasodilator. When a critical stenosis severity is reached (likely to be exceeding 85-90% 
diameter by formal QCA measurement, or FFR values below 0.60 as seen in our findings), 
coronary auto-regulation becomes saturated with limited vasodilatory response to 
exogenous agents such as adenosine. When a stenosis is beyond this critical point then 
resting flow velocity is also expected fall. Clinically this may manifest as angina on 
increasingly lower levels of exertion.  
 
 
3.5.2 A unique dataset to define physiology across human patients 
Whilst this has been shown in animals with external constrictors placed in open-chest 
models, and in humans undergoing PET – anatomy was used to define stenosis severity.  It 
is well established now that anatomical definitions of stenoses have limited value.  This is 
the first study to define stenoses according to physiology, using FFR, a commonly used 
reference standard that has been emphasized in clinical guidelines.  We have also utilized 
other commonly available physiological parameters in a comprehensive approach that has 
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not been performed before.  Furthermore, we provide a phasic analysis, assessing flow 
within the wave-free period while previous work has been limited by using only whole cycle 
averages.   
 
3.5.3 Anatomical and physiological markers of stenosis severity 
Cursory assessment of Figure 3.7 may suggest that FFR-classification and anatomical-
classification of stenoses are equivalent as the same patterns of change in flow and 
resistance are observed. However, as shown by many authors, there is a limited 
relationship between FFR and anatomical severity, which is confirmed in this cohort (Figure 
3.4).  The assessment is presented, not to state that anatomy and physiology are 
equivalent, rather because the overall trends are so strong that they are preserved even 
when the random scatter of the FFR-QCA relationship limits the potential relationship. 
Since anatomical assessment of stenoses remains the mainstay and is readily understood 
by clinicians making day-to-day decisions for patient care, it is appropriate to consider the 
underlying physiological response to an anatomical parameter, despite the crude limitations 
of diameter stenosis.  Figure 3.7 shows that when stratified according to diameter stenosis 
%, shows remarkable overlap with respect to the TG for the 50 – 59 and 60 – 60% groups 
as well as the 70 – 79 and 80 – 89% groups. This observation further indicates that 
angiographic stenosis assessment show great physiological overlap in stenosis of 
intermediate severity. 
 
 
3.5.4 The use of resting parameters to assess stenoses  
The stability of resting flow velocity for the majority of stenoses means that resting flow 
velocity alone cannot distinguish between stenosis severities. However, since distal 
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coronary pressure falls with increasing stenosis severity and falling microvascular 
resistance, a combined pressure and flow velocity measurement such as baseline stenosis 
resistance (BSR) or a resting pressure-only index such as iFR, can distinguish between 
different stenosis severities. This implies that non-invasive imaging modalities such as 
single photon emission computed tomography or PET, that measure myocardial perfusion 
without knowledge of distal coronary pressure, require induction of the hyperemic state, 
either by exercise or pharmacological vasodilators, to yield satisfactory diagnostic 
accuracy.141  
 
The change in a resting TG is predominantly driven by a change in microcirculatory 
resistance and the resistance imposed by the stenosis. Since the impact of physiological 
vasodilation at rest on the proximal driving pressure is negligible, changes in distal pressure 
represent the true physiological impact of the stenosis on the distal coronary bed. Small 
gradients at rest suggest little compensatory vasodilatation is required, while large 
gradients indicate substantial compensation. For a stenosis to have a physiological impact 
upon the vessel, it should therefore have a gradient that is detectible at rest and the 
induction of hyperemia only exacerbates this gradient; these may benefit from 
revascularization. Stenoses without a resting gradient which manifests only upon 
vasodilator administration more likely represents a situation in which the microcirculatory 
bed retains the capacity to dilate significantly and high flow velocities can be generated 
across a trivial stenosis with subsequent turbulence and pressure loss by the Bernoulli 
phenomenon.101  These changes may be manifest as a high (normal) coronary flow reserve 
(CFR), but a low (abnormal) FFR value. Invasive human data with 10 year follow-up confirm 
that when such patients are deferred from percutaneous coronary intervention, the clinical 
event rate remains very low – demonstrating a clear paradox between measurements of 
pressure and flow.87  
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3.5.5 Microvascular remodelling 
Resting microvascular resistance reduces with increasing stenosis severity. Theoretically, 
microcirculatory angiogenesis and arteriogenesis could explain this.142  However, if this 
phenomenon applies, it would not only be restricted to the resting situation and a 
substantial reduction in microvascular resistance would remain during hyperemia in flow 
limiting lesions. Our results indicate that this is not the case and instead we confirm 
observations from smaller studies, that hyperemic microvascular resistance actually 
appears to increase in critical stenoses.71,79,143  Various hypotheses may explain this 
phenomenon of increased hyperemic microvascular resistance with increasing stenosis 
severity. Hong et al, found that an artificial chronic LAD stenosis led to concentric 
remodelling of the small intramyocardial arterioles in a porcine model, which could possibly 
cause the raised microvascular resistance we found in severely diseased coronary 
arteries.144  However, Verhoeff et al found the revascularization of severe stenoses lead to a 
normalization of the microcirculatory response to hyperemia, suggesting a functional and 
rapidly reversal process is culpable.145  Since the microcirculation is pressure-distensible 
then a significant stenosis will reduce perfusion pressure with consequent reduction in 
microvascular distension. As resistance increases with the 4th power of vessel radius, then 
a significant increase in microvascular resistance is expected; removing the stenosis 
improves distal flow and thus restores normal microvascular behaviour.145  Furthermore, 
vasodilatation in other capillary beds in response to systemic adenosine administration 
could mean a superadded steal occurs and reduce proximal driving coronary pressure67 
leading to a compensatory vasoconstriction.71  Finally, the role of collaterals should be 
considered as in severe stenoses as there appears to be an impact of collaterals on the 
calculation of hyperemic microvascular resistance.143,146  Our findings suggest that the 
increased MVR in severe stenoses under hyperemic conditions appears to primarily be a 
 169 
systolic phenomenon. Because collaterals connect with the receiving vessel distal to the 
position of the Combowire, flow supplied by the collaterals will not be detected, while 
collateral pressure is transmitted through the vessels and is detected. Collateral pressure is 
mostly elevated during systole and much less so during diastole and thus could falsely 
increases MVR during whole cycle, but less pronounced during the wave-free period.137 
 
 
3.5.6 Animals and human coronary arteries 
Previous work focused upon animal models. Typically, young animals with little 
microvascular disease and smooth, unobstructed coronary arteries are used, other than 
that created by the investigator using external constrictors or compression. Since the 
obstruction is imposed from the outside there is a smooth endoluminal surface. 
Accordingly, frictional energy loss may be less than for a stenosis with an identical diameter 
stenosis but with more credible surface as found in humans. External constriction may also 
give very severe highly focal and discrete lesions, unlike the intermediate stenoses that are 
typically assessed in humans. Newly created severe stenoses in animals may contribute to 
local ischemia which may disturb both resting and hyperemic flow. In contrast, the majority 
of human stenoses assessed in stable disease will have taken some time to develop with 
corresponding microcirculatory compensation, flow adaptation and potentially in severe 
stenoses collateralization. Highly focal stenoses will accentuate turbulence related energy 
loss, meaning that distal pressure will be lower for a given rise in flow velocity compared to 
less discrete stenoses.  
Finally, human patients often have microcirculatory changes caused by a combination of 
diabetes, smoking, hypertension and chronic hypercholesterolemia that mean the human 
microcirculatory bed may respond differently to stenoses, as well as the means to 
interrogate them such as hyperemic agents.  
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Despite the anatomical differences, it is reassuring that human data across a wide 
spectrum of patients has similarities to the animal data collected. This strongly suggests 
the findings are credible representations of in vivo physiology. 
 
3.5.7 Value of wave-free period and resting physiology 
The findings of this study provide further details of the role of resting coronary physiological 
assessments.   The relationship between pressure and flow means that at rest, flow velocity 
alone cannot readily distinguish between mild, moderate and severe stenoses, since the 
pressure gradients generated may be similar despite the stenoses being distinct (Figure 
3.34).   
 
The wave-free period constrains assessment to a time when flow velocity is naturally 
higher, meaning that stenosis assessment occurs at a time when pressure gradients are at 
their largest at rest.  Therefore it provides additional diagnostic information at rest.  
 
Therefore while a resting flow based index cannot distinguish between stenoses, resting 
pressure gradients can.  Having the largest pressure gradient for a given stenosis severity 
will aid diagnosis most and this can be achieved at rest by using the wave-free period 
rather than the whole cardiac cycle (Figure 3.34). 
 
The increase in flow velocity over the wave-free period appears consistent across stenoses, 
as demonstrated by the consistent reduction in microvascular resistance (Figure 3.7). The 
increase is also consistent for true for tandem and diffuse lesions (Figure 3.13 and Figure 
3.14).  This enables the possibility of assessing the pressure loss of individual stenoses that 
are in series - without the difficulties of stenosis interaction.   
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3.5.8 Low pressure gradients at rest and high gradients during hyperaemia 
One concern of resting indices has been that there may be patients who have little gradient 
at rest, but have a significant pressure gradient detectable during hyperaemia.   
Whilst vasodilator reserve may be exhausted in very severe stenoses, there may be others 
in which the vasodilator reserve is preserved.   It is interesting however, that if flow does 
rise significantly, for example if flow can rise more than 2-3 times that present at rest 
(equivalent to a CFR of 2-3) then even if a pressure index suggests it is ‘significant’ because 
the value has fallen below a cut-off – it clearly cannot be limiting flow, as flow can be 
demonstrated to rise significantly.  This phenomena is driven by the Bernoulli effect and 
even a mild stenosis can generate a significant pressure gradient if there is sufficient 
increase in flow velocity across it.  A pressure-only index is blinded to the change in flow, 
while the combined indices such as HSR avoid this problem.  This problem can be 
identified by assessing the resting and hyperemic gradient together: if there is only a trivial 
resting gradient but a marked hyperemic gradient, then CFR is typically normal or high.101  It 
can be seen from Panel B in Figure 2 that few stenoses with a significant hyperemic 
gradient had no resting gradient at all; furthermore, when they did, the CFR was high. 
A criticism of this explanation has been that resting flow may be ‘low’, meaning that the 
hyperemic flow velocity appears artificially higher.  This has been expressed differently, 
including the suggestion that a given vessel or patient may require an even higher CFR than 
2-3 to be normal.   However, as we show in Table 3.3 and Table 3.4, resting flow velocities 
in non-significant stenoses are not substantially different from resting velocities in 
significant stenoses – suggesting ‘too low’ resting flow does not happen in the patient 
cohort reported here.  
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3.5.9 CFR in normal 
Although the reference vessels had a wide range of FFR values recorded, the lowest being 
0.85, there was no obstruction to flow.  CFR was normal and was significantly higher than 
found in stenosed vessels.  This suggests that hyperaemic pressure loss can occur through 
even mild perturbations of the endothelial surface which do not limit coronary flow velocity.   
 
These phenomena have been described as a consequence of the Bernoulli phenomenon 
where high flow across mild perturbations can cause large pressure drops due to energy 
loss created by turbulence.  Gould predicted this with pressure-flow curves that show that 
in even in the absence of a stenosis, a considerable pressure gradient could be created if 
the flow was high enough.15 
 
This likely contributes to the well established poor relationship between FFR and CFR - 
which in some data series has been reported to have only a 60% diagnostic agreement.  It 
also raises the possibility that if an FFR of 0.85 can be generated without an overt stenosis, 
that when a stenosis is present, how much of the value is generated by the stenosis itself 
rather than other pressure loss.  This is critical to determine if the purpose of identifying 
pressure-loss causing stenoses is to facilitate selection for revascularisation.  
 
3.5.10 Differences in patient groups 
One particular strength of this dataset that is useful for future analysis and studies is the 
diversity of the patient groups.  Indeed differences exist between patient populations of the 
different institutions, probably based on differences in clinical practice (e.g. the risk strata of 
patients sent to cardiac Catherisation), ethnic diversity, inclusion and exclusion criteria of 
study populations etc. This adds significant value to the dataset by making it more 
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representative than a small local dataset restricted to a narrow, and specific geography.  
Future analyses could assess the impact of race, gender and geography.   
 
 
3.5.11 Clinical implications 
First, we provide comprehensive flow velocity and resistance data from a wide spectrum of 
coronary stenoses and reference vessels. This data is valuable for the accurate 
development and improvement of computer flow dynamics model. Not only does this 
support research but also clinical tools such CT-FFR, which has found wide scatter in 
determining FFR based upon anatomical definitions alone. Limitations of existing models 
are that data is derived from animals or from small human studies without significant 
disease. Increased efforts must be expended in modelling the microvascular response to 
stenoses and appreciating the more limited responses of flow increase than observed in 
animal models. Improved algorithms for CT-FFR may lead to better prediction of invasive 
FFR and therefore clinical utility for patients at intermediate risk of coronary disease. 
Furthermore, the data presented here provides reference values stratified according to 
stenosis severity for the most commonly used physiological indices in patients undergoing 
coronary Catherisation. Exploration of the behaviour of less commonly used physiological 
parameters such as the instantaneous hyperemic diastolic velocity-pressure slope 
(IHDVPS) and zero-flow pressure (ZFP) may also be of future interest to better indicate their 
clinical applicability. 
 
Second, the data supports the concept that stenosis interrogation under resting conditions, 
as suggested by iFR, BSR or baseline Pd/Pa  78,79,97,109 has clinical utility beyond comparisons 
of classification match with hyperemic measures. We show that while resting flow is stable, 
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pressure gradients change with progressive stenosis severity with changes in resting 
gradient being in tandem with hyperemic gradients. The resting gradient reflect the 
physiological impact of a stenosis on the coronary bed – microvascular resistance changes 
occur when stenoses are important leading to a measurable change in distal pressure. 
When distal pressure is not significantly different from aortic, then the pressure-flow 
relationships of the vessels are similar to those seen in unobstructed reference vessels. 
This indicates that the absence of a resting gradient might be enough to safely defer 
revascularization. As an extension of this, the findings demonstrate that the wave-free 
period consistently provides a higher flow velocity and a lower resistance than assessment 
over the whole cardiac cycle at rest. This means resting gradients are consistently larger 
than over the whole cycle which may provide greater sensitivity in moderate stenoses. 
Prospective randomized clinical outcome studies including DEFINE-FLAIR and iFR-
Swedeheart will assess this formally.   
Third, the finding that flow velocity is preserved across stenosis severities under resting 
conditions can be applied to technologies that aim to predict the outcome of coronary 
haemodynamics upon stenosis removal. Clinical utility will be derived from the capacity to 
predict the change in coronary physiology prior to performing PCI in complex and tandem 
coronary disease. 
 
 
3.5.12 Limitations 
This study has a number of limitations. First, while the reference vessels were deemed 
angiographically unobstructed, this does not entirely preclude the presence of diffuse 
atherosclerotic disease that could account for pressure loss.(Bruyne et al. 2001) 
Secondly, volumetric flow was not assessed because of the limitations of accurate stenosis 
and vessel dimension calculation, as well as determining the mass of the subtended 
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myocardium can only be estimated from angiographic parameters. Theoretical models that 
estimate volumetric flow based on estimations of myocardial mass using a simplified 
approach of tapering an averaged mass, suggest that volumetric flow diminishes 
significantly from the proximal to distal vessel. The conservation of mass similarly suggests 
that at each vessel branch point the volume of flow would diminish, but since vessels taper, 
flow velocity will fall moderately less than volumetric flow.134,147,148   
Wedge pressure was not routinely measured and therefore definitive assessment of the 
impact of collaterals on the results cannot be made. However, measurements were not 
made in vessels with visible collaterals.  
While the reference vessels were free of angiographic disease, intravascular ultrasound 
studies have demonstrated significant burden of atherosclerosis in apparently unobstructed 
coronary arteries.121 Diffuse atherosclerosis can cause pressure loss which is accentuated 
under hyperemia and this may account for the wide-range of FFR values observed (lowest 
obtained 0.85). It remains uncommon to routinely perform intravascular imaging in 
unobstructed vessels, particularly when an alternative cause of angina is present in other 
vessels: therefore, together with the large size of unobstructed vessels, the findings should 
be applicable to patients undergoing invasive assessment.  
Although we have stratified data according to FFR and QCA diameter stenosis, both are 
imperfect measures. In the presence of microcirculatory dysfunction, FFR may 
underestimate true hemodynamic stenosis significance.149  QCA provides limited 
information of the physiological impact of a given stenosis. However, both measures are 
easy to comprehend and familiar to clinicians providing a familiar conceptual framework to 
interpret the data. Hyperemic stenosis resistance (HSR) and baseline stenosis resistance 
(BSR) could be used but are functions of pressure and flow and would thereby artificially 
alter the results.  
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Finally, It must be borne in mind however, that our results are inferred on group basis and 
heterogeneous factors such as microvascular dysfunction and diffuse epicardial disease 
could obscure these findings on a patient specific level.25,150  Theoretically however, any 
factor that impairs auto-regulatory responses to a stenosis could also impact upon 
microcirculatory responses to vasodilators such as adenosine. When there are 
discrepancies between resting and hyperemic factors, it remains unclear which parameters 
provide prognostic information. Randomized clinical outcome studies are currently being 
undertaken to assess the safety and performance of resting parameters to guide 
revascularization.54,110  
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3.5.13 Conclusion 
9&).%C2-&) 
This large retrospective multicentre study of trans-stenotic pressure-velocity measurements 
of stenosis severity suggests applicability of the general principles of coronary physiology 
determined in animals to patients with atherosclerotic lesions. The main difference 
observed is a relatively blunted response to hyperemia: flow velocity rose to half what has 
been observed in animal models in vessels with less than 50% diameter stenosis. This may 
explain the lack of obvious advantages in discriminatory power when hyperemic indices are 
plotted against resting indices in patients with increasing lesion severity.  
 
3.5.14 Synthesis 
The key findings from this study are that: 
1. Resting flow is stable across stenosis severities, regardless of how classified 
2. Resistance falls to maintain stability of flow 
3. Resting flow is still stable with serial, diffuse and complex disease 
4. Resting pressure is the marker of disease severity rather than flow velocity 
 
Therefore, a it is possible to assess stenosis severity using pressure alone at rest, and 
achieve a high degree of classification match with hyperaemic and flow-based measures.   
Following these findings, it remains to be determined what the reproducibility of pressure 
and flow measurements is over a short period pertinent to clinical assessment (e.g. 10 
minutes) and over a longer period pertinent to on-going care (e.g. 6-12 months). 
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3.6 Tables 
Table 3.1 Demographics and stenosis characteristics 
!
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Table 3.2 Baseline characteristics according to recruiting institution 
!
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Table 3.3 Flow velocity, TG, MVR and physiological indices 
!
!
!
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Table 3.4 Flow velocity, transtenotic gradient, microvascular resistance and 
physiological indices according to lesion severity defined by anatomical 
stenosis severity (% diameter stenosis) 
!
!
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Table 3.5 Trend analysis for the relationship between flow velocity, 
microvascular resistance and transtenotic gradient with stenosis anatomical 
parameters 
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Table 3.6. Trend analysis by vessel 
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Table 3.7. Trend analysis by stenosis location in vessel - stratified by FFR 
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Table 3.8. Trend analysis by stenosis location in vessel - stratified by diameter 
stenosis 
. Trend analysis for the relationship between flow velocity, microvascular 
resistance and trans-stenotic gradient per Stenosis Location in vessel when 
stratified by anatomical severity (Diameter stenosis %). 
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Table 3.9. Receiver Operating Characteristics compared to FFR and HSR 
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Table 3.10. Differences in Receiver Operating Characteristics compared to 
HSR 
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3.7 Figures 
Figure 3.1  Example of simultaneous coronary pressure and flow velocity 
measurement 
 
 
Top panel: Example of simultaneous coronary pressure and flow velocity measurement 
obtained distal to a LAD stenosis of 69% diameter stenosis by QCA with FFR of 0.79. 
Bottom panel: The analysed phases during the resting and hyperemic state respectively are 
shown. 
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Figure 3.2  Physiological and anatomical distribution of the coronary arteries 
assessed 
 
 
Distribution of the coronary arteries measured stratified according to both diameter 
stenosis % (upper panel) and FFR (lower panel).  
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Figure 3.3 Average CFR in reference coronary arteries without angiographic 
obstruction, stratified according to the FFR detected.  
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Figure 3.4  Relationship between stenosis diameter and FFR 
 
 
Distribution of stenosis diameter and FFR in the stenosed vessels. Despite a significant 
inverse correlation between diameter stenosis % and FFR, a substantial variability between 
the two parameters is noted. The curve was fitted by 2nd order polynomial and regression 
analysis was R%=0.23, p<0.01. 
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Figure 3.5 Relationship between minimum lumen diameter (MLD, mm) and FFR 
!
 
Minimum lumen diameter (MLD, mm) and fractional flow reserve.  A significant relationship 
was noted (R% 0.19, p<0.001). 
!
!
! !
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Figure 3.6 Relationships between transtenotic gradient and flow velocity 
 
Relationships between TG and flow velocity for coronaries grouped by stenosis severity (left 
panel according to anatomical severity by QCA, and right panel according to physiological 
severity by FFR). Relationships are described by TG = A*flow + B*flow2 and can be fitted by 
three points: the zero TG – zero flow crossing, the mean TG and flow during whole cycle at 
rest, and during hyperemia. Curve-fitting was performed by 2nd and 3rd order and 
fractional polynomial and regression analysis. The TG and flow during the wave-free period 
closely follow these relationships, both at rest and during hyperemic conditions. In this  
curves are fitting all plotted points.  
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Figure 3.7 . Behaviour of phasic coronary flow velocity, transtenotic gradient 
and microvascular resistance 
 
 
Behaviour of phasic coronary flow velocity, MVR and TG according to stenosis severity (left 
panel diameter stenosis by QCA, and right panel by FFR). Curves are fitted by 2nd and 3rd 
order fractional polynomial. Parameters are shown for resting and hyperemic conditions, 
both during whole cycle and wave-free period only. 
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Figure 3.8  Behaviour of phasic coronary flow velocity, transtenotic gradient 
and microvascular resistance when stenoses are classed by iFR 
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Figure 3.9 The relationship of microvascular resistance with increasing 
stenosis severity 
 
 
Panel A: Resting microvascular resistance (MVR) on Left and hyperemic MVR on 
Right is regressed against FFR.  
Left: With increasing stenosis severity, at rest MVR falls.  This is observed during diastole 
and systole.  However, systolic MVR always remains above diastolic MVR.   
Right: Under hyperaemic conditions, MVR rises during systole (dashed line), while the 
diastolic period during hyperaemia continues to show a trend to falling with increasing 
stenosis severity (purple line).  When averaged over the whole cycle during hyperaemia, 
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there is an increase in hyperaemic MVR.  This suggests the overall drive for increase in 
MVR in severe lesions is driven by changes in systole.   
 
Panel B: Resting and Hyperemic distal pressure and flow velocity are stratified 
according to systole or wave-free period and regressed against FFR.   
Left - Under resting conditions, both systolic and wave-free period (wfp) pressure fall with 
increasing lesion severity, but resting flow is unchanged.  Therefore overall resting MVR 
falls with increasing stenosis severity predominantly due to a reduction in distal pressure. 
Since diastolic pressure is lower than systolic pressure, then diastolic MVR is lower than 
systolic MVR. 
Right - Under hyperemic conditions, in mild stenoses, resistance is predominantly low 
because flow velocity is high.  As severity increases both pressure and flow fall significantly.  
The fall in diastolic pressure plateaus while the systolic pressure continues to fall linearly.  
Systolic flow falls with increasing severity but in critical stenoses appears to exceed 
diastolic flow.  Systolic pressure continues to exceed diastolic pressure in critical stenoses.   
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Figure 3.10  Relationship between lesion length (mm) with flow velocity, 
microvascular resistance and trans-stenotic gradient 
 
  
 199 
Figure 3.11  Relationship between stenosis diameter with flow velocity, 
microvascular resistance and trans-stenotic gradient. 
 
 
The relationship between flow velocity, trans-stenotic gradient and microvascular 
resistance according to stenosis diameter.  Stenosis diameter is divided into quintiles (5 
being the largest diameter and 1 being smallest).  
  
 200 
Figure 3.12  Relationship between stenosis area with flow velocity, 
microvascular resistance and trans-stenotic gradient. 
 
The relationship between flow velocity, trans-stenotic gradient and microvascular 
resistance according to stenosis area.  Stenosis diameter is divided into quintiles (5 being 
the largest diameter and 1 being smallest).  
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Figure 3.13  Relationship between flow velocity, transtenotic gradient and 
microvascular resistance according to the presence of predominantly focal or 
diffuse disease 
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Figure 3.14 Relationship between serial and singular stenoses with flow 
velocity, microvascular resistance and transtenotic gradient 
 
Flow velocity, trans-stenotic pressure gradient and microvascular resistance for single or 
serial stenoses. 
 203 
Figure 3.15   Relationship between hyperemic flow velocity, transtenotic 
pressure gradient and microvascular resistance stratified according to 
administration route of adenosine (intracoronary or intravenous). 
!
Flow velocity, trans-stenotic pressure gradient and microvascular resistance according to 
whether intracoronary or intravenous adenosine was used. 
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Figure 3.16  Impact of Inclusion and exclusion of post-PCI data 
!
Flow velocity, trans-stenotic pressure gradient and microvascular resistance across for the 
entire cohort, only the pre-PCI measurements and only the post-PCI measurements 
demonstrating that the overall physiological findings are preserved regardless of the post-
PCI measurements. 
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Figure 3.17   Relationship between hyperemic flow velocity, transtenotic 
pressure gradient and microvascular resistance stratified according to the 
vessel being assessed 
!
Flow velocity, trans-stenotic pressure gradient and microvascular resistance according to 
the epicardial vessel assessed.   
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Figure 3.18 Relationship between hyperemic flow velocity, transtenotic 
pressure gradient and microvascular resistance stratified according to the 
recruiting institution 
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Figure 3.19.  Relationship between hyperemic flow velocity, transtenotic 
pressure gradient and microvascular resistance stratified according to 
location of the stenosis in the coronary artery and FFR 
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Figure 3.20 Relationship between hyperemic flow velocity, transtenotic 
pressure gradient and microvascular resistance stratified according to 
location of the stenosis in the coronary artery and diameter stenosis 
!
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Figure 3.21 . Scatter plot of iFR and FFR for the IDEAL dataset 
 
 
Scatter plot of iFR and FFR for the IDEAL dataset.  Regression line shown in red, 
using a quadratic fit.  R! 0.79 P<0.001. 
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Figure 3.22 .  Scatter plot of Pd/Pa and FFR for the IDEAL dataset 
 
 
Scatter plot of Pd/Pa and FFR for the IDEAL dataset.  Regression line shown in red, 
using a quadratic fit.  R! 0.79 P<0.001. 
 
 211 
Figure 3.23 .  IFR and Pd/Pa relationships 
A.   
 
B. 
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C.   
 
 
D. 
 
A. The relationship between iFR and Pd/Pa at rest.  B.  Relationships of iFR and Pd/Pa 
with FFR.   C.  The difference between iFR and Pd/Pa according to stenosis severity  
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Figure 3.24  The impact of adenosine on rest measure 
 
Delta between resting index and FFR according to stenosis severity.  123 vessels had iFR 
values that were the same as or less than the FFR value.   
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Figure 3.25  V-Test assessment of indices classification match with FFR 
 
 
Diagnostic agreement for each index is plotted against FFR per 0.05.  This enables 
visualisation of where the greatest mis-match is likely to occur, and the degree of 
mismatch.  
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Figure 3.26 . Receiver Operator Characteristic Curves for indices compared to 
HSR 
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Figure 3.27  Pressure derived CFR 
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Figure 3.28  Total vessel resistance (calculated by microvascular resistance 
+stenosis resistance) according to anatomical stenosis severity 
 
 
 
TVR is calculated over the whole cardiac cycle and the wave-free period; it is calculated at 
rest and during stable hyperaemia.  
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Figure 3.29.  Total vessel resistance (calculated by microvascular resistance 
+stenosis resistance) according to stenosis severity determined by FFR 
 
 
 
TVR is calculated over the whole cardiac cycle and the wave-free period; it is calculated at 
rest and during stable hyperaemia.  
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Figure 3.30  Reduction in microvascular resistance offered by hyperemia and 
the wave-free period 
 
 
Graphs show the reduction in microvascular resistance achieved by adenosine over the 
whole cycle (left), the wave-free period at rest (middle) and the wave-free period during 
adenosine infusion (right). 
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Figure 3.31  . The relationship of microvascular resistance with increasing 
stenosis severity when stenoses are classified by iFR  
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Figure 3.32. The relationship of microvascular resistance with increasing 
stenosis severity when stenoses are classified by HSR 
The relationship of microvascular resistance with increasing stenosis severity.   
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Figure 3.33 Phasic microvascular resistance during systole 
 
 
 
 
With increasing stenosis severity, hyperemic MVR rises during systole (dashed line), while a 
more consistent flat pattern is observed during the wave-free period (purple line). Overall, 
the greater impact on systole means that overall whole cycle MVR rises in severe lesions 
during hyperemia (blue line). 
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Figure 3.34   Pressure-Flow relationships suggest increased flow velocity over 
the wave-free period provides greater pressure gradients to distinguish 
between stenoses. 
 
 
 
Adapted from Gould, K. L. 1978. “Pressure-Flow Characteristics of Coronary Stenoses in 
Unsedated Dogs at Rest and during Coronary Vasodilation.”  Circulation Research 43 (2): 
242–53. 
 
 
 224 
4 Short term reproducibility of pressure-
only indices 
 225 
4.1 Introduction 
Basal resting indices of coronary stenosis severity, such as the instantaneous wave-free 
ratio (iFR) and the basal stenosis resistance (BSR) could promote physiologically-guided 
coronary intervention by avoiding the side-effects, time-added and cost of adenosine 
administration.  
Recent study data from the DEFER study shows that clinical outcomes from patients with 
stenoses which were not causing ischaemia as defined by an FFR #0.75 had excellent 
clinical outcomes out to 15 years.  There was no significant difference in cardiac death or 
revascularisation in patients who had non-ischaemia causing lesions.119  The implication is 
that stenoses which are not flow limiting in a stable disease cohort do not significantly 
progress over a long period of time.  Since DEFER utilised FFR, a hyperaemic index, a 
further inference tis that hyperaemic indices do not significantly change over time if they are 
not flow limiting.     
Basal indices may, however, be susceptible to haemodynamic changes that fluctuate over 
time which may reduce their reliability.  This is particularly important because basal indices 
work within a narrower band of flow velocity and trans-stenotic gradient.  Small fluctuations 
over time may alter diagnostic classification. 
Short term reproducibility of iFR, performed within a long segment of basal recording 
(within 1 minute) was excellent (r=0.996, p<0.001).78  Studies utilising algorithms developed 
by other groups have also shown excellent reproducibility when performed 2 minutes 
apart.89  
We sought to determine the reproducibility of iFR and FFR 10 minutes apart, which is a 
time frame clinically applicable for most catheter laboratory cases.   
We also sought the reproducibility of the indices and the nature of pressure and flow 
velocity, when repeated at 6 months and 12 months.    
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4.2 Methods 
4.2.1 Study population 
Patients scheduled to have elective pressure wire assessment of intermediate coronary 
stenoses were prospectively enrolled to have repeated measurements made at rest and 
during hyperaemia during the same procedure.  The decision for physiological assessment 
was made by the physician responsible for their care.   Patients were recruited from the 
Imperial College Healthcare NHS Trust.  The protocol was approved by local institutional 
review boards and ethics committee and patients provided written informed consent (NRES 
09/H0712/102; NCT01118481). 
 
 
4.2.2 Coronary Catheterisation 
9&4&)+41!9+*0#*#4-2+*-&) 
Coronary angiography and pressure wire assessments of coronary stenoses were 
performed using conventional approaches.  Intracoronary nitrates were administered in all 
cases before pressure wires were introduced.  All patients received intravenous heparin 
according to weight to ensure an ACT of 250. 
 
Measurements were made according to the flow chart shown in Figure 4.1.   Pressure wires 
were normalised at the coronary ostia at the beginning of the procedure.  Once the stenosis 
was crossed, a recording of at least 5 beats was made to determine Pd/Pa and iFR 1.  The 
wire was then withdrawn to the ostium to assess for pressure wire drift: a recording of drift 
was made.  After 5 minutes, the wire was re-introduced and care was taken to ensure the 
location was the same as at recording 1.   A further resting measurement was made (Pd/Pa 
and iFR 2).  Intravenous adenosine was infused at 140mcg/kg/min and FFR was calculated 
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during stable hyperaemia (FFR 1).  The wire was then withdrawn and drift assessment was 
repeated.  Finally, after waiting for 10 minutes, the wire was re-introduced and a repeat 
resting assessment was made (Pd/Pa and iFR 3);  adenosine was administered again,  
 
 
 
4.2.3 Haemodynamic recordings 
Pressure wire recordings were made using the Prestige Pressure Guide Wire Plus (Volcano 
Corporation, San Diego, California).  Digital haemodynamic data was extracted from data 
storage systems (S5 console, Volcano Corporation) and processed off-line in a core 
laboratory using a custom software package with Matlab (Mathworks, Inc., Natick, 
Massachusetts).  
 
4.2.4 Calculation of Pd/Pa, iFR and FFR 
iFR, Pd/Pa and FFR were calculated as described in the main methods section.  
Hyperaemia was induced by adenosine infusion at a rate of 140mcg/kg/min, administered 
by femoral venous access in all cases.   
 
4.2.5 Drift correction 
Since drift was sought shortly after distal measurement, a simplified approach was used to 
correct for pressure-wire related drift.  To perform this correction, the index of Pd and Pa 
pressures at the vessel ostium was determined;  this was done either over the whole cycle 
or over the wave-free period.  The difference of this ratio from 1.0 is then calculated;  if the 
ratio exceeded 1, then this difference is deducted from the distally measured iFR or Pd/Pa.  
If the proximal ratio was below 1, then the difference is added to the distally measured 
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index.  For example, if the distal iFR is 0.81 and at the ostium a pressure ratio of 1.02 is 
calculated over the wave-free period, then 0.02 can be deducted from the 0.81, to give a 
final iFR value of 0.79.  Similarly, if the distal FFR is 0.72, and the postal pressure ratio is 
0.99, then a value of 0.01 is added to the distal value, to give a final FFR of 0.73.   
 
4.2.6 Data analysis 
Statistical analysis was performed using STATA version 11 (StataCorp, Texas).  Values are 
expressed as mean ± standard deviation.  Continuous variables were compared using the 
Student t test and using the repeated measures ANOVA. The relationship between the 
repeated measures were quantified by  Pearson’s product moment correlation coefficient, 
linear regression and a Bland-Altman plot.   
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4.3 Results 
4.3.1 Patient demographics 
Patient demographics are shown in Table 4.1. 26 stenoses in 25 patients were assessed in 
total.  A total of 20 stenoses in 20 patients were included in the final analysis due to 
protocol deviations in the other cases.   
 
4.3.2 Change in haemodynamics 
There was no significant change in proximal aortic pressure over the whole cycle or the 
wave-free period during any of the repeated measures (P>0.80 for all comparisons) [that is, 
there was no difference in Pa during rest].  Distal pressure, similarly did not change 
significantly (P>0.88 for all comparisons).   
 
Heart rate was unchanged across repeated measures at rest (P=0.668), and across 
repeated hyperaemic measures (p=0.83).  However, heart rate during hyperaemia was 
significantly faster than during rest (68.6±12.2 vs 74.1±10.2, p=0.006).  Similarly, aortic 
pressure was significantly lower during adenosine infusion than at rest (103.9±19.1 vs  
92.9±20.4, p<0.001).   
 
However, resting heart rate and aortic pressure measured 10 minutes after administering 
adenosine was not statistically different from measures made at rest before adenosine was 
administered (p=0.09 for heart rate and p= 0.86 for aortic pressure).  This suggests that 
resting conditions restored within 10 minutes of adenosine infusion. 
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4.3.3 Repeated measures 
The values of the indices is shown graphically in  
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Figure 4.2.  The mean values of the indices are shown in Table 4.2.  The mean 
delta between the indices is shown in  
 
 
Table 4.4.  There was no significant difference between any of the indices, with p>0.86 for 
all three indices on either repeated measures ANOVA or step-wise paired T-Testing.   
 
Pearson’s correlation coefficient was highly significant for all combinations (r >0.97, 
p<0.001 for all). Regression analysis demonstrated highly significant coefficient of 
determination between the repeated indices (R% #0.94, p<0.001 for all). 
 
The majority of the values were within the 95% limits of agreement between the indices.  
There was no gross bias observed.  The mean difference between repeated rest measures 
was 0.01 pressure units;  the mean difference between FFR measurement was 0.006.  
Comparing the mean difference in iFR between measures and the mean difference in FFR 
between measures found no significant difference (p=0.20).  
 
A single iFR value had a large change between readings 1 and 2 .  Raw trace analysis 
demonstrates that the initial recordings were made with damping of the pressure trace.  
Review of the angiogram suggests an ostial lesion of the assessed vessel was under-
appreciated which may have impacted upon the initial readings.  Second and third readings 
were made with the guide-catheter disengaged which gave consistent readings.  
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4.3.4 Degree of drift 
Drift was assessed on three occasions in each patient; at each time, drift over 
cycle and over the diastolic wave-free period was assessed.  The mean 
the vessel ostium to assess the degree of drift is shown in   
 
 
Table 4.4.  The degree of drift observed was not significantly different between the time 
points it was measured, and it was not different when measured phasically (p=0.72 across 
the whole cycle and p=0.68 across the wave-free period).   
 
4.3.5 Drift correction 
IFR, Pd/Pa and FFR can all be corrected according to the degree of drift observed.  Drift 
correction was sought but did not alter the results reported because the magnitude of drift 
was small (Table 4.4).   
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4.4 Discussion 
 
4.4.1 Short term reproducibility study 
This study demonstrates the following points.   First, that repeated measures of iFR, Pd/Pa 
and FFR are closely matched.  These findings are consistent with other published 
reproducibility studies.  
 
Second, that the difference in resting indices between repeated measures is small and not 
significantly different from the difference in repeated hyperaemic measures.   
 
Thirdly, we observe that resting physiology is restored within 10 minutes of exposure to 
adenosine.   This suggests that repeated resting measurements are feasible after recent 
adenosine exposure and this means that iFR-FFR hybrid approaches in different territories 
will be valid, even if adenosine was required for another territory.   
 
Finally we observe that pressure wire drift was small in the majority of cases.  This was 
within the constraints of performing short physiological assessments with assessment for 
drift shortly after the measurement of interest was performed.  Drift is a time-dependent 
phenomenon, with drift more likely occur when there are long delays between initial 
pressure normalisation and drift assessment.  In this protocol, drift assessment was made 
promptly and therefore, little drift was noted.  Longer study protocols may benefit from drift 
correction using the approach described in the methods.  
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4.4.2 Limitations 
An important limitation remains that the protocol did not specifically specify re-
administration of intracoronary nitrates prior to every recording.  Intracoronary nitrates are 
essential in stabilising epicardial resistance and even small fluctuations could alter the value 
of a resting index.  Although there was no significant difference between iFR readings, the 
mean value numerically increases and this may be due to changes in epicardial resistance. 
 
This remains a small cohort.  Only those cases that adhered to the protocol have been 
included in the final analysis; whilst other data sets do include repeated measurements, 
since there may be other sources of variability, they were not utilised for reproducibility 
assessment.  A more detailed reproducibility study is being performed as part of the 
ORBITA study which aims to recruit 200 patients (NCT02062593).151 
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4.5 Tables 
Table 4.1  Short-term reproducibility study demographics 
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Table 4.2 Mean Index values during reproducibility assessment 
 
 
 
Table 4.3 Delta values for indices during reproducibility assessment 
 
 
 
 
Table 4.4  Mean degree of drift observed.  The mean value of the pressure ratio 
over the whole cycle or the wave-free period (wfp) is shown when the sensor 
is returned to the ostium.  A value of 1.0 suggests no drift. 
 
 
 
 237 
4.6 Figures 
Figure 4.1 Flow chart to assess the short term reproducibility of pressure-only 
indices.  
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Figure 4.2 Reproducibility of pressure only indices 
 
 
For resting indices, iFR and Pd/Pa, readings 1 and 2 are taken 5 minutes apart; reading 3 is 
taken after 10 minutes after reading 2 and is performed after an infusion of adenosine.  For 
FFR, both recordings are made using the same dose of adenosine infusion 
(140mcg/kg/min); FFR 2 is made 10 minutes after the first. 
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Figure 4.3 Degree of change of pressure only indices 
 
Individual index values on repeat measurement.  
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5 Resting coronary artery 
haemodynamics remain stable when 
reassessed at 6 months and 1 year: 
Results of the REPEAT Study (Reproducibility 
of Resting Physiological Parameters and 
Adenosine-mediated Tests) 
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5.1.1 Introduction 
For further assessment of the stability we sought the reproducibility of the indices and the 
nature of pressure and flow velocity, when repeated at 6 months and 12 months.   
 
Patients who were undergoing serial angiographic follow-up as part of a larger study 
underwent simultaneous pressure and flow velocity measurements.  Cohort A had 
measurements performed at 6 months, while Cohort B had measurements performed at 12 
months.   
 
 
5.2 Methods 
5.2.1 Study Population 
A total of 27 patients with moderate coronary artery lesions undergoing serial coronary 
angiography as part of a study protocol at Emory University agreed to have simultaneous 
pressure and flow velocity measurements.  Patients were recruited in a non-randomised 
non-sequential manner from Emory University Hospital, Atlanta.  Inclusion criteria included: 
age over 18 years old and moderate coronary stenosis by angiographic assessment.  
Exclusion criteria were severe valvular disease, previous ST-elevation myocardial infarction, 
a left main stem lesion of >50%, a serum creatinine of >150µmol/L and patients who had 
had a previous CABG. All subjects gave informed consent for participation in the study, in 
accordance with the protocol approved by the local ethics committee. 
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5.2.2 Study Protocol 
Pressure and flow velocity measurements were made using a 0.014inch pressure and 
Doppler sensor-tipped wire (ComboWire® XT, Volcano Corporation, San Diego, CA).  The 
wire was normalised at the vessel ostium prior to any measurements.  Heparin 70-100IU/kg 
was administered prior to introduction of the wire.  Intracoronary nitrates (exceeding 
300mcg) were given before all recordings to stabilise epicardial resistance.  
Physiological recordings were made distal to the target coronary stenosis in the left anterior 
descending artery (LAD).  Measurements were made at rest and during adenosine-induced 
hyperaemia (central intra-venous access, at 140mcg/kg/min).  Optimal pressure and flow 
traces were obtained by careful manipulation.   
The EKG, pressures and flow velocity signals were directly extracted from the digital 
archive of the device console (ComboMap®).   Traces were analysed in a blinded fashion in 
a central core lab using a bespoke Matlab (Mathworks, Inc, Natick, Mass) environment 
without access to patient clinical or angiographic data.  
At the end of each recording the pressure sensor was returned to the catheter tip to assess 
for pressure drift.  
Patients returned for repeat angiographic and physiological assessment: 17 had 6 month 
follow-up and 9 had 12 month follow-up.   
Repeat measurements were made with the Combowire sensor placed at the same 
angiographic location as performed on the first study using anatomical markers to guide 
wire placement. 
 
5.2.3 Calculation of Pressure-only indices 
All data analysis was performed offline at the Core Laboratory at Imperial College London. 
Data analysis was performed in a blinded manner, without knowledge of clinical details or 
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angiographic data.  An adequate flow envelope was sought by core lab inspection of the 
pressure and flow velocity traces.  A minimum of five high quality heart beats were sought 
for analysis.  
iFR was calculated as a ratio of the distal coronary pressure to proximal coronary pressure 
at rest, using automated algorithms acting over the diastolic wave-free period.  iFR is 
measured using pressure-only, at baseline, without adenosine administration  (iFRa was 
calculated over the diastolic wave-free period  during stable hyperaemia induced by 
adenosine infusion (140mcg/kg/min). 
Pd/Pa ratio was calculated using the ratio of distal coronary pressure to proximal coronary 
pressure at rest over the entire cardiac cycle. 
FFR measurements were performed using a standard technique4, using the ratio of distal 
coronary pressure to proximal pressure during stable hyperaemia.  Hyperaemia was 
induced by adenosine infusion at a rate of 140mcg/kg/min, administered by femoral venous 
access in all cases. 
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5.2.4 Definition of flow based intracoronary indices 
 
!
5.2.5 Statistical analysis 
All data are expressed as mean± standard deviation or median (25th-75th Quartiles), as 
appropriate. Changes in resistance for each index are in relation to the whole cycle 
resistance at rest. 
We determined the sample variance (probability distribution) of the observed microvascular 
resistance values, of each index, as an estimate of true variance of the entire patient 
population using STATA (version 11, StataCorp, Texas, USA). The variance of the reduction 
in resistance for each of the three indices was compared using the F-test. A value of p<0.05 
was deemed significant.   
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5.3 Results 
 
5.3.1 Study population 
27 patients were recruited.  1 patient was excluded due to poor flow velocity traces which 
made analysis challenging; leaving 26 patients in total.  All 26 patients had baseline analysis 
(BASE).  17 returned for 6 month (6FU) and 9 for 12 month assessment (12FU).  
Demographics are shown in Table 5.1. There was no difference in the baseline 
characteristics between those attending for 6FU vs 12FU. 
 
5.3.2 Coronary haemodynamic stability over the follow-up 
Table 5.2 summarizes the principle coronary haemodynamic variables measured, 
comparing data at baseline visit 1 with data acquired at the same location on follow-up 6-
12 months later (visit 2).   
Under resting conditions, there was no significant difference in mean arterial pressure, 
systolic or diastolic blood pressures and heart rate when compared between visit 1 and 
visit 2.  This was true across the 6FU and 12FU subgroups and across the whole study 
group.   
Hyperaemic mean arterial pressure and diastolic pressure did show a statistically significant 
increase in the 6FU subgroup in blood pressure; systolic pressure showed a trend to 
increase that was non-significant.  However, when assessed as part of the overall study 
population, there was no significant difference in hyperaemic pressures or heart rate. 
Adenosine mediated hyperaemia caused significant reductions in blood pressure and 
increased  heart rate in almost all groups (p<0.01 for all comparisons marked with an 
asterisk in Table 5.2).   
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5.3.3 Angiographic change 
There was no significant change in the angiographic appearance of the stenoses on repeat 
angiography: diameter stenosis was 56±14% at baseline and 57±21% at follow-up 
(p=0.41).   
!
5.3.4 Indices of stenosis severity are stable over a 6-12 follow-up in non-ischaemic 
stenoses 
Table 5.3 demonstrates that pressure-only and combined pressure-flow based indices of 
stenosis severity are stable and reproducible in non-ischaemic stenoses over 6-12 months.  
There was no significant change between the measures measured at baseline and follow-
up.   
The individual case data is shown in Figure 5.1 with the change in indices shown in Figure 
5.2.  Bland-Altman Figures are shown in Figure 5.3 and Figure 5.4.  Table 5.5 demonstrates 
that the bias is small for all of the indices.   
!
5.3.5 Mean flow velocity is consistently higher during the wave-free period 
Mean flow velocity was measured at rest, over entire cardiac cycle (Flowwhole cycle) and over 
the wave-free period (Flowwfp) at both visit-1 and visit-2 (Figure 5.5) At both time points, 
Flowwfp was significantly higher than Flowwhole cycle (visit-1: 29±11 vs 22±8 cm/s, p<0.001; 
visit-2: 30±11 vs 22±6 cm/s, p<0.001).   
Measuring flow velocity during hyperaemia (Flowwhole cycle), over the entire cardiac cycle was 
significantly higher than either resting measure at both time points (visit-1 46±12cm/s and 
visit-2 46±11cm/s, p<0.001 for all).  However, selecting the wave-free period during 
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hyperaemia measured a higher flow velocity than Hyperemic Flowwhole cycle (visit-1 
62±16cm/s; visit-2 60±12cm/s, p<0.001 for both). 
 
 
5.3.6 Mean flow velocity is reproducible over a 6-12 month 
Resting mean flow velocity was well correlated between visit-1 and visit-2:  Flowwhole cycle r 
0.67, (p=0.0002) and Flowwfp r 0.77 (p<0.0001) (Figure 5.6).   Hyperaemic flow velocity over 
the whole cycle also correlated well:  Hyperaemic Flowwhole cycle  r 0.44 (p=0.02).  However, 
there was a poor correlation for Hyperaemic flow over the wave-free period (r 0.18, p=0.37).  
Bland-Altman plots demonstrate good reproducibility (Figure 5.7).   
 
5.3.7 Microcirculatory resistance does not change significantly over 6-12 months 
Microvascular resistance index was assessed and this mirrored the findings seen in flow 
velocity.  There was no significant difference in MVR comparing visit-1 and visit-2 for any of 
the parameters (Figure 5.8, p>0.36 for all); the MVR values were significantly correlated at 
both visits Figure 5.9 and the Bland-Altman assessment showed little bias (Figure 5.10).  
MVR measured over the wave-free period window (3.43±1.69) was significantly lower than 
resting whole cycle (Pd/Pa 4.82±2.09mmHg/cm.s; p<0.001) but higher than hyperaemic 
whole cycle MVR (FFR 1.86±0.63 mmHg/cm.s; p<0.01).  However, wave-free resistance 
during hyperaemia  (iFRa) was significantly lower still (1.18±0.48mmHg/cm.s; P<0.0001).  
Over both visits, iFRa offered 50±15% lower resistance than whole-cycle hyperemia.  The 
degree of change in MVR over the follow-up period was consistent for all four parameters 
with no difference found (p>0.18). 
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5.3.8 The degree of resistance reduction remains consistent over follow-up 
The reduction in resistance offered by iFR compared to the whole cardiac cycle (Pd/Pa at 
rest) was 29±9% on visit-1 and 33±8% on visit-2 (p=ns).  Similarly, FFR and iFRa offered 
57±13% and 74±9% reductions respectively on visit-1 and 56±13 and 74±8% reductions 
respectively on visit-2 (p=ns for both).  
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5.4 Discussion 
 
5.4.1 Key Findings 
This is the first study in which coronary haemodynamic measures have been 
comprehensively assessed and repeated over after a long-period of follow-up.   
The key findings in this study are: firstly, mean flow velocity is stable and does not change 
on average over a long period of follow-up in mild-to-moderate coronary stenoses whether 
measured at rest or during adenosine-mediated hyperaemia.   
Second, that mean flow velocity can be reproducibly measured at rest using the entire 
cardiac cycle and the iFR-period.   
Thirdly, that hyperaemic flow velocity is more variable and is less reproducible but on 
average does not change significantly across non-flow limiting stenoses.   
Fourth, that microvascular resistance is similarly stable and the magnitude of change 
between visit-1 and follow-up was similar at rest as it was during adenosine mediated 
hyperaemia.  Finally, that in the catheter laboratory setting, in elective patients at rest, 
resting blood pressure parameters are remarkably reproducible over a long-period of 
follow-up and that any changes that occur are comparable to those that occur due to 
hyperaemia or during hyperaemia. 
 
 
5.4.2 Stability of haemodynamic parameters 
The presence of a resting state in the catheter laboratory has been raised as a potential 
limitation of resting indices of stenosis severity.43 Potentially, patients undergoing invasive 
procedures are relatively dehydrated and may have a stress response to the procedure.  In 
contrast, a pharmacologically driven hyperaemic state has been accepted as an optimal 
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state for physiological assessment.  In order to accept this, we assume that hyperaemic 
stimulus elicits an identical response in every patient.  It is reassuring then, that 
haemodynamic parameters during the resting state are as reproducible as those during 
adenosine-mediated hyperaemia.  
 
5.4.3 The reproducibility of coronary stenosis severity indices 
Both basal indices and hyperaemic indices have excellent reproducibility when repeated 
within the context of a single invasive procedure.89  The reproducibility is within the 
boundaries of hyperaemic measures.53,89  However, there is little work into the 
reproducibility of these markers of lesion severity over longer time periods.  This question is 
particularly pertinent as patients who are deferred from angioplasty are done so based on a 
measure that may change over time.  When repeated over a six week period, the 
reproducibility of hyperaemic measures is comparatively reduced, although treatment 
dichotomisation was on the whole unchanged.58  
Longer term reproducibility data is not available prior to this study.  The possibility was that 
FFR values change with longer follow-up.  Certainly many observational studies have 
suggested that patients with FFR values close to the clinical treatment threshold of 0.80, 
are more likely to have revascularisation events.103  This is exaggerated when patients may 
have factors which create a fluctuating state of the microvascular bed such as a recent 
acute coronary syndrome.152  The implication being that the reproducibility of the test close 
to its threshold is limited and that moderate lesions may progress.   
Although detailed studies assessing the repeated index are not available, randomised 
clinical data from DEFER are available however.  DEFER study results over 2, 5 and now 15 
years suggests that patients with non-flow limiting stable lesions continue to be stable 
without any major events (cardiac death and revascularisation).49,119  The implication is that 
in stable patients with stable moderate lesions, the reproducibility of a hyperaemic index is 
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high and that if negative, it will continue to be negative for a considerable period of time.  
The limitations of the DEFER data have been noted to be an unusual bimodal distribution of 
FFR values with a relative paucity of patients with FFR values close to the threshold value.53   
Selective enrolment of patients into the study may have influenced this finding, since 
studies enrolling unselected patients having FFR for clinical reasons have a unimodal 
normal distribution of FFR values.88   Nonetheless, the high reproducibility of hyperaemic 
measures is accepted within the physiological community.  
It is reassuring then, that in this cohort of patients, all of whom had non-ischaemic stenoses 
as classified by a gold-standard pressure and flow based index (hyperaemic stenosis 
resistance), that there was no significant change in any of the basal parameters of stenosis 
severity.  Changes in the hyperaemic index are mirrored changes in the basal index.  This 
suggests, that resting indices are as reproducible as a hyperaemic index in moderate 
stenoses. 
 
This study focused upon predominantly non-flow limiting stenoses, since obstructive 
lesions are often mandated to revascularization and therefore difficult to recruit into a 
reproducibility study.   
Further work is required to know for certain what the reproducibility is in truly flow-limiting 
stenoses over a longer-period of time.  This can be challenging to ascertain as truly flow-
limiting stenoses may have intercurrent intervention due to symptoms or unstable events.  
To understand this in a comprehensive manner, the ORBITA study is currently enrolling 
patients.  In ORBITA, patients with a single discrete lesion undergo physiological 
assessment and then return for the further assessment after 6 weeks.151  All the stenoses 
are angiographically severe enough that operators are prepared to treat by angioplasty.  We 
may observe that in these tight stenoses, there will be some fluctuation in the pressure 
indices.  The outcomes of this study are eagerly awaited. 
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5.4.4 Resting flow measures are stable and reproducible  
Resting flow velocity, whether measured over the entire cardiac cycle or over the wave-free 
period, demonstrated good reproducibility over a prolonged time course.  The correlations 
found are credible and within the limitations of technology and biological variability.   
 
Great care was taken to ensure an adequate flow velocity profile was recorded and 
analysed each time.  Less assiduous assessment will likely result in less reproducible 
findings as the measurement of flow velocity remains a niche skill.  The manipulation of the 
wires while maintaining the wire-tip position coaxial to the vessel lumen can be challenging.   
 
Furthermore, although the Doppler signal may be satisfactory, the digital recording is reliant 
upon the quality of the tracking.  This remains the ultimate limitation of the technology. 
Accepting the limits of the technology, it is biologically plausible for resting flow to be 
consistent provided there has been no advancement of the lesion to a critical level.  The 
findings are strongly supportive of the central tenet of basal measurement - that is, at rest 
there are subtle variations in tone and microvascular resistance to ensure a steady state is 
maintained.  Although absolute flow has not been measured, flow velocity is an adequate 
surrogate in this situation as no changes to the vessel dimensions are occurring during the 
measurements.  The additional potential error imposed by vessel measurements can make 
absolute measurements of flow more susceptible to error than flow velocity alone. 
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5.4.5 Variability of hyperaemic flow velocity: technical and pharmacological factors 
It is note-worthy that hyperaemic flow velocity was less reproducible, whether measured 
over the whole cycle or over the iFR-window.  From a technical point of view, acquiring a 
Doppler signal of flow velocity during hyperaemia is less difficult than a resting signal: the 
surge in flow during hyperaemia can be sufficient to produce an adequate envelope and 
little-to-no manipulation is required to maintain the signal.  However, the digital tracking of 
the signal becomes a considerable weakness during hyperaemia - a change in scale is 
required and if not done sufficiently quickly then data can be lost or be insufficiently 
acquired.  A further difficulty is imposed when determining the wave-free period during 
hyperaemia.  The algorithms accuracy will be determined the quality of the data available.  
Errors present on the whole cycle data may become amplified when determining the wave-
free period in diastole where the highest flow velocity signal is present.  This may explain 
why, from a technical point of view, why there was poor reproducibility of hyperaemic flow 
velocity. 
A further issue is that hyperaemia is dependent upon the response to an exogenous 
stimulant.  In much the same way that is not expected for an anti platelet medication, it may 
be unreasonable to expect adenosine to achieve an identical response each time.  Natural 
fluctuation related to the pharmacokinetics and pharmacodynamics of the drug should be 
expected.  Adenosine receptor down-regulation may play a role.  Furthermore, there may 
be an interaction with other drugs that appear to act on the adenosine-related pathways - 
for example, Ticagrelor may cause increase adenosine concentrations which could lead to 
mean the response to exogenous adenosine is muted.153,154  Some may suggest that there 
would be an additive effect; however, if there was a true additive effect it would mean the 
hypothesis that adenosine causes ‘maximal hyperaemia’ would be nullified.   
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Previous work has suggested that the limitations of hyperaemic flow-velocity measures, 
such as CFR are attributed this to variable resting flow velocity. The concept being that 
high values of resting flow velocity will artificially reduce a CFR, while a low resting flow 
velocity will artificially inflate a CFR.155  Although numerically correct, it makes the 
assumption that the hyperaemic flow velocity is fixed and unchanging.   The present study 
suggests, at least some of the variability in measures such as CFR, may in fact come from 
the hyperaemia.  
 
5.4.6 Comparison to other studies 
The findings are in keeping with findings from animal models of coronary disease and it is  
complementary to previous work as it assess flow velocity over a much longer period. 
McGinn et al described exquisitely performed experiments in transplanted hearts with 
minimal coronary disease that resting flow velocity was stable and reproducible over 11 
months, when pacing, rapid left ventricular fluid-loading and hand-grip was avoided.156  It 
would be reasonable for clinicians to avoid such actions prior to making resting 
physiological measures and it is well understood that all of these manoeuvres are not a true 
representation of the resting state and create a sub-maximal hyperaemic state.  McGinn 
demonstrated that hyperaemic flow velocity was unaffected by haemodynamic 
perturbations when measured using supra-maximal doses of papaverine, given in 
increasing doses until flow velocity could no longer rise.  In this manner, they achieved CFR 
values of 3-7 –all supra-normal values that are not typically seen in patients undergoing 
physiological assessment.  The McGinn protocol of using escalating doses of a drug until a 
plateau in flow velocity is achieved creates a self fulfilling prophecy: when flow velocity 
cannot rise any further rises with a potent exogenous drug, then attempts to increase flow 
with techniques that generate sub-maximal hyperaemia will have little effect.156  
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5.4.7 Does the dose of adenosine affect the results? 
In this study, stable hyperaemia was achieved as is routinely performed in clinical practice, 
using intravenous adenosine (140mcg/kg/min).  This may have influenced the findings 
somewhat. A standard dose may mean greater flow velocity may have been achieved by 
giving higher dose, such as 200mcg/kg/min.  However, some studies have reported that no 
additional hyperaemic effect can be achieved with additional doses beyond 
140mcg/kg/min.17  Others have suggested incremental intracoronary adenosine to doses 
never previously used can profoundly lower the FFR value.74   If higher doses of adenosine 
can achieve higher flow velocities and lower FFR values, there is a conflict in the central 
tenet of FFR theory.  That is, flow and pressure index move in diametrically opposing ways 
rather than in a congruous manner.  Furthermore, the implication of this finding is that all 
clinical measures of FFR made with a fixed dose are not made during maximal hyperaemia 
and therefore do not fulfil the definition as originally validated.  Additionally, it is in conflict 
with the finding of DEFER and FAME which found clinical benefit with a fixed dose.  FAME-
2 suggests that clinical events can be predicted by every 0.05 reduction in FFR value in 
patients with ischaemic vessels but randomised to medical therapy.157  If lower FFR values 
can be achieved, then not only will stenosis treatment decisions will be affected, but there 
may be considerable prognostic information that is being lost.  While this may not matter in 
profoundly negative or positive lesions, in lesions closer to the treatment threshold, this 
would impact lesion classification.     
This study overcomes some of these limitations by also measuring indices which are 
indexed by flow velocity, specifically BSR and HSR.  With HSR, any escalation of flow that 
causes a worsening of the gradient is automatically accounted for by the calculation.  In 
this study we observe that these indices are relatively reproducible with lesion crossing the 
threshold for either index.  
 
 256 
 
5.4.8 Implications for basal parameters of lesion severity 
The drive and development for basal or resting indices of lesion severity has partly come 
from the need to make physiological assessment more appealing, easier and quicker to 
perform.  While resting measures may be quicker to perform depending upon the local 
catheter laboratory set-up, they must be reproducible to be reliable.  This study 
demonstrates that measures that utilize whole cycle resting flow, such as the basal stenosis 
resistance index (BSR), and pressure-only such as iFR and Pd/Pa are likely to be 
reproducible over prolonged follow-up.   
 
 
5.4.9 Limitations 
This remains a small study focusing on anatomically moderate lesions, that were all 
physiologically moderate.  This is a necessity of in vivo patient studies since the majority of 
physiologically significant vessels are inevitably stented.  The clinical question that the 
current study data pertains regards those lesions that would be otherwise deferred.   
Great care was taken to achieve an adequate flow envelope and to ensure that the 
angiographic positioning of the Combowire was identical upon repeat assessment.  The 
additional effort required is not clinically applicable but is appropriate for a research study 
protocol.   
 
5.4.10 Conclusion 
Coronary flow velocity and microcirculatory resistance are reproducible when measured at 
rest or hyperemia, 6-12 months later.  This suggests that coronary haemodynamics during 
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resting conditions are stable, consistent and reproducible in a manner similar to that 
observed during adenosine-mediated hyperemia.    
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5.5 Tables 
 
Table 5.1 Patient Demographics 
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Table 5.2 Blood pressure and heart rate at baseline and follow-up 
assessments 
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Table 5.3 Pressure and flow indices on repeat over 6-12 months 
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Table 5.4 Change in indices on repeat assessments over 6-12 months 
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Table 5.5 Bland-Altman findings for repeated indices over 6-12 months 
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5.6 Figures 
 
Figure 5.1  Value of indices at visit-1 and visit-2 
 
 
Entire spread of data and the value of individual stenoses on visit-1 and visit-2 is shown.  
Visit-2 occurred at 6-12 months from visit-1.    
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Figure 5.2  Change in indices between angiographic studies 
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Figure 5.3  Bland Altman analysis for pressure-only indices 
 
 
 
Bland-Altman plots for pressure only indices.  X-axis shows the average between the 
values measured at visit-1 and visit-2.  Y-axis shows the difference between the two visits. 
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Figure 5.4  Bland Altman analysis for flow-based indices 
 
 
 
Bland-Altman plots for flow-based indices.  X-axis shows the average between the values 
measured at visit-1 and visit-2.  Y-axis shows the difference between the two visits. 
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Figure 5.5  The change in flow velocity between angiographic studies 
 
 
Mean flow velocity at rest and hyperaemia are shown.  Analysis is performed over the 
wave-free period and the whole cycle.  No significant change is noted between the 
angiograms performed on Visit-1 and visit-2 (6-12 months). 
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Figure 5.6  Scatter plot of flow velocity 
 
 
 
Flow velocity was measured over the (A) whole cycle at rest, (B) the resting wave-free 
period, (C) the whole cycle under hyperemia and (D) the wave-free period under hyperemia.  
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Figure 5.7  Bland-Altman plot of flow velocity 
 
 
 
Flow velocity was measured over the (A) whole cycle at rest, (B) the resting wave-free 
period, (C) the whole cycle under hyperemia and (D) the wave-free period under hyperemia.  
Bland-Altman graphs are presented for flow velocity measured at the two assessment time 
points.  
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Figure 5.8  The change in microvascular resistance between angiographic 
studies 
 
 
 
Mean microvascular resistance at rest and hyperaemia are shown.  Analysis is performed 
over the wave-free period and the whole cycle.  No significant change is noted between the 
angiograms performed on Visit-1 and visit-2 (6-12 months). 
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Figure 5.9  Scatter plot of microvascular resistance 
 
 
 
Microvascular resistance was measured over the (A) whole cycle at rest, (B) the resting 
wave-free period, (C) the whole cycle under hyperemia and (D) the wave-free period under 
hyperemia.  
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Figure 5.10  Bland-Altman plot of microvascular resistance 
 
 
 
Microvascular resistance was measured over the (A) whole cycle at rest, (B) the resting 
wave-free period, (C) the whole cycle under hyperemia and (D) the wave-free period under 
hyperemia.  Bland-Altman graphs are presented for flow velocity measured at the two 
assessment time points.  
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5.6.1 Synthesis 
These two sets of experiments (in Chapters 5 and 6) have determined the reproducibility of 
pressure based indices and flow-based measurements within moderate coronary stenoses. 
 
The overall findings are reassuring that the measures are reproducible when performed 
during a carefully controlled protocol.  This is helpful for practicing interventional 
cardiologists who rely upon these measures to make decisions. 
 
It remains to be determined how pressure-based indices and flow velocity changes with 
active intervention to coronary stenoses.  These issues are addressed by the next two 
chapters. 
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6 Improvement in coronary pressure 
after percutaneous coronary 
intervention: assessment using the 
instantaneous wave-free ratio  
 
 
 
 
 
 
 
 
 
 
 
This chapter includes the findings published as: 
Nijjer SS, Sen S, Petraco R, Sachdeva R, Cuculi F, Escaned J, Broyd C, 
Foin N, Hadjiloizou N, Foale RA, Malik I, Mikhail GW, Sethi AS, Al-Bustami 
M, Kaprielian RR, Khan MA, Baker CS, Bellamy MF, Hughes AD, Mayet J, 
Kharbanda RK, Di Mario C, Davies JE. Improvement in coronary 
haemodynamics after percutaneous coronary intervention: assessment 
using instantaneous wave-free ratio. Heart. 2013;99:1740–1748. 
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6.1.1 Introduction 
iFR has been assessed as a tool to detect stenosis significance and has a high 
classification match with FFR and other ischaemic parameters prior to PCI. 
However, it is unknown whether iFR can detect changes in coronary haemodynamics 
immediately following percutaneous coronary intervention (PCI).  In the immediate-post PCI 
setting, it is conceivable that there is disruption of the normal auto-regulatory mechanisms 
at rest such that post-PCI measurements may not respond appropriately.  FFR is used to 
assess success of coronary angioplasty and typically rises after stenting.  Observational 
studies and registries suggest FFR values over 0.90 are associated with better clinical 
outcomes than lower values.158–160  
If it was possible to detect equivalent changes in pressure gradients as observed under 
hyperemia, then it would be possible to document improvements in haemodynamics after 
PCI using resting indices.  This would be useful for physicians aiming to avoid hyperaemic 
agents to have a clinical work-flow that is entirely performed at rest.  Both iFR and Pd/Pa 
are resting parameters that could be used in clinical practice. 
 
In this study, we explored whether  
(1) iFR and Pd/Pa change in patients undergoing PCI 
2) whether the size of the increment was similar in proportion to measurements obtained 
under adenosine-mediated hyperaemic conditions.   
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6.2 Methods 
6.2.1 Study population 
Patients with angina undergoing scheduled elective coronary angioplasty for clinical 
reasons were prospectively enrolled for pressure wire assessment before and after 
intervention.  FFR was used as the reference standard to detect significant epicardial 
stenoses and only patients with physiologically significant lesions (FFR values "0.80) were 
included.   
 
Diabetes was defined as the use of oral hypoglycaemic agents or subcutaneous insulin 
injection.  Hypertension was defined by a formal diagnosis by the referring physician.  
Hypercholesterolaemia was defined as requiring a statin with total cholesterol #5mmol/L 
and LDL#2mmol/L.  Smoking status was patient reported and dichotomised as currently 
smoking cigarettes (including recent discontinuation within 1 year) and those who are never 
smokers or stopped over 1 year ago.  
!
Patients were recruited from the Imperial College Healthcare NHS Trust, the Veterans 
Affairs Medical Center, Little Rock, AR, USA and the John Radcliffe Hospital, Oxford, UK.  
The protocol was approved by local institutional review boards and ethics committee and 
patients provided written informed consent (NRES 09/H0712/102; NCT01118481). 
 
 
6.2.2 Study Protocol 
Coronary Catheterisation: Coronary angiography and pressure wire assessments of 
coronary stenoses were performed using conventional approaches.  Intracoronary nitrates 
were administered in all cases before pressure wires were introduced. Pressure wires were 
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normalised at the coronary ostia before every pressure recording. If more than one stent 
was used within 1 coronary segment, the pressure analysis was performed for the complete 
segment. For post-angioplasty measurements, all stents were optimised with post-dilation 
where angiographically indicated before further assessment with the pressure wire.  
Repeated measurements were performed after the angioplasty balloon had been removed, 
the catheter flushed and re-administration of nitrates.  The pressure-wire was normalised at 
the vessel ostium and then measurements were made at the same coronary location as 
pre-angioplasty.  
 
All patients received an oral loading dose of aspirin 300mg and clopidogrel 600mg, and 
intravenous heparin according to weight, together with bivalirudin or GPIIbIIIa-antagonist 
according to clinical indication. 
 
Haemodynamic recordings:  Pressure wire recordings were made using the Pressure Wire 
Aeris (St. Jude Medical, Minneapolis, Minnesota) and Prestige pressure guide wire (Volcano 
Corporation, San Diego, California).  Digital haemodynamic data was extracted from data 
storage systems (Radiview, St Jude Medical and ComboMap, Volcano Corporation) and 
processed off-line in a core laboratory using a custom software package with Matlab 
(Mathworks, Inc., Natick, Massachusetts).  
 
Calculation of Pd/Pa, iFR and FFR:  iFR was calculated as a ratio of the distal coronary 
pressure to proximal coronary pressure at rest, using the validated automated algorithms 
with phase alignment acting over the diastolic wave-free period over a minimum of 5 beats.  
iFR is measured using pressure-only, at baseline, without adenosine administration[1] 
(Figure 1).   
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Pd/Pa ratio was calculated using the ratio of distal coronary pressure to proximal coronary 
pressure at rest over the entire cardiac cycle. 
 
FFR measurements were performed using a standard technique, using the ratio of distal 
coronary pressure to proximal pressure during conditions of stable hyperaemia.  
Hyperaemia was induced by adenosine infusion at a rate of 140mcg/kg/min, administered 
by femoral venous access in 96 (80%) stenoses and an intracoronary 60mcg bolus in 24 
(20%) stenoses.  
 
 
6.2.3 Data analysis 
Statistical analysis was performed using Matlab (Mathworks Inc, Massachusetts, USA) and 
STATA version 11 (StataCorp, Texas).  Values are expressed as mean ± standard deviation.  
Continuous variables were compared using the Student t test or Mann-Whitney U test. 
Subgroup data was assessed using ANOVA with repeated measures and the Bonferroni 
correction for multiple testing errors.  The relationship between the change in pressure wire 
indices and stenosis severity based upon QCA were quantified using Pearson’s product 
moment correlation coefficient. This study had 90% power to detect a difference of a 0.03 
or greater difference between the delta in iFR and FFR after PCI.  A p value <0.05 was 
considered significant.  
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6.3 Results 
6.3.1 Patient characteristics 
112 patients (63±10 years old, 84% male) with 120 coronary stenoses were included.  
Patient demographics are shown in Table 6.1.  Quantitative coronary angiography (QCA) 
demonstrated a mean diameter stenosis of 68±16%, and lesion length of 15.6±9.2mm.   
 
6.3.2 Haemodynamic parameters 
The mean haemodynamic parameters at rest and during adenosine infusion, before and 
after PCI are shown in Table 6.2.  Adenosine significantly increased heart rate and reduced 
systolic, diastolic and mean blood pressures compared to resting values and this occurred 
both before and after angioplasty.  The delta (&) in each parameter at rest, before and after 
PCI, was not significantly different from the hyperaemic delta before and after PCI (p>0.12).  
Responses did not differ within sub-groups conventionally associated with higher levels of 
microcirculatory disease including people with diabetes, hypertension or current smokers 
(Table 6.3). 
 
6.3.3 Pre-angioplasty stenosis evaluation 
Mean FFR was 0.66±0.14 (median 0.72, 0.56-0.78); mean Pd/Pa was 0.83±0.16 (median 
0.90, 0.81-0.93); mean iFR was 0.75±0.21 (0.84, 0.65-0.89).  The overall mean FFR was 
similar to the FAME and FAME-II studies.[6,7]  84 stenoses (70%) within FFR 0.6-0.80 (with 
mean FFR 0.75±0.05, mean iFR 0.85±0.08, mean Pd/Pa 0.91±0.04) whilst 71 stenoses 
(59%) were within FFR 0.70-0.80 range (mean FFR 0.76±0.03, mean iFR 0.86±0.07, mean 
Pd/Pa 0.91±0.04).  Using the iFR 0.90 cut-off to correspond to the FFR 0.80 cut-off, 86% 
classification match was found in this cohort. 
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Intracoronary adenosine was used in 24 stenoses: there was no significant difference in the 
FFR values measured using intracoronary adenosine versus intravenous adenosine 
infusion, either before (p=0.83) and or after PCI (p=0.79).   
 
6.3.4 Resting indices can be lower than hyperaemic indices 
In 26 stenoses (22%) the pre-PCI iFR value was numerically lower than FFR (iFR 0.45±0.20, 
FFR 0.55±0.16; Figure 6.2). This is a similar proportion to reported in other 
studies.[1,2,4,8,9]  These lesions were anatomically more severe (diameter stenosis: 
75±14% vs 66±16%, p=0.01) and were physiologically more significant (FFR 0.55±0.16 vs 
0.69±0.12, p<0.01) than the remainder of the study population.  There was no significant 
difference in heart rate or systolic and diastolic pressures between these individuals and 
the others (p#0.10).  There was also no significant difference in the rates of diabetes 
mellitus, hypertension or smoking status (p#0.26); although hyperlipidaemia was more 
common in the group where FFR was lower than iFR (75% vs 87%, p=0.03).   
 
In contrast, Pd/Pa was numerically lower than FFR in only 3 stenoses (2.5%; values 
0.70,0.20,0.50) and in all three cases iFR was lower (0.47, 0.13, 0.28 respectively) than both 
Pd/Pa and FFR (0.73, 0.23, 0.56 respectively).  iFR was lower than Pd/Pa in all stenoses, by 
a mean of 0.08±0.07 units, p<0.001.  Figure 6.1 shows the gain offered by iFR over Pd/Pa 
across the entire study. 
 
6.3.5 Haemodynamic changes induced by PCI 
The change in heart rate, measured during resting or hyperaemic conditions, after PCI had 
no relationship to the change in iFR (R% 0.004) nor FFR (R% 0.007).  Similarly, change in 
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mean arterial pressure after PCI had no relationship with change in iFR (R% 0.004) nor FFR 
(R% 0.002).   
 
 
6.3.6 Post-angioplasty stenosis evaluation 
Coronary intervention was angiographically successful in all cases and physiological 
measures were only performed once angiographic or intracoronary imaging based 
optimisation had been performed.  Mean residual stenosis after stenting, measured by 
QCA, was 14.1%±8.2%.  The mean of all three indices increased significantly after 
angioplasty (iFR 0.75±0.21 to 0.94±0.05, P<0.001; Pd/Pa 0.83±0.16 to 0.96±0.04, P<0.001; 
and FFR 0.66±0.14 to 0.89±0.07, p<0.001) (Figure 6.3 )   
!
6.3.7 Change in iFR, Pd/Pa and FFR after intervention 
Across the whole study population, the change after intervention was significantly higher for 
iFR than Pd/Pa ($iFR 0.20±0.21 vs $Pd/Pa 0.13±0.16, p=0.007) and was statistically similar 
for both iFR and FFR ($iFR 0.20±0.21 vs $FFR 0.22±0.15, p=0.25, Figure 6.4. The 
magnitude of change elicited by PCI, the delta as a percentage of the pre-PCI value, was 
not significantly different between iFR (48±92%) and FFR (42±47%; p=0.34).  The 
magnitude of change for Pd/Pa (23±45%) was significantly smaller than iFR (p<0.001) and 
FFR (p<0.001) (Figure 6.4).   
The findings were unchanged when both iFR and FFR agreed (iFR"0.90, FFR"0.80) in 103 
stenoses, $iFR 0.22±0.21 vs $FFR 0.24±0.15, was not significantly different (p=0.57); both 
were significantly greater than seen with $Pd/Pa (0.15±0.16, p<0.01 for both).  In the 17 
stenoses with iFR>0.90 pre-PCI, the $FFR was much smaller than when iFR"0.90 
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(0.12±0.06 vs 0.24±0.15, p=0.002).  Similarly, the $iFR was smaller (0.03±0.03 vs 
0.22±0.21, p<0.001) but remained larger than seen with $Pd/Pa (0.02±0.03, p<0.001).  
 
After PCI, 6 stenoses had iFR values lower than FFR (with a difference in value between the 
two indices of 0.05±0.04).  There was no difference in the QCA of these stenoses and the 
rest of the study population (9.8±2.1% vs 14.8±8.5%, p=0.24).  In the subset of 26 
stenoses in which pre-PCI iFR was lower than FFR, the change in iFR post-PCI was 
significantly greater than the change in FFR and Pd/Pa in the same lesions: &iFR 0.47±0.23 
(magnitude 158±148%) vs &FFR 0.32±0.18 (magnitude 74±64%), p=0.01; vs &Pd/Pa 
0.33±0.18 (magnitude 70±76%), p=0.02.   
 
6.3.8 Stenoses remaining ischaemic or worsening after intervention 
The majority of lesions showed haemodynamic improvement after PCI.  However, in a small 
number of cases the post-PCI values were lower.  This was found in all indices in similar 
proportions (iFR:4%, FFR:2% and PdPa:7%, p>0.25 for all) (Figure 4), with overall very 
small falls in index values (iFR:0.05±0.05, FFR:0.04±0.02, PdPa:0.02±0.02).  Overall 15 
stenoses had an FFR"0.80 post-PCI (FFR 0.76±0.04), and 12 cases with iFR (iFR"0.90; 
mean iFR 0.85±0.06).   
!
6.3.9 Lesion severity and impact upon physiological improvement 
Pre-PCI lesion severity as determined by anatomical stenosis influenced the magnitude of 
physiological improvement (Figure 6.5).  Pre-angiographic QCA was related to the delta in 
physiological index ($FFR r=0.57, $iFR r=0.49, $Pd/Pa r=0.51).  Regression analysis 
demonstrated strongly significant positive relationship of initial lesion severity by QCA 
(percentage change in FFR R% 0.26, iFR R% 0.16, Pd/Pa R% 0.16, each p<0.0001).  
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Post-PCI, residual stenosis severity measured by QCA had no strong relationship with 
either physiological measure (iFR r=0.24; FFR r=0.12).  There was a modest relationship 
between the degree of improvement in angiographic severity (&QCA) and change in iFR 
(r=0.34) and change in FFR (r=0.40). !
!
6.3.10 Impact of diabetes, smoking status and hypertension on magnitude of increase 
of iFR and FFR post-PCI 
No significant difference was observed when patients with hypertension, diabetes or 
smokers were compared with patients without these conditions (Table 3).  The change in 
iFR was significantly larger than Pd/Pa after PCI in hypertensive patients, those without 
diabetes and non-smokers. 
 
6.3.11 1 year follow-up data 
12 month follow-up data was available in all the UK patients.  No urgent revascularisation, 
myocardial infarction, stroke or death occurred in the first 12 months in the Imperial College 
cohort. 3 patients in the Oxford cohort underwent revascularization.  Data from the USA 
was not unfortunately available and is being sought.  These numbers are not sufficient to 
determine a meaningful threshold for the iFR value post-PCI to minimize clinical events.  
Data collection is on-going to determine an optimal iFR post-PCI to minimize events.  
Greater randomised data will be available from the FLAIR study.   
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6.4 Discussion 
6.4.1 Key Findings 
In this study, we found that in stenoses that typically undergo intervention  
(1) resting indices of stenosis severity can detect a change after PCI, with both iFR 
and Pd/Pa values improving after successful PCI;  
(2) the change in iFR and FFR after PCI is similar;  
(3) the change seen is larger with both FFR and iFR than seen with Pd/Pa.   
 
Gruntzig’s demonstration that resting trans-stenotic pressure gradients could detect 
change after angioplasty was limited by bulky low-fidelity pressure-sensing equipment.76  
Hyperemia improved sensitivity for whole-cycle averaged measures by increasing flow 
across stenoses to accentuate gradients. iFR provides an alternative approach to 
increasing sensitivity, by identifying a phase in diastole when trans-stenotic flow is highest 
during the resting cardiac cycle.  Our findings confirm that using either of these approaches 
it is possible to observe a similar improvement in trans-stenotic pressure gradients after 
PCI.  
 
6.4.2 A historical perspective for FFR assessment post PCI 
Changes in trans-stenotic pressure gradients after coronary intervention, to remove an 
obstruction to flow, are a measure of the effect of the procedure.14,15,76  However, it is 
possible despite successful anatomical resolution of a coronary stenosis, unwanted or 
unaccounted for effects of PCI itself may pose difficulties for post PCI physiological 
evaluation.  Such effects included altered haemodynamics,161  changes in micro-circulatory 
resistance,145 and altered responsiveness to adenosine due to micro-embolisation.162  The 
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impact may vary according to initial lesion severity,71,163 the stenting strategy164  and even 
concomitant drugs.165  
Nonetheless, FFR has been shown to be of use to measure the incremental improvement in 
trans-stenotic gradient after balloon angioplasty, stent deployment, and following post-
stent high pressure balloon inflation and many of the theoretical concerns of a blunted 
microcirculatory response to adenosine after PCI have proved unfounded.58,158,159,166,167 
 
The value of physiology post-PCI was ostensibly to recognise which patients would suffer 
restenosis.  In the early era of PCI, restenosis due to excessive intimal hyperplasia was a 
considerable problem for both plain balloon angioplasty (PTCA) and for stenting.  Since 
angiography was limited in being able to assess the post-PCI result, alternative 
technologies were sought.  FFR was perceived as an approach of identifying whether the 
stenosis in question was still flow limiting.  If there was residual ischaemia, it was felt 
conceptually that the elevated shear stress induced by the residual stenosis would 
accelerate restenosis.  Since the early studies all recruited single-vessel disease cases with 
straight-forward lesions requiring a single stent, then this is a reasonable assumption.  The 
challenge comes when more diffuse disease is present, which can be the driver for residual 
pressure loss.   
Several studies were performed to determine the predictive nature of FFR post-PCI. 
Bech et al presented a cohort of patients from 1994 that had undergone plain balloon 
angioplasty (PTCA, with only bail out stenting) with FFR measurements made post-
procedure.158  All 60 patients, had single vessel disease, and had a positive exercise 
tolerance test 24 hours prior to the angioplasty. Based on the information provided in the 
paper, the timing (1994) and the location of the recruiting hospitals (Catharina Hospital, 
Eindhoven; Cardiovascular Center, Aalst) these 60 patients were part of the original 
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validation dataset of FFR.163  After PTCA, patients had a rise in FFR from 0.56±0.14 to 
0.88±0.07 (p<0.001).  In the 58 patients having successful PTCA, they all had reversion 
from a positive to negative exercise test.  24 month follow-up data was available and 
demonstrated that a total of 16 adverse events occurred (an event rate of 27% over 2 years 
in a pre-stenting era): there were no deaths or myocardial infarction, only repeat PTCA or 
referral for CABG.   The only strong predictor in both univariate and multivariate analysis 
was FFR (p=0.03 and p=0.008 respectively).  ROC analysis determined an FFR #0.90 as 
being the optimal threshold for events.  When utilising this cut-off for a physiologically 
successful PTCA, they found that patients that had both an angiographically successful 
(residual diameter stenosis "35%) and had post-PTCA FFR #0.90, had significantly less 
clinical events than those in whom the angiographic result and FFR were less 
satisfactory.158  An important limitation is that the angiographic criteria was not pre-
specified allowing the potential for bias during follow-up in an unblinded cohort.  The value 
was chosen because the DEBATE, DESTINI and FROST trials had suggested residual 
diameter stenosis of >35% was associated with diminished CFVR and a higher restenosis 
rate.168–170   
Furthermore, by using a ROC analysis to determine a threshold for clinical events, and then 
comparing the differences between groups for those same events by that threshold is an 
unsound scientific approach.  They showed that 50% of the patients with residual diameter 
stenosis "35% still had an FFR of <0.90 suggesting that anatomical assessment alone was 
not a good marker of the physiological success of PCI.  Nonetheless, the conclusion was 
that while an FFR >0.75 after PTCA was satisfactory for relieving ischaemia, the best 
clinical outcomes were achieved only once FFR #0.90.   
This was followed by a second publication that appears to be the same study with an 
extended discussion without additional data.159  However, a further study was performed as 
part of an international collaboration performed in 15 hospitals in 8 countries160  750 
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patients had post-stent FFR measurement and had 6 month follow-up data sought.  76 
patients had a total of 90 adverse events: with 5 deaths, 19 myocardial infarctions and 54 
repeat target vessel revascularisation.160  Post-PCI FFR and stent length were the strongest 
predictor of an adverse event; with logistic regression revealed that the lowest event rate 
was observed when FFR>0.95 post-PCI, with the highest number of events in patients with 
FFR values between 0.80-0.76 and those with 0.81-0.85.160 
Several other studies have sought to use FFR to detect restenosis rates.171–173  Certainly, 
physiological parameters are related to the end-PCI lumen area and the presence of 
residual disease.174,175 However, intravascular ultrasound (IVUS) and/or optical coherence 
tomography (OCT) should remain the standard to assess quality of stent deployment and 
apposition. 
!
!
!
6.4.3 Resting markers of lesion severity can detect lesion significance before PCI 
It was previously unclear whether resting measures would have sufficient dynamic range to 
detect improvement after PCI.   
In this study, iFR, a resting index, could distinguish improvement in stenosis severity 
similarly as FFR in a wide-range of stenoses that would be selected for PCI.  Pd/Pa also 
detected improvement albeit with a significantly smaller increment when compared to either 
FFR or iFR.   
All three measures, despite representing quite different physiological states, have a close 
correlation and therefore have clinical utility. However, as the onus falls upon the 
interventionalist for demonstrating physiological functional gain after PCI, having a greater 
dynamic range, as offered by iFR and FFR, may be considered preferable.  This is 
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particularly pertinent to determine the significance of residual disease.  The larger dynamic 
range offered by iFR and FFR over Pd/Pa means they have a greater range to diagnose 
stenoses and detect potentially small incremental improvements.  If the potential dynamic 
range of improvement is small, important but smaller residual gradients may not be 
detected using a whole cycle Pd/Pa approach. Theoretically, this greater dynamic range 
may also be helpful in serial stenoses where greater discrimination is required to 
understand the impact of each stenosis and the effects of PCI to a given stenosis. 
With FFR and iFR offering an equivalent magnitude of change on average for stenoses 
selected for intervention, procedures could be performed without vasodilators while being 
able to assess the change in an equivalent manner as when vasodilators are used.  
However, we did not seek to find an optimal ‘cut-off’ for post-PCI iFR that predicts 
outcome or vessel size as initial event rate data was low. Further work with long-term 
follow-up and intravascular imaging is warranted. 
 
In this study FFR<0.80 was used as the entry criteria.  As a result, in some cases both iFR 
and PdPa were negative, whilst by study design FFR was always positive.  In these cases, 
the rise in iFR and Pd/Pa was significantly smaller after PCI, than when iFR agreed with 
FFR. The implications as yet are unclear.! Furthermore, iFR matches CFR more closely than 
FFR with the implication that the resting index is a better predictor of the flow states.  As 
has been shown by the clinical outcome data in Amsterdam, when FFR was positive but 
CFR negative, clinical outcomes without stenting are good.  This raises the prospect that in 
some of these lesions, although FFR was below 0.80, there was no true flow limiting 
stenosis.  Rather, the increased pressure gradient observed during hyperaemia exists as a 
function of increased flow.   
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The next chapter will discuss experiments in which flow velocity changes after PCI are 
assessed.  Further clinical studies are also needed to evaluate the clinical significance of 
these differences. . !
 
 
6.4.4 Practical assessment of iFR after PCI 
It is frequently thought that significant haemodynamic shifts caused by PCI may affect the 
ability of basal parameters to detect change after PCI.  However, in this study, 
haemodynamic parameters at rest changed in a similar manner to those parameters 
measured during hyperaemia.  Under both resting and hyperaemic conditions, the absolute 
change after PCI was small and there was no relationship between the change in heart rate 
or blood pressure with the change in iFR or FFR post-PCI. This is similar to the relative 
heart rate and blood pressure independence reported in CLARIFY and by Johnson et 
al.79,176  
Immediately after balloon deflation, dynamic changes associated with occlusive reactive 
hyperaemia may produce artificially lower iFR values.  This is similar to injecting intra-
coronary nitrates or contrast.14  When this occurs it may lead to a lower values of iFR. 
Reactive hyperaemia following transient balloon occlusion is similar to hyperaemia from 
intracoronary adenosine, typically lasting a short duration (5-30 seconds) with a rapid return 
to basal conditions.37,177–179   
Our finding show that provided post-PCI iFR measurements are made in a manner similar 
to FFR, that is after the deflated balloon is withdrawn and the guiding catheter is flushed, 
that the hyperaemic effect is extremely short-lived and of little clinical consequence as both 
iFR and FFR have similar numbers of cases in which the post-PCI value is lower than the 
pre-PCI.  
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6.4.5 iFR values can be lower than FFR values in severe lesions 
In this study sample of stenoses suitable for PCI, 1 in 5 (22%) stenoses had a pre-PCI iFR 
lower than FFR: that is the resting trans-lesional pressure ratio was lower at rest than 
achieved during stable maximal hyperaemia.  Whilst apparently counter-intuitive, this 
phenomenon is well recognised in pressure-flow based studies, and occurs in all iFR-FFR 
comparator studies.78,79,88,89,176  The chance of an iFR measurement being lower than an FFR 
measurement increases with increasing disease severity.  However, even in intermediate 
populations this occurs with a frequency of 8-15%.  With increasing stenosis severity, 
where each patient undergoing PCI had and FFR "0.80, the proportion of patients with a 
lower iFR than FFR increases significantly.     
However counter-intuitive a lower resting than hyperaemic measurement may appear, the 
physiological principles underlying the phenomena are well described.71,72,123  Coronary flow 
is maintained during resting conditions even in the presence of a coronary stenosis up to 
90% because the microcirculation naturally vasodilates, reducing resistance, to preserve 
basal flow.72,123,180  In such severe stenoses, trans-stenotic flow is strongly influenced by 
proximal driving pressure which itself is maintained by autoregulation.  In this setting, 
adenosine offers no additional vasodilation than naturally present, and resistance does not 
fall by as much as seen in non-flow limiting vessels.71,79  However, the fall in central blood 
pressure particularly with intravenous adenosine can be sufficient to reduce the driving 
pressure across the stenosis with reduction in distal distending pressure.  A loss in 
perfusion pressure leads to protective microcirculatory vasoconstriction, much like that 
seen in the peripheries during shock.  This paradoxical vasoconstriction of the 
microvasculature leads to a rise in distal resistance,71,181 and may be sufficient to attenuate 
trans-stenotic gradients during stable hyperaemia.  A typical case, from the ADVISE study, 
is demonstrated in Figure 6.6 where the resting iFR was 0.56 and the FFR 0.81.   
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The clinical implications of this paradox is unclear, particularly because the occurrence rate 
in trials such the FAME studies is unknown.  Furthermore, many cardiologists would choose 
not to give adenosine if the resting gradient is already below the treatment threshold, while 
some cardiologists choose to use lowest Pd/Pa ratio during adenosine infusion and thus 
may have inadvertently missed or disregarded rising FFR values caused by paradoxical 
effects of adenosine.  Further assessment of this phenomenon is required and it is the 
subject of upcoming studies.  
After PCI, an iFR lower than FFR could represent the effect of residual stenosis, but also of 
either residual hyperaemia as a consequence of balloon-inflation, which may artificially 
reduce the iFR or the impact of microemboli preventing maximal hyperaemia in response to 
adenosine.  Intra-coronary flow velocity was not measured in this study, so it is not possible 
to identify whether this differences was due to an increase in flow (leading to a low iFR) or 
an increase in resistance (leading to a higher than expected FFR) was the likely causes of 
the differences between iFR and FFR.  Overall this cohort was small, and there was no 
difference in the anatomical residual disease post-PCI to account for the six cases where 
iFR was lower than FFR. 
 
6.4.6 Relationship between anatomical stenosis severity and physiological pressure 
indices 
It is intuitive that the potential for either iFR or FFR to increase following successful PCI was 
governed by the initial physiological severity of the lesion.  In this study we also found 
angiographic significance demonstrated a relationship.  This is likely to be due to our study 
design, where only patients with anatomical stenosis with FFR "0.80 were included.  If 
physiological assessment had been made pre-post PCI in lesions deemed anatomically 
significant, with disregard for FFR, it is likely that the relationship between stenosis QCA 
and improvement in post-PCI physiology would have been significantly worse.   
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6.4.7 Potential value and application of iFR to aid coronary angioplasty 
Despite the utility of FFR, physiological guidance pre-PCI is performed in <10% of 
interventional cases.182,183  Less data for post-PCI assessment is available but is likely to be 
a fraction of pre-PCI assessment.184  Unmet needs include the cost of pressure wires and 
reimbursement costs.  Others are the time taken, the availability of vasodilators and 
certainty of reaching maximum hyperaemia.185  Even in the best hands, using intracoronary 
vasodilators in a single vessel adds a median of 9 (IQR 7-13) minutes onto a PCI procedure, 
while an infusion approach adds 11 (IQR 10-17) minutes.186  Multi-vessel assessment takes 
significantly longer.186  Simplification, of measurements could promote physiological 
assessment in more vessels and in more patients. Documenting incremental changes in 
physiological markers may gain clinical importance as interventionalists are increasingly 
required to document the appropriateness of the procedure187  and the benefit accrued.  
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6.4.8 Limitations 
FFR has been afforded a significant bias towards detecting a greater change because only 
patients with FFR"0.80 were included.  Therefore, while anatomically the lesions were 
moderate, many were severe physiologically as seen in the pioneering FFR trials.   
FFR was measured using intracoronary adenosine in 20% of patients.   This reflects the 
routine clinical practice, and the interchangeable way in which adenosine is administered.  
While several studies have reported an overall excellent classification match between the 
techniques36, it may have inadvertently introduced additional variability into the FFR 
measurements, which was not seen in the iFR arm which was always measured at rest prior 
to administration of adenosine. 
Central venous pressure (RAP) correction of the simplified FFR calculation can improve the 
accuracy of the FFR measurement, though it is rarely performed clinically and was not used 
in the FAME studies.  Future studies should consider formal assessment of the impact of 
venous pressure measurement upon the relationship between physiological indices, as well 
as defining the confidence boundaries of change by performing repeated measures both 
before and after PCI. 
Future work should also measure coronary wedge pressure to assess the impact of 
collateral vessels and the collateral flow index upon iFR measurement and how this affects 
iFR post-PCI.  The differing effects of collateral vessels between resting and hyperaemic 
indices may explain important differences between iFR and FFR, and requires further 
assessment in future studies.  
In keeping with routine clinical practice, this study did not measure coronary Doppler flow 
velocity, and therefore did not evaluate the specific impact of microcirculatory disease on 
flow-derived or pressure-flow derived indices.  This will be specifically examined in the next 
chapter.  
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6.4.9 Final conclusions 
The incremental improvement in iFR following coronary angioplasty is similar to that of FFR 
and greater than Pd/Pa.  Resting indices such as iFR have the potential to be used as 
objective measures of improvement in physiology following coronary angioplasty.   
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6.5 Tables 
Table 6.1. Patient demographic data 
!
Patient demographic data.  Values are n, mean±SD or n (%); CABG = coronary 
artery bypass grafting; EF = ejection fraction; LV = left ventricular; QCA = 
quantitative coronary angiography.  Risk factors are defined in the text.   
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Table 6.2 Haemodynamic changes observed during PCI 
!
!
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Table 6.3 Patients with risk factors for microcirculatory disease have a similar 
change in iFR and FFR produced by PCI 
!
!
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6.6 Figures 
 
Figure 6.1 The difference in pre-intervention iFR and Pd/Pa values 
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Figure 6.2 IFR falls below FFR when stenoses are severe 
!
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Figure 6.3 The change in pre- and post-angioplasty FFR and iFR values for 
individual stenoses 
 
!
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Figure 6.4 The mean change in pre- and post-angioplasty Pd/Pa, iFR and FFR 
values 
!
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Figure 6.5 Improvement in iFR, Pd/Pa or FFR is closely associated with the 
angiographic severity of the stenosis. 
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Figure 6.6 Paradoxical rise in FFR value with on-going adenosine infusion 
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6.6.1 Synthesis 
The results of this study confirm that distal resting pressure will change with the stenting of 
a stenosis; in the majority of cases distal pressure improves once a stenosis is removed.  
This means that a resting pressure index will rise upon stenting and that on average, within 
a population of patients undergoing PCI 
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7.1 Introduction 
7.1.1 Coronary angioplasty is presumed to increase flow  
The purpose of percutaneous coronary intervention is to relieve epicardial stenoses and 
thereby increase coronary flow ostensibly to relieve symptoms of angina.  However, some 
studies suggest PCI offers little clinical benefit over medical therapy6 while others show that 
when PCI is guided by markers of physiological severity such as fractional flow reserve 
(FFR)  outcomes can be improved.49,50,52  Since physiological parameters offer additional 
information about ischaemia over angiographic assessment the disparity in findings and 
improved outcome by application of physiology is likely due to improved differentiation of 
lesions into those with the highest likelihood of ischaemia, and deferring those with lowest 
likelihood of ischaemia.188   However, the uptake of physiology prior to PCI remains low.189   
Even in centres with high-volume use, clinicians may choose to stent vessels in which 
physiological parameters, such as FFR, are above their thresholds (for example, 
FFR>0.80).189  Furthermore it remains unconfirmed whether coronary physiological 
parameters identify stenoses which will demonstrate an improvement in coronary flow and 
whether the increase in flow following PCI is predicted by physiological parameters.  
 
7.1.2 Does resting physiology change after coronary intervention 
Additionally, new resting measures of stenosis severity have been proposed, such as the 
basal stenosis resistance index (BSR) and the instantaneous wave-free ratio (iFR).  
Although intracoronary pressure alone is known to increase after intervention,84 it is unclear 
how resting flow velocity, either over the whole cycle or the wave-free period relate to each 
or behave after intervention.  Furthermore, since most application of physiology in clinical 
practice has been focused upon pressure-only methodology the precise relationship 
between pressure and flow velocity after PCI must be determined.  
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7.1.3 Study aims 
To investigate these issues we assessed the change in both hyperemic and resting flow 
velocity after coronary intervention to a wide spectrum of stenoses in patients referred for 
PCI as part of the JUSTIFY study.101  Stenoses were treated according to anatomical and 
clinical information and the change in flow velocity after PCI was assessed in relation to the 
physiological significance of the stenoses prior to PCI.  Stenoses were defined 
physiologically by the reference standard pressure-only index (FFR).  Further assessment 
was performed in relation to other physiological indices available in the catheter laboratory.  
Specifically we sought to assess what increase in flow velocity should be expected for a 
change in a pressure index.   
 
7.2 Methods 
 
7.2.1 Study population 
The purpose of the JUSTIFY-PCI studies is to better understand the relationship between 
different indices of coronary stenosis.  In this analysis, patients who had undergone PCI 
with stent placement with paired assessment using a single Combowire to acquire 
simultaneous pressure and flow velocity data before and after stenting were assessed.  In 
total 75 stenoses underwent PCI.  Patients were recruited from the Hammersmith Hospital 
(Imperial College Healthcare NHS Trust, London, UK) and the Academic Medical Center 
(Amsterdam, Netherlands).  
Patients with significant valvular disease or previous coronary artery bypass grafts were not 
included in this study.  The local ethical review boards approved the respective study 
protocols, and all subjects gave written informed consent. 
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7.2.2 Study Protocol.  Coronary Catheterisation 
Coronary angiography and pressure-flow velocity assessments of coronary stenoses were 
performed using conventional approaches via the femoral artery.  Intracoronary nitrates 
(300mcg) were administered in all cases prior to the introduction of coronary wires.  
Combined pressure and flow velocity wires (Combowire XT, Volcano Corporation, San 
Diego, California) were normalized at the coronary ostia before every pressure recording.  
Measurements were made in the proximal vessel and distal to the stenosis.  Adenosine was 
administered by central femoral vein in 43 stenoses (140mcg/kg/min) and by intracoronary 
bolus in 32 stenoses (60mcg).  The dose of intracoronary adenosine exceeds the dose of 
adenosine originally validated for use in man (20-40mcg).17  The same dose was used 
before and after intervention.  Coronary intervention was performed at the operators 
discretion based upon usual clinical care including angiographic and non-invasive findings.  
For post-angioplasty measurements, all stents were optimized with post-dilation where 
angiographically indicated before further assessment with pressure wire.  Repeated 
measurements after angioplasty were performed at the same coronary location as pre-
angioplasty.   
 
7.2.3 Haemodynamic recordings 
The electrocardiogram, pressures and flow velocity signals were directly extracted from the 
digital archive of the device console (ComboMap, Volcano Corporation).  At the end of each 
recording the pressure sensor was returned to the catheter tip to ensure there was no 
pressure drift.  Where drift was identified the measurements were repeated. An adequate 
flow velocity envelope was obtained in all patients permitting the calculation of flow-based 
indices.  Data were analysed off-line, using a custom software package designed with 
Matlab (Mathworks, Inc, Natick, Mass). 
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7.2.4 Calculation of Pressure-only indices 
iFR was calculated as a ratio of the distal coronary pressure to proximal coronary pressure 
at rest, using automated algorithms acting over the diastolic wave-free period as previously 
described in ADVISE78  and validated in RESOLVE.109  iFR is measured using intracoronary 
pressure-only, at baseline, without adenosine administration; its clinical cut-point is 0.90 
while has an ischaemic cut-point of 0.86.79  FFR measurements were performed using a 
standard technique,129 using the ratio of distal coronary pressure to proximal pressure 
during stable hyperaemia; the clinical cut-point is 0.80 and has an ischaemic cut-point of 
0.75.47 
 
7.2.5 Calculation of flow velocity based indices 
Lesions were categorized by CFR, calculated by the ratio of whole cycle resting flow 
velocity to hyperemic flow velocity128  values below 2 and 1.7 have been considered 
abnormal previously and both thresholds were tested.  The hyperemic stenosis resistance 
(HSR) was calculated using the hyperemic trans-stenotic gradient indexed by the 
hyperemic flow velocity; values over 0.80 mmHg/cm.s are abnormal.91  The basal stenosis 
resistance (BSR) was similarly calculated, but utilizes resting trans-stenotic gradient and 
resting flow velocity; values over 0.66 mmHg/cm.s are abnormal.97 
Equations for the intracoronary indices are shown below:    
!
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7.2.6 Calculation of flow velocity over different windows 
Calculation of flow velocity over different windows 
Flow velocity was assessed as shown in the main Methods section of the thesis (Figure 
2.9).  It was assessed at rest over entire cardiac cycle (Rest Flowwhole cycle) and over the 
specific diastolic wave-free period during which iFR is calculated (Rest Flowwave free period!). 
Flow velocity was also assessed during adenosine-mediated hyperemia over the whole 
cardiac cycle (Hyperemic Flowwhole cycle) and the wave-free period (Hyperemic Flowwave free period!
).  Flow velocity is reported for the whole group or FFR strata as mean ± standard error.  
Additionally it is reported as a ratio of flow velocity before and after PCI: for example, a pre-
post hyperemic flow velocity ratio of 1 would suggest no increase in flow velocity after PCI, 
while a ratio of 2 would suggest flow velocity had doubled.   
 
Microvascular resistance was calculated before and after PCI according to the following 
equations (where Flow indicates Flow velocity (cm/s) and Pd indicates distal coronary 
pressure (mmHg).  
!
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Microvascular resistance was used to estimate the presence of PCI-related micro-
embolisation which can impact upon post-PCI measurements.  Since micro-embolisation 
would prevent the microcirculation from responding to adenosine, the degree of 
embolisation can be quantified by measuring the capacity of adenosine to reduce 
microvascular resistance (vasodilator reserve) post-PCI.  This was compared to the 
reduction in resistance offered by adenosine in stenoses with FFR>0.80 pre-PCI, as 
physiologically non-flow limiting stenoses are the most responsive to adenosine.  
Additionally, CFR was measured post-PCI to provide an additional manner to assess for the 
impact of embolisation. 
!
7.2.7 Data analysis 
Data are expressed as mean ± standard error (SEM), unless otherwise stated.  Patient 
demographics are presented as counts and percentages where appropriate.  Correlations 
were assessed by Pearson’s correlation coefficient.  Linear regression analysis was used to 
determine the coefficient of determination (R%) between quantitative variables.  Regression 
analysis was used with polynomial best-fit curves to determine the relationship between 
quantitative variables.  Relationships were determined to be linear or curvilinear based upon 
appearance.  Independent data was compared using Student’s t-test and Mann-Whitney U 
test.  Where data was paired, for example before and after PCI, paired t-tests were used.  
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Comparisons of means between multiple groups was performed using analysis of variance 
with Bonferroni, Sidak and Scheffe corrections for multiple testing; this was followed by 
pairwise analysis using the Tukey HSD test.  Repeated measures correction was applied 
where appropriate.  For all analyses, a p value <0.05 was considered significant.    
Statistical analysis was performed using Matlab (Mathworks Inc, Massachusetts, USA) and 
STATA version 11 (StataCorp, Texas).    
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7.3 Results 
 
7.3.1 Patient characteristics 
Measurements were made before and after coronary PCI in 67 patients (75 stenoses, 76% 
male, 62±9 years old).  Demographics are shown in Table 7.1.  Flow velocities are shown in 
Table 7.2, while physiological indices before and after PCI are shown in Table 7.3.  The 
mean FFR pre-PCI was 0.68±0.02, which was comparable to FAME-2.51 The mean stenosis 
diameter was 56±1.3% by quantitative coronary angiography (QCA).  Mean arterial 
pressure had only a very limited relationship with flow velocity; this was true of flow velocity 
measurements made at rest and hyperemia and also true before and after PCI (R% for all 
comparisons were less than 0.04).  
 
7.3.2 Assessment of coronary flow velocity before PCI 
Mean flow velocities at rest and during hyperemia were assessed and assessed in relation 
to physiological parameters typically used to categorise stenoses as significant or not 
(Table 7.2).  In all cases, regardless of the physiological parameter used to stratify the study 
population, by restricting the flow velocity measurement to the wave-free period (Resting 
"#$%!"#$%&'$$%($')*+!) elicited flow velocities that were significantly higher than those measured 
over the whole cardiac cycle at rest (Resting Flowwhole cycle).  Hyperemic Flowwhole cycle was not 
different from Rest Flowwave free period! in stenoses classed as physiologically significant by any 
of the parameters and cut-points assessed (Table 7.2) but was greater when stenoses were 
classed as non-significant.  Measuring flow velocity only during the wave-free period under 
conditions of hyperemia elicited significantly greater flow velocities than over the whole-
cycle (p<0.001). 
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7.3.3 The change in hyperemic flow velocity after intervention 
After PCI, the mean Hyperemic Flowwhole cycle across all stenoses rose significantly to 
51.0±2.87cm/s (Figure 7.1).   
Stratification by FFR demonstrated that when stenoses had pre-PCI FFR values >0.80, 
Hyperemic Flowwhole cycle velocity increased by 4.6±2.3cm/s; this was significantly less than 
when FFR values "0.80 (28.5±3.8cm/s, p<0.001) (Figure 7.1 and Figure 7.2 and Figure 7.3).  
Expressed as a ratio of flow velocity pre:post PCI, a similar finding was noted (FFR "0.80, 
pre:post flow velocity ratio of 2.83±.0.29 vs 1.17±0.08,  p<0.001).  The behaviour of 
hyperemic flow velocity over the wave-free period was similar to the whole cycle.  
Stratification by the other physiological parameters elicited a similar relationship (Figure 
7.5).   
Stratification of by FFR severity revealed that the most severe lesions had the greatest 
increase in hyperaemic flow velocity, while there was little increase for borderline or non-
physiologically significant stenoses (Figure 7.2) 
Stenoses with an FFR 0.71-0.80 had a small but statistically non-significant increase in 
hyperemic flow velocity (△11.2±7.1 cm/s, p=0.14).  Much larger increases in flow velocity 
were observed for stenoses with FFR 0.61-0.70 (△18.0±3.2cm/s, p=0.007) and FFR"0.60, 
△40.8±4.6cm/s, p<0.001, Figure 7.2).   
Smaller 0.05 stratification steps are possible to assess the change in flow velocity within 
the grey-zone (Figure 7.3).  There is a reduction in number of stenoses per strata compared 
to using 0.10 steps and therefore detecting statistically significant increases (p<0.05) is 
more challenging.   The overall findings confirm that only stenoses with FFR"0.70 have a 
significant increase in flow velocity.   
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7.3.4 Changes in the Grey-Zone 
We sought to determine how flow velocity changes in stenoses with FFR values between 
0.75-0.80: nine stenoses were included.  PCI to stenoses in the 0.75-0.80 zone had no 
significant increase in hyperemic flow velocity: only a mean difference of 7±4.8 cm/s in flow 
velocity was observed for these cases.  This was no different statistically from the 
4.6±2.3cm/s gain observed in treating FFR values >0.80.   
 
7.3.5 The change in resting flow velocity after intervention according to FFR 
The change in resting flow velocity measured over the wave-free period was assessed 
(Figure 7.2).  In stenoses with FFR>0.80 prior to PCI, no significant increase in flow velocity 
was observed (0.3±2.4cm/s, p=0.90).  Similar small changes were noted for stenoses with 
FFRs of 0.6-0.70 and 0.70-0.80 (Figure 7.2A).  Only when stenoses had FFR values of "0.60 
was a significant increase in Rest Flowwave-free period% observed (13.7±2.2cm/s); this threefold 
smaller than the change in hyperemic flow velocity for this range.  In all cases, when the 
pre-PCI FFR was <0.80, the change in hyperemic flow velocity after PCI was significantly 
greater than observed at rest (Figure 7.2B, p<0.01 for all).   
 
7.3.6 Change in resting flow velocity when stenoses are classed by other indices 
ANOVA with post-hoc testing demonstrates that only the most significantly diseased 
stenoses had a significant rise in resting flow over the wave-free period after PCI (Figure 7.5 
& Figure 7.6).  Only stenoses with FFR values !0.60, iFR !0.60, HSR >1.60, BSR > 1.20 
and iFRa !0.40 had a significant rise in wave-free flow after PCI (Figure 7.6).  CFR had not 
relationship with the change in resting flow velocity with no significant difference. 
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These findings confirm there is only a small rise resting flow over the wave-free period, and 
it is predominantly in the domain of stenoses with very significant values, which in normal 
clinical practice would not undergo physiological assessment. 
 
7.3.7 The behaviour of flow velocity during wave-free period under hyperaemia is the 
same as the whole cycle 
Hyperemic flow velocity over the wave free period is consistently higher than observed over 
the whole cycle (Table 7.2).  The deltas after PCI are accordingly larger also per strata of 
FFR.  The overall pattern observed is, however, no different from that of the whole cycle 
with a gradual decline in the gain in flow velocity (Figure 7.4).   
 
7.3.8 The influence of microvascular disease on the results 
In patients undergoing PCI, there can be significant microvascular disease that can alter the 
response to the hyperaemic agents and may even alter the response of the microcirculation 
to a stenosis at rest. 
 
CFR is a marker of microvascular disease as well as stenosis severity. In this cohort since 
there is a stenosis in every case, CFR is providing a combined measure of stenosis 
significance as well as microvascular disease. The CFR post-PCI provides an assessment 
of the responsiveness of the microcirculation post-PCI and therefore the potential capacity 
to increase flow. 
 
In this study we found that CFR rose to above 2 in the majority of stenoses after PCI when 
FFR values are <0.80.  CFR did not rise significantly after PCI when FFR was >0.80. 
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In the cohort, 14 stenoses did not have rise in CFR after PCI – having a mean reduction in 
CFR of -0.74±0.18.  Of these stenoses mean CFR pre-PCI was 2.43, and mean FFR 0.83.   
Post-PCI, the mean CFR was 1.69 and a mean FFR 0.85.  Hyperemic microvascular 
resistance in the post-PCI setting in these patients rose by 13%, while resting resistance 
fell by 25%.   This suggests that the failure of CFR to rise in these cases is not likely related 
to vasospasm (since resting resistance reduces) but that there may be true microvascular 
non-responsiveness to adenosine.   
 
In the cohort of 61 stenoses which demonstrated a rise in CFR, a mean rise was 1.04±0.09 
from a pre-PCI CFR 1.60 to 2.64 post-PCI.  FFR in this cohort rose from 0.64 to 0.90.  In 
these cases, hyperemic resistance fell by 20% after PCI suggesting post-PCI resistance 
was not impacted upon by microcirculatory embolisation (since this was stable PCI, it was 
not expected to be a major issue).  Overall, these results suggest that in the cohort, there 
was not significant microvascular disease acting as a confounding factor.  
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7.3.9 The change in pressure indices when stenting stenoses not classified as 
physiologically significant 
All the physiological parameters demonstrated significant increases after PCI (Table 7.3). 
When stenting stenoses with FFR>0.75, the mean incremental benefit in iFR is 0.02±0.01; 
the mean increment in FFR is 0.05±0.01.  Both of these increments are significantly smaller 
than the increments seen in either index when stenoses were FFR"0.75 (iFR 0.34±0.04 and 
FFR 0.33±0.02 respectively).   
When considering the change using the 0.80 cut-point:  for non-significant stenoses, FFR 
changes by 0.04±0.01 and iFR by 0.01±0.01.  It can therefore be seen that only small trivial 
pressure changes may occur when stenting stenoses with negative physiological values.  
 
7.3.10 Using pressure indices to predicting the change in flow velocity prior to PCI 
The change in resting flow velocity according to the pre-PCI iFR and FFR values is shown 
in Figure 7.7.  Essentially pre-PCI iFR and FFR have to be profoundly significantly before an 
increase in resting flow is observed.   
In contrast, the change in hyperemic flow velocity after PCI had a curvilinear relationship 
with both pre-PCI FFR and iFR values (Figure 7.8). Plotting the change in either pressure 
index with the change in flow velocity (Figure 7.9), shows that over the typical range of 
improvement in the index seen in clinical practice (around 0.20), then hyperemic flow 
velocity is likely to double while resting flow velocity had little rise.  For larger changes in 
either index, then the increase hyperemic flow rises exponentially while resting flow shows 
significant rises only when increments in pressure are very large. 
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7.3.11 The change in microvascular resistance after intervention 
The change in raw microvascular resistance is shown in Figure 7.10.  To assess the impact 
of micro-embolisation upon the post-PCI measurements, the gain in resistance reduction 
offered by hyperemia over the whole cycle and the wave-free period at rest was compared 
to the resting whole cycle (Figure 7.11).  A significant reduction in the vasodilator reserve 
would suggest embolisation.  Hyperemic vasodilator reserve rose after PCI (48±3% to 
61±2%, p<0.001) and there was no difference between post-PCI vasodilator reserve and 
that observed in stenoses with pre-PCI FFR values >0.80 (61±2% vs 58±3%, p=0.44) 
suggesting there was no important embolisation.  This was confirmed by measuring CFR, 
which significantly improved across all strata of FFR-positive stenoses (Figure 6b) and had 
no significant relationship with either pre- or post-PCI FFR values (all p=ns).  Under resting 
conditions, the wave-free period offered a consistent reduction in resistance across all 
stenoses (33±01%); and there was no difference per strata when pre-PCI FFR was >0.60.  
In the most significant stenoses, (FFR"0.60), pre-PCI, the wave-free period offered a 
greater reduction in resistance than compared to those with FFR>0.60 (p<0.001).  It is likely 
severe stenoses are maximally vasodilated at rest to maintain resting flow.  In this strata 
alone, post-PCI resting resistance is lower than before PCI (p<0.001); however, the value is 
consistent with that of other strata.  Since vasodilator reserve is maintained in these 
stenoses (as shown by the adenosine response post-PCI in this strata), this does not 
suggest embolisation, rather a relative physiological vasoconstriction in response to the 
increased resting flow observed in these stenoses following the removal of a flow limiting 
stenosis.   
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7.3.12 Calculating the True Flow Reserve based upon flow velocity changes 
The original definition of FFR was based upon animal studies:  a vessel had maximal 
hyperaemia induced either by papaverine or by a short occlusion to trigger reactive 
hyperaemia.  After this, a stenosis was created and distal pressure and flow recorded.  The 
true FFR was the flow velocity in the presence of a stenosis divided by the flow velocity in 
the absence of the stenosis.  This was correlated to the ratio of distal pressure to proximal 
pressure, taking into account venous pressure and wedge pressure. 
 
It stands to reason that the post-PCI setting is the closest setting in humans that allows 
replication of this animal work.  The flow velocity post-PCI in theory should be the 
maximum flow velocity achievable without an obstruction.   We sought to determine to 
replicate the original validation experiments by comparing FFR measured in the routine 
clinical way to the ‘true flow velocity reserve’  - computed by the equation shown below. 
 
 
Correlation between FFR and true flow reserve was statistically significant (r = 0.59, 
p<0.001, with an R% of 0.35).  True flow was predicted by the equation y= -0.337 + 1.51(pre-
PCI FFR value) (Figure 7.12A).  Removing 14 observations where the true flow reserve 
exceed 1.0 (suggesting that flow velocity had fallen after PCI), the correlation is 0.68 
(p<0.001) with an R% of 0.46 (Figure 7.12B)    
 
There are some differences in the way FFR was computed (without wedge pressure 
correction and without accounting for venous pressure).  Furthermore, this finding is very 
reassuring within the limits of the reproducibility of flow velocity measurements. 
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7.4 Discussion 
 
7.4.1 Key Findings 
In this study, we have demonstrated that (1) physiological severity of the lesion predicts the 
likelihood of coronary flow velocity increasing after coronary intervention, (2) hyperemic flow 
velocity changes most after PCI while resting flow velocity changes little.  We also find that 
the increase in hyperemic flow velocity is similar regardless of the physiological parameter 
used to dichotomize stenoses.  Additionally we have determined a model for estimating the 
change in flow velocity after a change in pressure index. 
 
Pressure-only indices are known to improve after intervention to a stenosis84,158  but since 
they use pressure as a surrogate estimate of flow, the increase in distal pressure could 
reflect other changes caused by PCI, such as micro-embolisation or epicardial vessel 
spasm.  Flow velocity is also known to change, but previous reports were limited by 
categorizing stenoses based upon visual estimation of severity.145,190  In this study, we 
report the change in flow velocity according to pre-PCI physiological parameters which 
overcomes the considerable limitations of visual or anatomical definitions of lesion severity.  
Furthermore since the microvasculature continued to respond to adenosine after PCI in a 
manner similar to physiologically unobstructed vessels before PCI, then any impact of 
micro-embolisation upon the flow velocity post-PCI was small.  
!
7.4.2 Hyperemic flow velocity before and after intervention 
Hyperemic flow considers all the potential blood flow that can occur when the tightly 
controlled myocardial-coronary auto-regulatory processes are uncoupled by the use of a 
vasodilator.  Hyperemic flow velocity declines in presence of stenoses occupying 50% of 
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the vessel lumen.15,77  Conceptually, if a stenosis can be reduced to less than 50%, one 
would expect an improvement in hyperemic flow velocity, to similar levels seen in vessels 
when there is no stenosis.  Since the angiographic appearance of stenoses can reflect 
poorly its importance, we chose to classify stenoses by FFR, which is a familiar and easily 
understood alternative.  Furthermore, the concept of FFR should lead to predictable 
increases in coronary flow velocity after PCI.   
 
Prior to PCI, in physiologically-significant stenoses, hyperemic flow velocity measured over 
the whole cardiac cycle was greater than resting flow velocity measured over the whole 
cycle.  However, it was not significantly different from resting flow velocity measured over 
the wave-free period.  This demonstrates that constraining flow analyses to a period in 
diastole provides a higher flow velocities than measurable over the whole cardiac cycle and 
also that in significant stenoses there is little difference between what is calculable at rest 
and hyperemia.  This is in keeping with the CLARIFY study that showed ischaemic stenoses 
demonstrated comparable microvascular resistance both over the resting wave-free period 
and during whole-cycle hyperemia.79   
 
A higher flow velocity in the pre-PCI setting is pertinent for the diagnostic sensitivity of 
pressure-only indices which rely upon the highest trans-stenotic gradient possible to 
sufficiently distinguish between mild, moderate and severe stenoses. 15  FFR uses 
exogenous hyperemia to increase flow velocity to a level where it is more easy to 
distinguish stenosis severities than possible by Pd/Pa at rest.  For iFR, a resting pressure 
index measured only over the wave-free period, the higher velocities would mean greater 
stenosis discrimination at rest than a whole cycle resting index. 
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Since the resting wave-free flow velocity and hyperemic whole cycle flow velocity were 
statistically similar for stenoses classed as significant whether by FFR, iFR, BSR, HSR or 
CFR then it likely this finding is valid by whatever means is used to stratify stenoses.     
The findings of HSR and BSR are pertinent since these parameters index trans-stenotic 
gradients by flow velocity and thereby limit possible false-positives that may occur with 
pressure-only indices.87,101,191  Although rarely considered and not previously detected 
without simultaneous flow velocity measurement false-positive pressure-only indices will 
occur when flow velocity can increase significantly during hyperemia (which by definition 
cannot be flow limiting, can generate an apparently important pressure gradient).126  Most 
importantly, these lesions carry the same prognosis over 10 years as those which are 
negative using FFR guidance.87   
 
After PCI, hyperemic flow velocities were broadly similar to the values seen in presence of 
stenoses labelled as physiologically non-significant (either by FFR>0.80, or any of the other 
indices) (Figure 2A).  That is, stenoses with FFR>0.80 had a mean hyperemic flow velocity 
of 41±5cm/s; after PCI the entire cohort had a flow velocity of 53±3cm/s, while those with 
FFR 0.61-0.70 had a mean of 47±5cm/s, and those with FFR 0.71-0.80 had a mean 
42±6cm/s.  All of these values are statistically similar, suggesting this value of flow velocity 
should be expected, on average, after intervention.  The greatest increment in hyperemic 
flow velocity was seen in stenoses when FFR"0.70 pre-PCI (Figure 2B), which is similar to 
the FFR value that is most closely related to ischaemia on non-invasive testing (FFR < 
0.75).47  This value is also remarkably similar to the FFR value (0.67) determined to have 
prognostic value on a large meta-regression.29  
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Smaller, less significant increments in hyperemic flow velocity are noted for higher FFR 
values, with little increase in stenoses typically considered non-ischaemic (FFR>0.80).  
These findings are in keeping with the basic tenets of FFR and likely account for the 
findings of DEFER and FAME – concentrating PCI to stenoses most likely to increase flow 
should lead to more favourable outcomes.  At present it remains unclear what degree of 
flow velocity increase is required to achieve symptomatic benefit or reduce clinical events.   
 
Other indices of stenoses significance also predicted similar increases in hyperemic flow 
velocity after PCI: when stratified by CFR, HSR, BSR and iFR, the change in flow velocity 
was always significantly higher when stenoses were classed as significant by the given 
parameter than when classed as non-significant (Figure 7.5).   
 
Higher values of post-PCI flow velocity may be achievable in animal models which utilize 
external constrictors to mimic a lesion; typically in those models, there can be a lack of 
atheroma, or and lack of microcirculatory disease.  In this study, in humans with coronary 
artery disease, the post-PCI flow velocity will be modulated by many factors including 
atheroma and the completeness of PCI which will differ from the release of an external 
constrictor.  The values of post-PCI hyperemic flow velocity are consistent with those 
measured in unobstructed vessels in humans.17,71  
 
 
7.4.3 The impact of adenosine dose upon flow velocity recordings 
There remains controversy surrounding the dose of intracoronary adenosine and this has 
impact upon how the intracoronary data is interpreted.  The data from the Academic 
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Medical Center (AMC, Amsterdam, Netherlands) used 60mcg of adenosine which in the 
modern era is felt to be too small a dose to have achieved maximal hyperaemia.   
 
Professor De Bruyne recently spoke about this during ESC 2014, where he was critical of 
the hyper-high doses utilized by some authors such as De Luca et al 2013.74  As shown by 
his data, both in his original manuscript from 2003 and novel data, flow velocity becomes 
maximal between 60-100mcg of intracoronary adenosine.  
 
Unpublished data from De Bruyne shows that for larger increases in adenosine, the 
potential incremental gain in flow velocity will be small.  This will be most relevant for 
stenoses with borderline severity – where flow velocity can still increase.  Stenoses which 
are severely flow limiting, cannot increase their flow velocity regardless of the dose of 
adenosine given.  Indeed, high doses of adenosine in very severe stenoses can reduce 
hyperemic flow velocity as haemodynamic disturbance from adenosine spill-over can 
perturb the trans-stenotic flow. 
 
The consequences are that stenoses with a borderline values (>0.80) may become included 
lower FFR strata, potentially diluting the effect observed (that is an increase in flow velocity 
for significant stenoses).  For example, a stenosis with an ‘FFR’ of 0.82 using 60mcg 
adenosine, may have an FFR of 0.78 with 100mcg adenosine.  This means the minimal gain 
in hyperemic flow velocity observed in the 0.70-0.80 FFR range of stenoses would become 
even smaller. 
An important other factor is that if additional adenosine doses increase flow velocity while 
also reducing the distal pressure, higher doses of adenosine do not make pressure and 
flow more congruous - rather, they increase incongruity.  This is relevant for measures such 
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as CFR - where mismatch is blamed on rest, rather then the more-likely hyperaemic phase.  
Furthermore, if higher flow velocity is achieved with an increase in adenosine dose, then it 
is possible that the delta achieved by PCI would be even smaller.  This is because it 
appears that the mean post-PCI hyperaemic flow velocity is uniform, suggesting it truly is 
the maximal hyperaemia achievable by adenosine. 
 
Clearly these concerns regarding adenosine dose would have no impact on the resting 
results, since rest flow in these strata changed little.   
 
In terms of data interpretation, since the data in this study is paired with before and after 
PCI measurements, then using the same dose of adenosine to make comparisons in flow 
velocity is the most pertinent issue.   
 
7.4.4 Resting flow velocity changes little after Coronary Intervention 
Previous studies assessing Doppler flow velocity suggested that post-PCI CFR may be 
underestimated due to a rise in resting flow velocity.192  Others showed modest change in 
resting flow velocity immediately after balloon angioplasty.170   In this modern cohort, 
undergoing PCI as per current practice, resting flow velocity only changed significantly after 
stent placement and optimization in highly significant lesions.  The maintenance of resting 
flow velocity at a steady figure despite the removal of a stenosis likely demonstrates in-vivo 
coronary auto-regulation.  Only profoundly significant stenoses (with FFR <0.60 or iFR 
<0.50) demonstrated significant change in resting flow velocity.  Nonetheless, mean post-
PCI CFR values exceed normal levels and increased significantly for all stenoses with pre-
PCI FFR<0.80 (Figure 6b).  Note that CFR has been criticized since a value of 3 may be half 
of normal, if a given vessel has a CFR of 6.193  However, whilst normal unobstructed vessels 
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in young patients or animals may have exceptionally high CFRs, in this cohort of patients 
with coronary disease requiring PCI, such high CFRs are not observed even once the 
vessel is ‘normalised’ after PCI.  It is possible diffuse epicardial resistance limited 
exceeding high post-PCI CFRs.  Alternatively, the suggestion that a CFR of 3 is abnormal 
may represent a straw-man argument to suggest a falsely significant pressure drop is a 
truer representation of flow than flow itself.   
!
7.4.5 Predicting the change in flow velocity using pressure 
Both the pre-PCI FFR and iFR values significantly predict the change in hyperemic flow 
velocity significantly, in a curvi-linear fashion.  Both indices had similar predictive power, 
despite the difference in calculation (iFR measured at rest and FFR measured during 
hyperemia).  Similarly, the delta of the pressure index demonstrated a complex curvilinear 
relationship with the change in flow velocity.  However, for both iFR and FFR, change in the 
index over the typical range seen clinically (0.22 for FFR and 0.20 for iFR,84 lead to little 
change in resting flow velocity and a more linear increase in hyperemic flow velocity after 
PCI.   This means for typical stenoses showing average changes in either pressure index, 
interventionalists can be reassured that increments in the pressure ratio directly reflect 
increments in flow velocity increase.     
 
 
7.4.6 Understanding the change in microvascular resistance after PCI 
Pre-PCI, in severe stenoses, the microvasculature is relatively vasodilated at rest to 
maintain steady state resting flow;  there is little vasodilator reserve in response to 
adenosine.  Performing PCI removes the stenosis, such there will be relative 
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vasoconstriction as the microvasculature responds to the removal of the flow limitation.  
When adenosine is then given, the microvasculature can then respond normally to it.   
 
Assessing raw microvascular resistance and comparing pre-PCI and post-PCI values 
reveals the following .  There was no significant increase in microvascular resistance after 
PCI suggesting there was no significant micro-embolisation to affect the results.   
 
If there had been micro-embolisation, resting resistance would be high and the response to 
adenosine would be blunted; fortunately this was not observed here. 
 
Since raw microvascular resistance values are non-comparable (as they are dependent 
upon the vessel and area subtended) and also there is a relationship between MVR and the 
severity of the stenosis, then assessing the gain in resistance reduction offered by 
hyperemia or the wave-free period over and above the resting whole cycle provides an 
alternative assessment (Figure 7.11).  If there was microcirculatory embolism, then 
hyperemia would be less able to reduce resistance.  In Figure 7.10 the raw microvascular 
resistance is shown (higher the bars, the greater the resistance).  In Figure 7.11 the capacity 
to respond to adenosine is shown - higher the bars, the greater the reduction in resistance.  
 
This demonstrates that after PCI the degree of hyperemia achieved is similar to pre-PCI.  In 
the most severe stenoses, where the pre-PCI vasodilator reserve is exhausted, there is a 
greater increase in hyperemia post-PCI.  The level achieved post-PCI is however the same 
across all stratifications (mean of 58%, hence the comment in the paper).   
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Under resting conditions, the wave-period offers the most reduction in resistance in severe 
stenoses (FFR<0.60) – these lesions are maximally vasodilated at rest.  After PCI, this 
reduction in resistance falls to the same level seen in other stenoses (around 30-40%).  
That is removing a stenosis allows the microcirculation to stop being maximally vasodilated 
at rest.  In these stenoses, giving a vasodilator achieves a significant reduction in resistance 
(as shown in the dark blue columns in Figure 7.11), suggesting they have returned to a 
normal responsiveness to adenosine by relatively vasoconstricting.  
!
7.4.7 Should the data take into account the possibility of collateral flow? 
For stenoses with FFR<0.60, microvascular resistance was calculated in the same manner 
as it was in the other stenoses.  In our dataset, wedge-occlusion with simultaneous 
measurement of flow was not performed in sufficient patients for meaningful interpretation.  
We acknowledge this as a limitation of the study. 
 
Since wedge occlusion was not performed which means in the very severe stenoses, the 
true microvascular resistance under hyperemia may have been overestimated.  It remains 
debated whether correction for collateral flow is required in all instances, since actual 
collateral flow remains a challenge to measure in clinical practice and because wedge 
pressure itself, is affected by venous pressure, heart rate and myocardial wall stress as well 
as collateral flow (Spaan et al, Circulation 2006; 113:446-455).   
 
There remains no accepted technique to properly correct for collateral flow and the debate 
continues 194,195  Since both resting and hyperemic resistance values have no established 
thresholds, and because resistance will vary according to location of the stenosis and the 
vascular bed supplied it is appropriate to treat resistance in pairs and how it changes in 
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response to adenosine (vasodilator reserve).  As such, the lack of correction would not 
impact the results. 
 
If significant collaterals were to be present, it would be likely that they are present in very 
tight stenoses with very significant FFR values.  If there are collaterals, they may account 
for the flow velocity seen distal to the stenosis; without them, the flow may be even lower.   
 
Many studies have suggested that such collaterals close quickly after removal of a 
stenoses, such that the flow elevation post the PCI would only be dependent upon the main 
vessel after restoration of its anatomy rather than from the collateral.  Therefore the flow 
elevation seen in these stenoses post-PCI in our dataset would not be likely affected by 
collaterals.   
 
In more moderate stenoses, collaterals are less likely to occur and therefore again, less 
likely to affect the results.  What is telling is that after PCI, the overall mean hyperaemic flow 
velocity is consistent across groups regardless of initial severity suggesting that the overall 
contribution of flow from collaterals post-PCI is small or trivial. 
One counter-argument is that one may consider that flow velocity measurement would not 
pick-up on the collateral flow, as the flow is being contributed more distal to the flow 
velocity sensor.  In this situation, the distal pressure generated by the additional flow would 
be detected, but not flow.  However, meaningful interpretation is challenging without wedge 
occlusion pressures.    
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7.4.8 Prior studies assessing resting flow before and after PCI 
A single modern study Chalumeau et al (2003) which specifically assesses the change in 
resistance in vessels after intervention.71  Within the publication, a table presents some data 
of whole cycle flow velocity at rest providing another recent study to compare our results.  
Overall, the findings are similar.   
 
However the Chalumeau paper has important limitations, which our present study 
overcomes.  Firstly, they did not use physiological parameters such as FFR to categorise 
stenoses.  Instead, they chose a visual estimation of ‘normal’, ‘intermediate’ and ‘severe’ 
coronary stenosis.  They did not provide either anatomical assessment of what these terms 
mean or how they were chosen – instead we see only the median diameter stenoses for 
vessels chosen to be in those categories.  The use the operator’s visual estimation also 
adds significant limitation as this is now well recognised to have limited relationship with 
physiological importance.   
 
Secondly, by using cases in which there was two-vessel disease but including the data 
from reference vessels could confound the results, as the reference vessel may be 
supplying collaterals to the more significantly stenosed vessels. 
 
Thirdly, measurements were made with a single purpose Doppler flow wire without 
simultaneous pressure data.  Pressure wires were not used in all cases and in the reference 
vessel Pd was inferred from Pa without actual measurement in the distal vessel:  given that 
microvascular resistance is dependent upon the Pd, this could significantly alter the results. 
Its also well recognised that in even reference vessels, under hyperemic conditions the Pd 
is rarely the same as the Pa if there is even slight perturbations in the smoothness of the 
vessel. 
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7.4.9 The indications for stenting stenoses with FFR > 0.80 
One criticism of the study has been performance of PCI to lesions with FFR >0.80.  
In this study patients were scheduled for elective coronary angioplasty and underwent 
physiological assessment for the basis of research.  Every case had a clinical indication to 
be scheduled for angioplasty, including non-invasive stress testing and/or typical 
symptoms with angiographic stenoses that the operators felt were sufficient to proceed to 
intervention.  Patients with true acute coronary syndrome with high troponin level were not 
included; there were 4 patients admitted with ‘unstable angina’ without troponin rise.   
All stenoses included were considered angiographically important rather than intermediate. 
In this study 31 patients had an FFR>0.75 and 23 had FFR >0.80.  In each case, the 
operator was allowed discretion in decision-making, taking into account the clinical 
situation: the most common reason was an angiographically significant stenosis together 
with a compelling history of angina and non-invasive testing suggesting ischaemia. 
Inclusion of this data adds significant value to this study and is not truly controversial or 
against guidelines.   
First, we should consider that the majority of the PCI studies do not conduct FFR and there 
will be including patients who do not have per-vessel level of ischaemia. 
Second, the American Guidelines do not accord Level 1 recommendation to the use of 
intracoronary physiology.  The European guidelines do make a Level 1 recommendation, 
but in fact, states that FFR should be used if other modalities or ischaemia testing has not 
been done.  Therefore, in our patient cohort, there has been no transgression of the 
guidelines. 
Third, although FFR has been treated as a gold standard for ischaemia, this is based upon 
the concept that it is likely to match at least one of many different non-invasive ischaemic 
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tests.  Given that the patients who underwent PCI all had other evidence of ischaemia, then 
it follows that if these patients were part of the initial validation study of FFR then the FFR 
would be classed as falsely negative. 
 
7.4.10 What is the change in flow in stenoses within the grey-zone? 
An on-going source of controversy within the physiological community has been the 
change in FFR cut-off from the initially validated 0.75 (based upon ischaemia tests and PET 
flow data) and the clinically tested 0.80 threshold.  Ostensibly, the 0.80 cut-point was 
chosen to ensure that FFR did not miss patients with ischaemia (that is to increase 
sensitivity at the expense of specificity).  Some controversy remains that the shift was made 
at the behest of the industry influence who were concerned there would be a significant 
reduction in stent usage if physiological guidance became established.   
 
The use of the two cut-points has created a unique situation in which data from DEFER 
suggests that patients with FFR>0.75 are unlikely to have events, while FAME and FAME-II 
suggests that FFR<0.80 accrue benefit.  The apparent discrepancy between the data has 
created a 'grey zone' in which physicians may use their discretion for revascularisation 
decisions when stenoses have FFR values between 0.75-0.80. 
In our study, we found there was no significant increase in flow velocity for stenoses within 
the grey-zone.  This raises the interesting possibility that the original cut-point, determined 
using correlation to other ischaemia tests is more likely to identify lesions that will improve 
with intervention.  The overall numbers are small and it is difficult to draw clinical parallels 
from the data but it does present an interesting finding. 
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7.4.11 Practical clinical implications 
Overall, our findings strongly support the use of physiological techniques to detect lesions 
which are both likely ischaemia producing, but also likely to benefit from PCI, and provide 
mechanistic support to the established clinical trials (FAME, FAME-2).50,52    By reducing the 
number of stents being implanted the likelihood of procedural complications is reduced.  
This is particularly emphasized whenever compared to an approach that attempts to stent 
all stenoses whereby the theoretical risks of stenting apply to each one placed while the 
potential benefit of flow increase may be confined to a few.  By focusing on treating 
stenoses most likely to lead to a measurable flow increase, PCI may be more likely to 
improve symptoms and potentially reduce cardiac events.   
The relative little change in resting flow velocity may have important clinical applications for 
the interrogation of tandem lesions or in diffuse disease, particularly for planning 
intervention, where the greater change in hyperemic flow velocity can limit practical 
prediction of the impact of stenting a given stenosis when multiple stenoses are present.196  
 
7.4.12 Limitations 
This study is comparatively smaller than pressure-only studies that assess change in 
pressure before and after PCI.  However, it is one of the largest reported using 
simultaneous pressure-flow velocity wire before and after PCI in the modern era. 
In this data set, assessments were paired and the doses of adenosine used post-PCI 
measurements were consistent with pre-PCI doses allowing direct comparisons of FFR 
values and hyperemic flow velocities.  Those stenoses assessed by intracoronary 
adenosine were done so utilizing a conservative dose that although exceeding original 
validation work, has been superseded in clinical practice (doses 100-150mcg are now 
favoured). Higher doses of adenosine may elicit higher flow velocities but this is dependent 
upon the true severity of the underlying stenosis: truly flow limiting stenoses are likely to 
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have little gain in flow velocity regardless of the dose (e.g. stenoses with FFR "0.60) while 
those not truly flow limiting will have a greater increase in flow velocity (e.g. those stenoses 
with FFR>0.80).  Higher doses may also make FFR values become marginally lower,74 with 
greatest impact upon stenoses with borderline FFR values most (those just above 0.80 may 
be reclassified as just below 0.80). This may mean that the marginal increase in hyperemic 
flow velocity observed for stenoses with pre-PCI FFR values of 0.70-0.80 may be even 
smaller than shown here.  For the change in resting flow velocity, no difference in results is 
expected as measurements are made without adenosine and change in resting flow was 
only observed for stenoses with pre-PCI FFR "0.60.   
Physiologically non-significant stenoses demonstrated some improvement in flow velocity; 
on average this was a small amount compared to when stenoses were significant.  Since it 
is still unclear what degree of flow velocity increase will improve symptoms or produce 
prognostic benefit, we cannot be sure whether such increases are worthwhile.   
Coronary flow velocity measurements in truly significant stenoses can be difficult to 
perform as velocities are diminished.  The two centres involved in stenosis assessment 
have over 10 years of experience each in performing these measurements meaning the an 
adequate wave-form for phasic analysis was possible. 
Flow velocity measurements were taken once operators had completed PCI.  It is unclear 
whether flow velocity would continue to improve or worsen at a later date.  
Wedge pressure recordings to estimate the impact of collateral flow were not routinely 
performed in this study. Visible collaterals were avoided during this study, but non-visible 
vessels may have been present in those with very significant FFR values.  Since collaterals 
are expected to close upon removal of the stenosis, it is not expected they would 
significantly alter the findings.  Wedge occlusion can also be used to correct hyperemic 
resistance measurements, which may otherwise be overestimated in very severe stenoses 
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(FFR<0.60).  In this study, since vasodilator response was used only to exclude a significant 
impact of embolisation the overall interpretation is not altered.   
Volumetric absolute coronary flow was not measured since the potential error, imposed by 
the technical limitations of measuring vessel size, are large.  Whilst coronary size will 
change around the lesion, flow velocity measurements were made at the same location 
distal to the region of interest, in an area which did not change size.  Thereby the changes 
in flow velocity are likely to equate to changes in absolute flow.  
This study was performed in humans with coronary artery disease referred to the catheter 
laboratory for assessment and treatment.  As such, the results are applicable to other 
patients.  The results may differ from animal studies however - particularly in young animals 
with distensible microcirculation and external constrictors used for simulating a stenosis 
simulation.  In these models, removal of a stenosis may manifest even higher flow velocities 
than seen in humans, – though the clinical relevance is unclear. 
 
7.4.13 Conclusion 
Physiological assessment tools can strongly predict the likely increase in coronary flow 
velocity after PCI.  This change is most marked in physiologically more severe lesions 
where the difference between resting and hyperemic flow velocity measurements are small.    
!
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7.5 Tables 
Table 7.1 Demographics 
 
Values are n, mean±SD or n (%). CAD indicates coronary artery disease; EF, ejection 
fraction; JUSTIFY, Joined Coronary Pressure and Flow Analysis to Determine Diagnostic 
Characteristics of Basal and Hyperemic Indices of Functional Lesion Severity; LV, left 
ventricle; PCI, percutaneous coronary intervention; and QCA, quantitative coronary 
angiography.  
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Table 7.2 Comparison of flow velocities measured either over the whole cycle or the 
diastolic wave-free period, either at rest or during hyperemia 
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Table 7.3 The change in physiological indices before and after coronary 
intervention. 
 
 
Data show mean and SE. CFR indicates coronary flow reserve; FFR, fractional flow reserve; HSR, hyperemic 
stenosis resistance; iFR, instantaneous wave-free ratio; and PCI, percutaneous coronary intervention.  
*P<0.001 for difference in the size of delta when comparing significant and non-significant stenoses.  
!
!
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Figures 
 
Figure 7.1 Mean change in flow velocity according to ischaemic and non-
ischaemic lesions 
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Figure 7.2 Mean change in wave-free period and hyperemic flow velocity 
according to FFR 
 
 
A. Paired mean flow velocity shown before and after PCI measured during hyperemia (blue) and the 
wave-free period (red). Hyperemic flow increases most for highly physiologically significant lesions 
(FFR"0.70). Flow over the iFR-window is remarkably stable throughout all levels of lesion severity 
and changes little after PCI. Rest Flowwave-free period has little variability between FFR categories of 
stenosis severity. B. The change in flow velocity after PCI. Hyperemic Flowwhole cycle increases 
significantly more than the increases in Rest Flowwave-free period for every FFR category of stenosis 
severity. * denotes p"0.01.  
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Figure 7.3 Mean change in hyperemic flow velocity across FFR strata 
 
 
A.  Paired pre-(light blue) and post (dark blue) flow velocity measurements according to 
0.05 steps in FFR.  Statistically significant increases (p<0.05) after PCI are shown by *. 
B. The delta or change in hyperaemic flow velocity  
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Figure 7.4 Mean change in hyperemic wave-free period flow after PCI 
 
 
 
A.  Mean hyperaemic wave-free period flow velocity before (light purple) and after PCI (dark 
purple).  B.  Delta in hyperaemic wave-free period flow velocity compared to whole cycle   
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Figure 7.5 The change in hyperemic and resting flow after percutaneous 
coronary intervention (PCI) according to different pre-PCI indices. 
 
The change in hyperemic flow after percutaneous coronary intervention (PCI) according to 
different pre-PCI indices. Coronary flow reserve (CFR), fractional flow reserve (FFR), 
instantaneous wave-free ratio measured at rest (iFR), or during adenosine-mediated 
hyperemia (iFRa), basal stenosis resistance (BSR), and hyperemic stenosis resistance (HSR) 
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were used to classify stenoses as physiologically significant (!) or physiologically non-
significant (") according to their respective cut points, as described in the Methods section 
of this article. The change in hyperemic flow velocity after PCI (top) was significantly higher 
when stenoses were physiologically significant (!) than when non-significant ("), 
regardless of the index used. *P=0.01, **P<0.001. Bottom, The change in resting wave-free 
period flow using the same annotation.   
 346 
Figure 7.6 The change in wave-free period flow velocity according to CFR, 
HSR and BSR stratifications 
 
The change in wave-free period flow velocity after PCI was stratified according to stenosis 
severity according to different indices.  ANOVA demonstrates that stratification within each 
index that change only occurs when stenoses are critically stenosed  
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Figure 7.7 Change in Resting Flow velocity according to iFR classification 
 
 
 
 
Regression of pre-PCI iFR and FFR values compared to the change in resting flow velocity.  
Overall, there is only change when stenoses are critically significant (iFR <0.50, FFR <0.60). 
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Figure 7.8 The relationship between pre-PCI pressure-only physiological 
indices and the increase in hyperemic flow velocity after PCI 
 
 
 
The relationship between pre-percutaneous coronary intervention (PCI) pressure-only 
physiological indices and the increase in hyperemic flow velocity after PCI. Hyperemic flow 
increases significantly following PCI. A ratio of pre-PCI and post-PCI hyperemic flow 
velocity was plotted  using a third-order polynomial against the pre-PCI fractional flow 
reserve (FFR) value. Ratios above 1 suggest an increase in flow velocity, whereas those 
below 1 suggest a fall. iFR indicates instantaneous wave-free ratio.  
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Figure 7.9 Estimating the change in flow velocity based on the " or change in 
pressure-only index after percutaneous coronary intervention (PCI) 
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Estimating the change in hyperemic flow velocity based on the ! or change in pressure-only 
index after percutaneous coronary intervention (PCI). Pressure-only indices increase after 
PCI and demonstrate a curvilinear relationship with the change in resting and hyperemic 
flow velocity. For a change in instantaneous wave- free ratio (iFR), the change in wave-free 
flow velocity was predicted by the curve y=7.522x3'2.863x2+0.6754x+1.1943, whereas the 
change in hyperemic flow velocity was predicted by the curve y=18 
.96x3'11.94x2+5.6048x+1.304. For fractional flow reserve (FFR), the change in resting 
wave-free flow velocity was predicted by a curve y=20.7x3'9.1852x2+2.0422x+1.1019, 
whereas the change in hyper- emic flow was y=17.175x3'0.1665x2'3.0192x+1.0898.  
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Figure 7.10 The change in raw microvascular resistance after PCI. 
 
 
 
 
The change in raw microvascular resistance after PCI.  Changes are shown for hyperaemic 
(blue) and resting wave-free period (red).   
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Figure 7.11 Change in reduction of microvascular resistance and flow reserve 
after PCI 
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Change in microvascular resistance and flow reserve after percutaneous coronary 
intervention (PCI). Top, Both sets of columns represent the capacity of microvascular 
resistance to be reduced by either adenosine (blue) or the wave-free period (red).  The 
shaded or dashed columns are the paired values after PCI for the same stenoses.  The 
capacity for hyperemia and the wave-free period to reduce resistance compared with the 
resting whole cycle was compared before and after PCI as a marker of micro-embolization. 
On the right side, only those stenoses with FFR"0.60 have a change in the reduction in 
microvascular resistance offered by the wave-free period.  Before PCI, stenoses with 
FFR"0.60 have a greater reduction in MVR offered by the wave-free period than after PCI.  
However, it does not reflect micro-embolisation because in the same stenoses, when 
adenosine is administered (on the left side of the figure), there is a significant increase in 
resistance reduction.  That is, the microvasculature can respond to adenosine normally, 
which it could not if there was embolisation.   
Bottom, This was confirmed by assessing the capacity of coronary flow reserve (CFR) to 
increase after PCI. FFR indicates fractional flow reserve.  
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Figure 7.12 True FFR computation using the flow velocity measured before and 
after PCI 
A. Relationship between True Flow Reserve with pre-PCI FFR 
 
B. Relationship between True Flow Reserve with pre-PCI FFR with the removal of 14 
outlier values where True Flow Reserve exceeded 1 
  !
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7.5.1 Synthesis 
The wave-free period provides an increase in flow velocity across stenoses, that is largely 
independent of stenosis severity.  This means it provides the greatest transtenotic pressure 
gradient at rest that is possible; the trans-stenotic gradient detected will be dependent only 
upon the stenoses proximal to the sensor rather than any interaction between stenosis 
severity and the potential gradient calculable under hyperaemia. 
 
The change in resting and hyperemic flow velocities is of interest when developing 
technologies that can predict the physiological result of a given stenting strategy.   
 
A question is whether this additional increase is present across all stenoses severities and 
whether it is maintained after PCI.  This manuscript addresses those issues. We 
demonstrate that the behaviour of the wave-free period is consistent before and after 
coronary intervention.   
 
This has an additional benefit  is for the prediction of haemodynamic result post-PCI.  If it is 
sought to predict the haemodynamic impact of removing a given stenosis, it is pertinent to 
have highest flow velocity which is consistently observed across all stenoses.   
 
Hyperemic indices pose a challenge because after intervention, both the trans-stenotic 
gradient and the degree of flow velocity observed changes.  Since high flow velocity can 
create a trans-stenotic gradient in even a trivial residual stenosis (as explained by the 
Bernoulli phenomenon), then predicting how a hyperemic index will behave when a stenosis 
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is removed is challenging.  In the context of tandem disease the challenge is accentuated.  
In contrast, since on average resting flow velocity changes comparatively little, then the 
only change that needs to be predicted is the change in trans-stenotic gradient.   
 
Therefore, understanding the change in velocity has a practical application for predictive 
systems.  This will be of use to those developing non-invasive techniques such as Heart 
Flow, as well as the iFR-Pullback technology with Virtual PCI.196  
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8 Change in Resting Flow in a vessel : 
Understanding the change in flow 
velocity within vessels with stenoses 
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8.1 Introduction 
We have demonstrated that resting flow velocity measured in the distal vessel is unaffected 
by the presence of diffuse or focal anatomical stenoses.  We have seen that it is preserved 
regardless of stenosis severity, whether it is assessed anatomically or physiologically. 
We sought to determine the behaviour of resting flow within a given vessel, to see if there is 
change in flow velocity within a given vessel. 
 
8.2 Methods 
Coronary flow velocity was measured in the proximal segment of the vessel away from the 
stenosis being investigated, using a combined pressure and Doppler flow velocity wire 
(Combowire XT, Volcano Corporation).  Flow velocity recordings were made at rest and 
during adenosine-mediated hyperaemia.  Analysis was performed over the whole cycle and 
over the wave-free period.  The same recording was made in distal to the coronary 
stenosis.  The difference in flow velocity between the proximal and distal recordings was 
computed and the results averaged according to stenosis severity as quantified by 
anatomical stenosis severity and FFR. 
 
8.3 Results 
8.3.1 Study population 
Paired recordings were made available in 55 coronary stenoses in 45 patients from the 
JUSTIFY-PCI cohort.  There were no statistical differences in the demographics of those 
patients in whom who and the measurements made and those in whom a paired recording 
was not made.  The most common reason for not having a full paired recording was patient 
intolerance to repeated adenosine infusions.  
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Table 8.1 demonstrates the mean flow velocities detected at rest and under hyperaemia in 
the proximal and distal segments.   
 
8.3.2 Resting flow velocity is preserved within the vessel regardless of a stenosis 
Resting flow velocity is preserved within the vessel despite the presence of a stenosis.  The 
mean reduction in resting flow was 5.5±1.8 cm/s over the whole cycle and 6.0±2.4 cm/s 
over the wave-free period.  Distal resting flow velocity was 96% of the value of the proximal 
resting flow velocity over the wave-free period; it was 89% over the whole cycle.  
 
In contrast, under hyperaemia, there was a significant reduction in flow velocity in the distal 
vessel compared to the proximal vessel.  Under the whole cycle, the distal flow velocity 
was 78% of the proximal flow velocity. 
Table 8.2 demonstrates the relationship between proximal and distal flow according to 
stenosis severity.   
 
8.3.3 The ratio of hyperaemic flows proximal to distal are comparable to FFR 
The ratio of proximal to distal hyperaemic flow velocity was compared to FFR.  Overall 
there was a good relationship, with an R% of 0.12 (p=0.02;  r 0.35, p=0.02) (Figure 8.1).  
Removing outlying values of flow velocity which may represent measurement error 
produced a correlation of 0.57 (p<0.001) with an R% of 0.33.  
 
Similar findings were observed with the hyperaemic wave-free period (Figure 8.2).  With 4 
outlying values, the correlation was 0.27 and R% 0.07 (p=0.08).  Removing the outlying 
values produced a correlation of 0.62 (p<0.001) and R% 0.39 (p<0.001). 
 360 
No such relationship existed with resting iFR or Pd/Pa because the flow velocity was 
uniform across stenosis severities. 
 
8.3.4 Proximal flow velocity is unchanged by PCI to a stenosis 
The change in proximal flow velocity after PCI to the target stenosis was assessed and is 
shown in Table 8.3. Overall there was only a modest change to the proximal flow velocity 
which was not significantly different from zero (p = 0.51 for whole cycle at rest, p=0.56 for 
wave-free period at rest;  p = 0.26 for whole cycle hyperaemia and p=0.24 for hyperaemic 
wave-free period).  Paired T-Testing also revealed no significant change.  
 
8.3.5 After PCI there is no difference between proximal and distal flow velocity 
After PCI there is no difference between proximal and distal flow velocity  
After PCI to the coronary stenosis, the distal flow velocity is not statistically different from 
the proximal flow velocity at rest either over the whole cycle (distally 22.6±1.3 vs proximally 
27.6±2.3, p = 0.07; $5.02±2.7cm/s) or the wave-free period (29.6±1.9 vs 33.7±3.0, p=0.25; 
$4.07±3.5cm/s).   
The same was true under hyperaemia: whole cycle (distally 49.0±6.3 vs proximally 59.6±6.5 
cm/s, $10.7cm/s, p=0.27) and the wave-free period (distally 61.2±6.8 vs proximally 
75.2±9.1 cm/s, $14.0±12.0, p=0.25). 
 
8.3.6 Resting flow properties during Combowire Pullback 
The behaviour of resting flow velocity was sought as a ComboWire was withdrawn within a 
vessel under slow continuous motorised pullback.  This was performed in 13 patients with 
tandem and diffusely diseased vessels. 
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Flow velocity over the wave-free period at rest was 22.5±6.3cm/s; proximally it was 
27.1±10.6cm/s (p = 0.08, no significant difference).   
 
Within the lesion in question, flow acceleration was observed in 7 of the pullback traces. In 
these vessels, resting flow was observed to be 44.2±18.4cm/s, representing a two-fold 
increase compared to the distal flow velocity (p=0.007).   
 
Flow velocity over the wave-free period distal to the distal stenosis was not significantly 
different from the flow velocity between the two stenoses or that flow velocity proximal to 
the proximal stenosis. 
 
8.4 Conclusions 
We make the following observations 
1. That resting flow velocity is preserved within a vessel even in the presence of a stenosis 
with only a small attenuation observed 
2. Treating a stenosis with PCI does not alter resting proximal flow velocities 
3. Removing a stenosis brings the distal flow velocity closer to that observed in the 
proximal vessel; the offset observed is larger under hyperaemic conditions than under 
resting conditions. 
 
This suggests that resting state will have reduced flow interaction between stenoses; 
changes to a stenosis will be manifest by changes in pressure gradient that is dependent 
upon the remaining stenoses alone and not due to flow interaction between stenoses.   
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8.5 Tables 
 
Table 8.1 Mean Proximal and Distal Flow velocities in a stenosed vessel 
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Table 8.2 How much proximal  flow velocity is preserved distally in the 
presence of a stenosis?   
All values are percentages (%) 
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Table 8.3 Change in Proximal Flow after PCI 
 
How much does proximal flow velocity change after PCI to a stenosis distal to it?  
Values are flow velocity in cm/s. 
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8.6 Figures 
 
Figure 8.1 The relationship between pressure derived FFR and the ratio of 
proximal to distal flow velocity 
A.   
B.   
The relationship between pressure derived FFR and the ratio of proximal to distal flow 
velocity.  A. Whole data.  B. Outlying flow velocity measurements removed.   
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Figure 8.2 The relationship between pressure derived iFRa and the ratio of 
proximal to distal flow velocity 
A.  
B .  
The relationship between pressure derived iFRa and the ratio of proximal to distal flow 
velocity.  A. Whole data.  B. Outlying flow velocity measurements removed.   
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9 Curves from Pre-Post Flow: 
Understanding pressure-flow velocity 
relationships before and after coronary 
intervention 
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9.1 Introduction 
 
9.1.1 Pressure-Flow velocity curves 
Each coronary stenosis can be described by a unique pressure-flow velocity curve.  
Understanding the change in curves before and after coronary angioplasty may permit 
greater awareness of how to predict the change in coronary haemodynamics after 
removing a specific stenosis.  If the pressure flow relationships after PCI are comparable to 
those proximal to a stenosis, then measurements proximal to a stenosis may provide a 
convenient method of setting an upper limit to what can be achieved by PCI in terms of 
haemodynamic change.  
 
 
9.2 Methods 
9.2.1 Curves Distal to a Stenosis 
Stenoses were grouped according to FFR values.  Mean flow velocity at rest over the whole 
cycle and over the wave-free period was plotted against resting trans-stenotic pressure 
gradient at rest.  Data points were also plotted during adenosine-mediated hyperaemia, 
over the whole cycle and the wave-free period.  Second order polynomial curves were 
constructed by fitting the quadratic equation $P = FS% + Sv + constant; where F is the 
coefficient of pressure loss due to viscous friction and S is coefficient of pressure loss due 
to flow separation and turbulence downstream to the stenosis.  Curves were plotted for the 
haemodynamic states pre-PCI and for the same matched stenoses post-PCI.   
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To produce mean results applicable to wide groups of stenoses, data was grouped 
according to the stenosis FFR value (pre-PCI) and the anatomical stenosis severity 
(percentage diameter stenosis). 
 
Curves were also generated for each individual stenosis by plotting the flow velocity and 
pressure gradient per beat during a period of rest and hyperaemia.  Instantaneous pressure 
and flow velocity data was averaged per heart beat over a 90 second recording which 
including a period of rest, the induction of hyperemia and stable hyperemia.  This was 
performed for each stenosis within the cohort and ensemble averaged.  These curves were 
similar to those generated using averaged data-points.  
 
9.2.2 Curves from the proximal vessel  
Curves were constructed for pressure and flow recordings taken in the vessel, proximal to 
the stenosis.  Curves were generated in the same manner as described for distal vessel.   
 
 
9.3 Results 
9.3.1 Pre-PCI Curves are in keeping with animal experiments 
Figure 9.1 demonstrates the curves generated for the JUSTIFY-PCI cohort, with 
stratification according to physiologically significant or non-significant using iFR and FFR.  
The curves could be further stratified to clearly delineate disease severity.  Curves were 
constructed according to FFR (Figure 9.2) and iFR classification (Figure 9.3)  as well as 
anatomical definitions of disease severity (Figure 9.4).   
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Curves based upon mean results utilising the whole cycle and wave-free period at rest and 
hyperaemia allowed efficient assessment of multiple stenoses.  There was no significant 
difference from curves generated by ensemble average grouped by FFR or QCA. 
The curves are consistent with those found within the IDEAL dataset from human data and 
from those described by Gould.15 
 
9.3.2 Changes in pressure flow relationships with coronary intervention 
Post-PCI curves were more shallow than pre-PCI curves with a lower gradient suggesting 
that lesion severity had been reduced by the intervention.   
When data was stratified according to the pre-PCI FFR, it can be seen that stenoses where 
FFR was not restored to non-ischaemic levels continued to have steep pressure-flow 
relationships.  When post-PCI values were above 0.90 the curves were not different from 
the curves generated from reference vessels without obstruction.  This was true for post-
PCI iFR values over 0.95. 
 
9.3.3 Pressure flow relationships proximal to a stenosis 
It was possible to generate curves utilising the trans-stenotic gradient and flow velocity 
measured proximal to stenosis.  Curves were generated per FFR ranges (Figure 9.5) and 
per iFR ranges (Figure 9.6). 
Curves generated from the proximal segment of the vessel were consistent with 
unobstructed vessels or those with FFR>0.90 or iFR values over 0.95.   
The proximal flow curves were also similar to the post-PCI curves when the post-PCI FFR 
value was over 0.90 or an iFR value over 0.95. This suggests that an optimal post-PCI iFR 
would be 0.95. 
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Curves generated from the proximal part of the vessel were unchanged after coronary 
intervention to the stenosis in question.  This suggests that intervention to stenoses in the 
distal vessel will not alter the pressure-flow relationships in the proximal vessel drastically.  
The least change is observed for the resting flow velocities while there is a large increase in 
hyperaemic flow velocities after PCI.   
 
 
9.3.4 Using flow curves to predict the post-PCI result 
Curves were plotted per case, using the average per beat whole cycle flow velocity and 
trans-stenotic gradient, over a period of rest and hyperaemia.  Curves were plotted before 
and after PCI, from measurements made distal to a stenosis and proximal to one.   
 
In case of vessels with a single stenosis, the curves elicited in the proximal segment of the 
vessel matched closely with the post-PCI result elicited in the distal vessel. 
 
Figure 9.7 demonstrates an example in which the proximal segment curves matched 
perfectly with those of the post-PCI result.  Assessing over the resting part of the curve, it 
can be seen that the only change is the pressure gradient, and resting flow velocities are 
not changed.   
 
In Figure 9.8 there is uncoupling of the basal-hyperaemic curve prior to PCI (A).  It can be 
seen that the pre-PCI resting gradient is higher than that observed during hyperaemia; the 
overall curve is steep and consistent with a critical stenosis.  Post-PCI, in (B) the curve is 
similar to that observed proximally both before and after PCI. However, note the change in 
scale, with dramatically higher flow velocities elicited under hyperaemia post-PCI, which 
 372 
continue to create a gradient.  Under resting conditions, the pressure gradient is closer to 
what was predicted. 
 
In Figure 9.9, although the PCI has been performed to the severe lesion, the post-PCI result 
does not match the proximal curve perfectly.  A residual gradient can be observed at both 
rest and hyperaemia.  Note that post-PCI that hyperaemic flow velocity has increased 
considerably, which accentuates the residual pressure gradient.  In terms of FFR 
measurement, the FFR changes from 0.63 to 0.83, with HSR changing from 1.43 
(profoundly ischaemic) to 0.43 (non-ischaemic).  IFR changed from 0.43 to 0.90.    
 
9.3.5 Pressure-flow velocity curves in cases with tandem stenoses 
The presence of multiple stenoses appears to have only a small impact upon resting flow 
over the wave-free period. 
 
Pressure-flow velocity curves plotted distal, between and proximal to tandem stenoses 
should be possible to plot. Figure 9.10 demonstrates a characteristic example.   
 
Part 1 demonstrates the tandem stenoses separated by diffuse disease within a circumflex 
artery.  With both stenoses present, three separate curves can be plotted.  Part 2A shows 
curves generated from the distal vessel which accounts for the physiological impact of both 
stenoses, the mid-vessel which accounts for the proximal stenosis but hyperaemia may be 
blunted by the distal stenosis and finally in the proximal vessel where both tandem 
stenoses will impair the effect of hyperaemia.  Part 2B demonstrates the impact of 
removing the distal stenosis by performing PCI.  In this case, a new curve is generated from 
the Combowire placed in the distal vessel - this curve is closer to that generated in the mid-
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vessel prior to the PCI.  Part 2C demonstrates that removal of the mid-vessel stenosis 
creates a pressure flow velocity curve that is more akin to the curve detected in the 
proximal vessel.  The final curve is consistent with the shallow curves seen in reference 
vessels suggesting that a haemodynamically optimal result has been achieved.  
 
9.4 Conclusion 
The key finding is that the curves reveal the utility of the resting part of the pressure-flow 
relationships.  Performing PCI causes a new pressure-flow curve to be generated.  
However, at rest, the predominant change is in pressure while flow velocity does not 
change.   Therefore if the resting pressure gradient proximal to a stenosis is known, then it 
is possible to predict the gradient after PCI which completely removes the stenosis and any 
pressure loss caused by it. 
 
Under hyperemic conditions, increased flow velocity after PCI means an additional gradient 
is generated by separation losses across the stent; this is in addition to the resting pressure 
gradient.  Therefore after PCI, under hyperemic conditions, both pressure and flow change 
which makes prediction of post-PCI results more challenging to determine (Figure 9.11). 
 
Therefore, resting physiological approaches to mapping vessels should be sought. 
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9.5 Figures 
 
Figure 9.1 Pressure-Flow velocity relationships for stenoses stratified by 
positive or negative FFR before and after PCI  
  
 
 375 
 
Figure 9.2 Pressure-Flow velocity relationships for stenoses stratified by FFR 
before and after PCI   
 
 
Pressure-Flow velocity relationships for stenoses stratified by FFR before and after PCI .  
Stenoses are stratified by their pre-PCI FFR; curves are generated using the pressure-flow 
relationships as described in Chapter 3.  Two curves are shown per strata - prior to PCI and 
the paired post-PCI curve.   
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Figure 9.3 Pressure-Flow velocity relationships for stenoses stratified by iFR 
before and after PCI 
 
 
Pressure-Flow velocity relationships for stenoses stratified by iFR before and after PCI .  
Stenoses are stratified by their pre-PCI iFR; curves are generated using the pressure-flow 
relationships as described in Chapter 3.  Two curves are shown per strata - prior to PCI and 
the paired post-PCI curve.   
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Figure 9.4 Pressure-Flow velocity relationships for stenoses stratified by 
percentage diameter stenosis before and after PCI 
 
 
 
Pressure-Flow velocity relationships for stenoses stratified by percentage diameter stenosis 
before and after PCI .  Stenoses are stratified by their pre-PCI diameter stenosis on formal 
QCA of the lesion in question; curves are generated using the pressure-flow relationships 
described in Chapter 3.  Two curves are shown per strata - prior to PCI and the paired 
post-PCI curve.   
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Figure 9.5  Change in Distal and Proximal Pressure-Flow Curves after PCI – 
according to FFR 
 
 
 
Pressure-Flow velocity relationships for stenoses and the proximal part of the same vessel 
before after PCI.  In the majority of cases, the post-PCI curve approximates the curve 
observed proximally.   
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Figure 9.6 Change in Distal and Proximal Pressure-Flow Curves after PCI – 
according to iFR 
 
 
 
Pressure-Flow velocity relationships for stenoses and the proximal part of the same vessel before 
after PCI.  In the majority of cases, the post-PCI curve approximates the curve observed 
proximally 
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Figure 9.7 Single lesion pressure-flow velocity curves before and after PCI 
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Figure 9.8 Single lesion pressure-flow velocity curves before and after PCI 
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Figure 9.9 Single lesion pressure-flow velocity curves with imperfect post-PCI 
result 
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Figure 9.10 Tandem lesion pressure-flow velocity curves 
A.  Tandem stenoses
 
 
B. Pressure-flow velocity curves for tandem stenoses
 
 384 
Figure 9.11 Change in Pressure-Flow curves after PCI 
 
 
In tandem disease, resting indices offer an advantage because there is little change in 
resting flow after PCI.  This minimises the flow interaction that occurs between tandem 
stenoses under hyperaemia.  If pressure ratios or transtenotic gradients are known 
throughout the vessel or at least proximal to the stenosis, then the impact of PCI to a given 
location can be predicted. It would be expected for the gradient to be reduced to that 
present proximal to the stenosis.  Although the post-PCI curve is different, since only 
pressure is changing and not flow, then it is predictable.  In contrast, under hyperemic 
conditions, two simultaneous changes occur - pressure gradient is changed and flow 
velocity increases.  Knowing both these changes is less predictable. 
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10 Pre-angioplasty instantaneous wave-
free ratio (iFR) provides virtual 
intervention and predicts 
hemodynamic outcome for serial 
lesions and diffuse coronary artery 
disease 
 
 
 
 
 
 
 
 
 
 
This chapter includes the findings reported and published as: 
Nijjer SS, Sen S, Petraco R, Escaned J, Echavarria-Pinto M, Broyd C, Al-Lamee R, 
Foin N, Foale RA, Malik IS, Mikhail GW, Sethi AS, Al-Bustami M, Kaprielian RR, 
Khan MA, Baker CS, Bellamy MF, Hughes AD, Mayet J, Francis DP, Di Mario C, 
Davies JER. Pre-Angioplasty Instantaneous Wave-Free Ratio Pullback Provides 
Virtual Intervention and Predicts Hemodynamic Outcome for Serial Lesions and 
Diffuse Coronary Artery Disease. JACC: Cardiovascular Interventions. 
2014;7:1386–1396. 
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10.1 Abstract 
Objective: Perform hemodynamic mapping of the entire vessel using motorized pullback of 
a pressure-guidewire with continuous instantaneous wave-free ratio (iFR) measurement. 
 
Background: Serial stenoses or diffuse vessel narrowing hamper pressure-wire guided 
management of coronary stenoses. Characterization of functional relevance of individual 
stenoses or narrowed segments constitutes an unmet need in ischemia-driven 
percutaneous revascularization.   
 
Methods:  The study was performed in 32 coronary arteries with tandem and/or diffusely 
diseased vessels. An automated iFR physiological map, integrating pullback speed and 
physiological information, was built using dedicated software to calculate physiological 
stenosis (1) severity, (2) length and (3) intensity ($iFR/mm). This map was used to predict 
the best-case post-PCI iFR (iFRexp) according to the stented location, and this was 
compared to the observed iFR post-PCI (iFRobs). 
 
Results: After successful PCI, the mean difference between iFRexp and iFRobs was small 
(mean difference 0.016±0.004) with a strong relationship between $iFRexp  and $iFRobs 
(r=0.97, p<0.001). By identifying differing iFR intensities, it was possible to identify 
functional stenosis length, and quantify the contribution of each individual stenosis or 
narrowed segment to overall vessel stenotic burden.  Physiological lesion length was 
shorter than anatomical length (12.6±1.5 vs 23.3±1.3, p<0.001), and targeting regions with 
the highest iFR intensity predicted significant improvement post PCI (r 0.86, p<0.001).  
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Conclusions:  iFR-measurements during continuous resting pressure wire pullback provide 
a physiological map of the entire coronary vessel. Prior to PCI, the iFR pullback can predict 
the hemodynamic consequences of stenting specific stenoses and thereby may facilitate 
the intervention and stenting strategy.     
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10.2 Introduction 
Coronary physiological assessment is now routinely applied in the catheter laboratory to 
guide percutaneous coronary intervention (PCI). Currently most physiological assessment is 
performed in a binary manner to determine if a vessel requires intervention or not.32  While 
studies have reported the high diagnostic efficiency of physiological assessment in 
minimizing the number of vessels requiring treatment, it is widely recognized that 
interrogation of individual stenosis in the presence of tandem lesions or diffuse disease 
under hyperemic conditions makes PCI planning complex and less practical.124  
These difficulties arise due to relative hemodynamic interdependence of stenoses under 
conditions of hyperemia: hyperemic flow through one stenosis is limited by the presence of 
another stenosis and vice versa.  Since hyperemic flow declines significantly whenever any 
50% reduction in lumen diameter is observed77,123 then even mild secondary lesions can 
affect hyperemic pressure-only indices.   Removing a stenosis by intervention will increase 
hyperemic flow, which alters the significance of secondary lesions.  Since the change in 
flow can be unpredictable for a given stenosis, predicting the hemodynamic impact of 
removing a stenosis under hyperemia is difficult and not readily practical in the catheter lab.   
In contrast, under resting conditions, flow is maintained at a constant and stable level until 
a critical stenosis develops.77  Since resting flow is more constant, consistent and 
predictable across different stenoses, then resting pressure changes measured along the 
length of a vessel will be more predictable.  Utilizing this property of resting flow should 
allow the production of a physiological vessel map, highlighting significant lesions while 
also offering the possibility of prospective simple computerized ‘virtual PCI’ to assess the 
potential hemodynamic impact prior to actual stent implantation.   
In this study we use instantaneous wave-free ratio (iFR), an index of stenosis severity that is 
measured at rest using conventional pressure wires. iFR is calculated as the ratio of distal 
coronary pressure to proximal aortic pressure, over a specific period in diastole known as 
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the wave-free period.  This period of the cardiac cycle has the lowest, and most stable, 
resistance attainable under resting conditions without administration of a vasodilator drug.79  
The concept of iFR was applied to a resting pressure wire pullback to develop an iFR-
Pullback. 
We hypothesize that (1) using motorized pressure wire pullback it would be possible to 
produce a physiological map showing lesions severity, (2) the physiological map could be 
used to perform ‘virtual PCI’ and predict the physiological impact of stenting in tandem and 
diffusely diseased vessels, and (3) physiological map could be used to measure 
physiological lesion length and intensity.  
 
 
10.3 Method 
10.3.1 Study population 
Patients with a clinical indication for elective PCI of a major native epicardial coronary artery 
with #2 stenoses separated by a more normal segment of 10mm, and/or those patients 
with discrete stenoses with diffuse atheroma without a clearly normal segment, were 
prospectively enrolled at the Imperial College Healthcare NHS Trust.  Patients with previous 
coronary artery bypass grafting were excluded.  All patients provided written consent and 
this study had ethical approval from the local committees (NRES ref: 09/ H0712/102).  
 
10.3.2 Coronary Catheterisation 
Coronary angiography and pressure wire assessments of coronary stenoses were 
performed using conventional approaches.  Intracoronary nitrates (300mcg) were 
administered in all cases before pressure wires were introduced. Pressure wire 
normalization was performed at the coronary ostia before each recording prior to resting 
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pressure wire pullback being performed. The distal position of the pressure wire was 
documented fluoroscopically.  Angioplasty was performed using second generation drug 
eluting stents, which were all angiographically optimized. Post-angioplasty measurements 
were made at same coronary location.  
 
10.3.3 Hemodynamic recordings 
Pressure wire recordings were made using either the 0.014-inch pressure tipped wires 
(Prestige pressure guide wire, Prestige pressure guide wire PLUS) or the pressure and 
Doppler sensor-tipped wires (ComboWire® XT) (Volcano Corporation, San Diego, 
California).  Digital hemodynamic data was extracted from data storage systems 
(ComboMap, Volcano Corporation) and processed off-line using a custom software 
package with Matlab (Mathworks, Inc., Natick, Massachusetts).   
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10.3.4 Pressure wire pullback 
Pressure wire pullback was performed at rest in a mechanized manner using a Volcano 
Pullback device (R100, Volcano Corporation, San Diego, California).  Pullback speed was 
0.5mm/sec and continued until the pressure sensor reached the left main stem ostium or 
right coronary ostium (Figure 10.1).   
 
In three cases, the pullback recordings were repeated because drift was noted when the 
wire was returned to the ostium (4mmHg, 4mmHg and 7mmHg).  The pressure traces were 
normalized and measures were repeated.  During the pressure wire pullback, regular 
fluoroscopic recordings of the wire position were made, together with time stamps linking 
angiographic and pressure wire systems.  This was used to co-register the pressure wire 
data with the angiographic location during the off-line analysis. 
 
10.3.5 iFR-Pullback analysis 
iFR-Pullback analysis was performed off-line using customized iFR-pullback Matlab 
environment (Mathworks Inc, Massachusetts, USA).   iFR is calculated using pressure-only, 
ECG-triggered algorithms to identify the diastolic wave-free period as described in the 
ADVISE studies78,106  and externally tested in the RESOLVE and ADVISE-II.105,109  iFR and the 
iFR-gradient was automatically calculated for every heartbeat during the pullback.  This is 
used to generate a physiological map of the vessel (Figure 10.2).  The change or fall in iFR 
for every millimetre of the vessel was calculated, allowing assessment of intensity of iFR 
change (iFR-intensity, iFR/mm) (Figure 10.2).  This data can be plotted and aligned and 
overlaid onto the angiogram using the time stamp data recorded during the pullback.   
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Using a fixed pullback speed allowed calculation of the length of physiologically determined 
lesions.  Where stenoses are longitudinally displaced by 4mm or more (as detected by no 
change in pressure loss) the automated algorithms treat these as separate lesion. This 
allowed automated detection of individual stenoses with measurements of physiological 
length.  Whether disease was predominantly focal or diffuse could be visualized upon the 
plot of iFR intensity (Figure 10.3). 
 
10.3.6 Virtual PCI analysis 
Once the iFR physiological map was created, computer-aided simulations were performed 
to simulate the haemodynamic effect of removing a stenosis.  The bespoke software was 
used to perform ‘virtual PCI’, by which stenoses were manually selected for removal once 
identified on the physiological map (Figure 10.4).  The algorithms automatically calculate a 
post-PCI iFR value that would be expected if that stenosis was removed by intervention 
(iFRexp).  In diffusely diseased vessels, where wire-position is important, the expected-iFR 
result would be valid for further measurements taken at the same location post-PCI.  The 
iFRexp represents a best case PCI scenario as the algorithms assume an anatomically 
perfect PCI result.  The ‘virtual PCI’ approach allows assessment of the relative merit of 
different angioplasty approaches in terms of physiological outcome (Figure 10.5). Using this 
technology two distinct experiments were performed.   
 
First, the virtual PCI was performed with a view to replicate the anatomical PCI performed 
in the real world in the patients by integrating the iFR-Pullback onto the coronary 
angiogram.  The purpose was to generate an iFRexp from the iFR-Pullback and compare 
this to the iFRobs to assess the predictive capability of iFR-Pullback. 
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The second experiment performed new virtual PCI on the iFR-Pullback to only the areas of 
highest iFR intensity loss with the aim to achieve the same iFRexp as the iFRobs.  In this 
distinct experiment, the measure of interest was the length of the virtual stent with aim to 
compare this to anatomical stenosis length and real-world stent length.  In this experiment, 
the virtual stent length was equivalent to the ‘physiological length’ of the lesion.   
 
10.3.7 Anatomical lesion measurement 
Lesion length and severity was measured using quantitative coronary angiography (QCA; 
McKesson, San Francisco) using the contrast-filled catheter for calibration.  Lesion lengths 
were measured three times in a blinded fashion, by trained QCA operators.  Lengths were 
then averaged.  
 
10.3.8 Data analysis 
Statistical analysis was performed using Matlab (Mathworks Inc, Massachusetts, USA) and 
STATA version 11 (StataCorp,, Texas).  Data is presented as counts (percentages) for 
categorical variables and numbers for continuous variables.  Mean values are expressed as 
mean ± SEM Means were compared using paired T-tests. Continuous agreement between 
iFRobs and iFRexp was analysed using the Bland-Altman method.  Linear regression 
analyses were used to investigate the proportion of iFRobs variance predicted by iFRexp. A 
p value <0.05 (two-sided) was considered significant.    
 
10.4 Results 
10.4.1 Study demographics 
32 coronary arteries in 29 patients (69% male, 64±9 years old) undergoing elective coronary 
intervention were prospectively assessed.  Only disease deemed stable was assessed.  
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Patient demographics are shown in Table 10.1.  Mean diameter stenosis of the region 
stented based upon angiographic findings was 59±14% by formal quantitative coronary 
angiography (QCA);  mean lesion length by QCA was 23.3±1.3mm. Mean vessel iFR pre-
PCI was 0.79±0.03.  
 
 
10.4.2 iFR-Pullback feasibility 
Motorized iFR-Pullback was feasible in all vessels creating an iFR physiological map for the 
entire length of each vessel, plotting the iFR and iFR-gradient over the pressure wire 
pullback, together with an the change in iFR intensity (Figure 10.2).  This enables detection 
of locations and lengths of greatest pressure loss, which represent the physiological lesion 
length (Figure 10.2).  The intensity of pressure loss is plotted as iFR units lost per millimetre 
of vessel (iFR-intensity, △iFR/mm).  This map could be integrated and overlaid upon the 
coronary angiogram to improve visualization of areas of pressure loss and assess which 
lesions contributed the most physiological impact upon the vessel.  The physiological 
length of stenoses can be measured and the pattern of iFR-intensity allows recognition of 
focal or diffuse areas of pressure loss (Figure 10.6). 
 
10.4.3 Identification of diffuse or focal physiological disease 
Whether disease was predominantly focal or diffuse could be visualized upon the plot of 
iFR intensity (Figure 10.6).  Areas with more diffuse coronary disease cause a more gentle 
change in the iFR ratio or the iFR-gradient.  Areas of more focal disease cause more 
discrete and marked changes visualised as steps on the iFR-ratio or the iFR-gradient. . 
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10.4.4 iFR-Pullback prediction of post-PCI iFR result and length of stent required 
For each iFR-Pullback – two distinct assessments were made.  (1) A comparison of iFRexp 
and iFRobs to assess the predictive capabilities of iFR-Pullback.  This was achieved by 
performing virtual PCI on the iFR-Pullback in a manner that replicated the ‘real-world’ PCI 
performed in the patient.  (2) An assessment of physiological stenosis length.  This was 
performed by performing virtual stenting specifically to areas identified on the given 
pullback as being of high iFR intensity loss for that vessel.  The purpose was to achieve the 
same physiological outcome as observed in the real-world; the length of virtual stenting 
required to achieve that result could then be compared to the real-world stent length.  
 
10.4.5 Matched virtual PCI with real-world PCI:  iFR-Pullback prediction of post-PCI 
iFR 
The iFR-Pullback predicted the mean expected iFR post-PCI to be 0.94±0.01; the 
measured iFR post-PCI was 0.93±0.01. The continuous agreement between iFRexp and 
iFRobs is provided as a Bland-Altman plot in Figure 10.7. The latter revealed a small mean 
bias of 0.016±0.004 (mean±SD of difference) without proportional error or 
heteroscedasticity. iFR-Pullback predicted the post-PCI iFR result within 2±1% error and 
there was a strong linear relationship between the $iFRexp and $iFRobs (r=0.97, p<0.001).   
 
10.4.6 Physiological stenosis length 
A hypothesis-generating analysis was performed.  Figure 10.8 demonstrates schematically 
the approach used.  Physiological lesion length was significantly shorter than anatomical 
length determined by QCA (12.6±1.5mm vs 23.3±1.3mm, p<0.001), and significantly shorter 
than the mean length of stent implanted (27.5±2.3mm p<0.001).  Accordingly stenting the 
physiological length, that is areas of high iFR intensity loss, was associated with the highest 
gain in iFR after PCI ($iFRexp r=0.86 and $iFRobs r=0.80, both p<0.001). 
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This approach suggest that if only the physiological length were stented with disregard to 
anatomical lesion length then a maximum 54% reduction in treatment length is theoretically 
possible, with a significant reduction in stent length deployed (14.3±2.7mm shorter, 
p<0.001), while maintaining the same physiological end result for the vessel.  
 
10.4.7 The gain in iFR per mm of stent 
Overall, following real-world PCI, iFR values improved by 30±10% compared to pre-PCI 
values (0.78±0.03 vs 0.93±0.01, p<0.001).  This represented a 1.1±0.3% iFR gain per mm 
of stent deployed.  If only the physiologically most important stenosis was treated, then the 
corresponding shorter stent length meant a statistically significant (p=0.005) increase of 
2.5±0.72% iFR gain per mm stent would have been achieved representing a two-fold gain 
in physiological benefit per mm of stent.  
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10.5 Discussion 
 
10.5.1 Key Findings 
This proof of concept study demonstrates that iFR-Pullback: (1) can be performed under 
resting conditions (2) can predict the likely improvement in iFR by PCI and (3) can measure 
the physiological length of a lesion.  The findings suggest this tool may assist the planning 
of coronary intervention. 
 
10.5.2 iFR-Pullback is a feasible technique to physiologically map the coronary artery 
Pressure wires distal to a single lesion can determine the hemodynamic significance of the 
lesion and estimate the presence of inducible ischaemia.126  However, coronary disease is 
commonly tandem or diffuse and in such situations it is less common for physiological 
assessments to be used to directly guide where coronary intervention is performed.  Even 
when used diligently before all PCI, assessment in the distal vessel frequently does not 
resolve decisions for stent placement when multiple lesions are present or in diffuse 
disease.  With increasingly complex disease, application of physiological assessments may 
help interventional decision-making.  
 
This study demonstrates that iFR can be calculated along the entire length of a coronary 
vessel in a fully automated manner permitting measurement of a pressure-gradient at any 
given location.  Hemodynamic information throughout the vessel can be used to display the 
locations, severity and length of regions of pressure loss. The physiological lesion length 
can be computed if the pullback speed is known.  Importantly for interventional planning, a 
prediction of the hemodynamic impact of removing a given stenosis can be made.  In short, 
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a physiological map of the entire coronary vessel can be made to complement anatomical 
information gained from angiography and/or intra-coronary imaging. 
 
 
10.5.3 iFR-Pullback can measure lesion length and predict changes by stenting 
This study demonstrates that iFR-Pullback can predict post-stenting iFR result with no 
evidence of systematic physiological bias; the difference between the predicted and 
observed improvement in IFR following PCI is <5%.  This may enable pre-procedural 
planning allowing operators to estimate the likely improvement in treating different stenoses 
prior to PCI. Identifying lesions most likely to lead to an improvement in coronary 
physiology, and deferring those of lesser importance could assist lesion selection in the 
presence of multiple lesions.  This may be valuable when some lesions are considered to 
have higher procedural risk than others.  
 
One of the important questions for our time is distinguishing between focal disease that 
may benefit from stenting from diffuse disease that may benefit little.  In this way, by using 
a iFR-Pullback we can distinguish between focal from diffuse disease, we may reduce the 
length or number of stents required in a vessel.  
 
We performed a hypothesis-generating analysis to assess the physiological length of 
stenoses. Our findings suggest physiological lesion length is typically shorter than 
angiographic lesion length.  This in keeping with many studies that show that physiological 
assessment offers different information from anatomical assessments.  This information 
generates hypotheses that application of physiological length could lead to shorter stent 
implantations.  However, since all stenting outcomes are based upon lengths chosen 
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angiographically, and with concerns of geographical miss then considerable caution is 
required in the application of this information.  Practically, stenting is typically performed 
normal-to-normal which limits geographic miss, stent oversizing and strut malaposition.  
Nonetheless, physiological length may provide complementary information for 
interventionalists.  
 
A further application of this approach may be to assist surgical revascularization: 
identification of where a bypass graft can be placed in a diffusely diseased vessel may help 
maximise the hemodynamic benefit.  
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10.5.4 How can iFR predict the outcome of PCI 
 
The coronary circulation has evolved for auto-regulatory systems to make small constant 
changes to microcirculatory resistance to maintain basal flow stable even in the presence 
of a severe stenosis up to 90%.77,197  Therefore, every stenosis within a vessel is exposed to 
a similar flow velocity at rest.  Since PCI to an intermediate-to-severe stenosis causes a 
comparatively smaller change in resting flow 117,198,199 then any remaining residual disease 
should maintain a pressure-flow velocity relationship that is very similar to that present prior 
to the intervention.  This makes prediction of post-PCI pressure changes more feasible.  
 
In contrast under hyperemia, flow declines rapidly in the presence of stenoses over 50% 
and consequently increases significantly after removing a stenosis.198  Whilst rarely 
problematic when assessing focal or solitary lesions, it is widely recognized as a limitation 
for assessment of serial or tandem stenosis, where the hyperemic interaction between 
stenoses means the severity of a given stenosis is not constant, specific or independent of 
other stenoses and cannot be made by simple interrogation.200  Large increases in 
hyperemic flow after PCI will contribute to an increased pressure drop across remaining 
stenoses117. Therefore prediction of how hyperemic pressure ratios will change post-PCI is 
difficult.  Complex mathematical formula and wedge occlusion can be used to approach 
this problem30,201 but are rarely used in clinical practice.  A useful compromise is to perform 
a hyperemic pullback which suggests where the gradient is greatest.124  However, it 
remains a limitation that the interventionalist must commit to balloon dilatation of at least 
one lesion before repeating pullback as the values will have changed and outcome of 
removing one stenosis on the others cannot be predicted.  A further limitation is that 
prolonged infusions of adenosine can have unexpected consequences with changing 
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pressure ratios which may go unnoticed during a pullback and affect its 
interpretation.67,69,85,202 
The stability of resting flow overcomes many of these fundamental physiological difficulties 
posed by hyperemic flow, but the flow velocity must be of sufficient magnitude to detect 
pressure gradients.  By measuring trans-stenotic pressure gradients over a specific period 
in diastole, flow during the iFR wave-free window is on average a third higher than seen 
over the entire cycle.79  This is particularly important when looking for small incremental 
changes or steps in pressure over the entire lesions length.  
Since a physiological map of the coronary vessel can be generated, it is also possible to 
predict the hemodynamic outcome of intervention to a specified location.  This assumes 
that no residual gradient is present across the stent after PCI and as such the resulting 
predicted-iFR should be the highest expected with optimal PCI results.  
 
10.5.5 Future developments: co-registration and manual pullback 
In this study a motorized pressure wire pullback was used to provide a distance co-
ordinate corresponding to each iFR measurement and allow precise recording of distance 
and length.  The use of a mechanical device is common in intravascular imaging, but 
manual pullbacks can be preferable.  Since iFR calculation can be performed beat-by-beat 
manual pullbacks over 20-30 seconds are possible (Figure 10.9) and yield similar lesion 
identification as the motorized pullback.  Currently manual pullback means that 
measurements of distance cannot be made but this does enable rapid deployment into 
clinical practice (Figure 10.10 and Figure 10.11). 
 
There has been rapid development of live angiographic co-registration means that it is now 
possible to track the position of an intracoronary device as it is moved.  Such systems are 
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already used for integrating IVUS images directly onto angiography.203   By using co-
registration systems in a similar manner to track the position of a pressure wire along the 
course of the vessel rather than an IVUS catheter, it will be possible to perform a manual 
pressure wire pullback whilst simultaneously attaining a distance co-ordinate from co-
registration Figure 10.12. This will remove the need for motorized pullback but provide 
similar quantifiable information.   
 
 
10.5.6 Future clinical applications: the value of iFR pullback 
The value of mapping the iFR intensity in diffusely diseased vessels enables identification of 
any focal areas of disease that may cause the predominant pressure loss, and therefore be 
targeted for percutaneous intervention.  The percentage contribution of pressure loss can 
be displayed to assist decision-making.  The mapping can be displayed in a number of 
different ways (Figure 10.2 and Figure 10.12).  With co-registration, the pressure wire 
pullback can become integrated with the angiographic findings to enhance the ease of 
understanding of the data.  ‘Dots’ representing units of pressure loss can help identify 
which stenoses are most haemodynamically important.  In addition, iFR intensity plotted as 
a function of distance can give additional information regarding the length over which the 
pressure drop occurs (Figure 10.2). This may assist in identifying which lesions in the vessel 
contribute most to pressure loss and allow operators to estimate the physiological length of 
a stenosis to help decide between different revascularisation strategies (PCI/CABG) (Figure 
10.5).  
 
This approach also allows the operator to predict the haemodynamic effect of their 
intervention by modelling the expected improvement in coronary physiology for a given 
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stenting approach.(Nijjer et al. 2014) Since length has been integrated into the information, 
a haemodynamic map can be overlaid the coronary anatomy and stenting strategies 
modelled to predict physiological improvement from stenting prior to PCI (Figure 10.5).  In 
simple disease, this could be used to predict the post-intervention iFR result.  In more 
complex disease, such technology permits the clinician to simulate multiple different 
stenting approaches to identify the most appropriate for the most favourable 
haemodynamic outcome. 
 
The concepts of producing a physiological map of the vessel, to aid planning and virtual 
PCI represent a change in the application of physiological measurements.  Previously, there 
may have been temptation to use physiology as a binary value, with a ‘stent everything’ and 
‘stent nothing’ approach.  However, pullback assessment of complex and diffuse disease 
exposes physiological assessment as a continuous variable along the length of the vessel.  
This objective physiological approach has the potential to offer an important adjunct to the 
armamentarium of the interventional cardiologist.  
 
One area of potential clinical utility may be that focal areas causing pressure loss within a 
diffusely diseased vessel could be specifically targeted for intervention.  Presently, coronary 
intervention is typically performed from normal-to-normal segments with a view to avoid 
geographical miss, which has been associated with higher rates of target vessel 
revascularisation, myocardial infarction; imaging studies with IVUS have suggested stent 
edge plaque burden and geographical miss are associated with early stent thrombosis and 
restenosis.204,205 However, it is also known that excessive stent length is associated with 
increased lumen loss, which may itself have further implications.206  Achieving an optimal 
physiological result without total coverage of all possible atheroma may be a compromise.  
With the advent of physiological mapping there is now an opportunity to assess this in 
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detail.  At present these concepts are nascent, and there is no outcome data for either 
approach of physiologically focused stenting versus stenting covering larger lengths.  
Detailed future studies will be required before such an approach can be advocated.   
 
 
10.5.7 Limitations 
This study should be interpreted as a proof of concept.  The physiological basis underlying 
iFR-Pullback is that resting flow, on average, is maintained regardless of stenoses.  
However, when the diameter of a stenosis is reduced by >90% (by formal measurement 
rather than by eye) resting flow is significantly diminished and thus may rise after PCI.  In 
practice such stenosis are highly significant and are likely targets for PCI regardless of 
physiological assessment.  Even so, the increase in resting flow is typically several fold less 
than seen in hyperemic flow after PCI. 
Whilst the physiological map can predict physiological lesion length, this approach is novel 
and should be viewed as hypothesis generating.  Stenting is typically performed from 
normal-to-normal segments on the angiogram, regardless of physiological techniques used 
to determine the need for stenting.  As such, there is no data regarding the safety, or 
clinical outcomes of stenting according to physiological length only.  Further prospective 
studies would be worthwhile and necessary to explore this.  Not all lesions should be 
expected to have stent length reduced, as in some cases, the predominant physiological 
lesion corresponded directly to the anatomical lesion.  Equally, many factors can mean the 
physiological length of the lesion and anatomy it will not match perfectly, including: three-
dimensional lesions being mapped in two-dimensions, subtle changes in the vessel 
dimensions during the cardiac cycle, inherent variability in measuring lesions regardless of 
the anatomical technique used.  These issues are not expected to significantly affect the 
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finding that iFR-Pullback can estimate the post-PCI iFR result which can be applied to 
traditional stenting techniques.  
Co-registration of physiological and angiographic data presently requires careful recording 
and use of timestamps to align the data.  Great care was taken to align the pressure wire 
data with the angiographic data but angiographic foreshortening can limit the anatomic 
length measurements.  Future work will utilize state of the art live co-registration, whereby 
the position of the pressure wire can be actively tracked by the software.  Biplane imaging 
may help in some tortuous vessels. 
This study was performed using off-line with a centralized analysis by experts familiar with 
the bespoke software, which may allow inadvertent bias.  The present work does 
nonetheless demonstrate that longitudinal iFR measurement is feasible and can be used to 
predict post-PCI iFR values.  Future work will assess the software in a live on-line 
environment, being used by clinicians in the catheter laboratory, which will broaden the 
applicability of the results.  Further prospective randomized studies are underway.    
 
10.5.8 Conclusion 
iFR-Pullback is a feasible technique which can provide a physiological map of the entire 
coronary vessel, measure physiological stenosis length and predict the outcome of stenting 
in tandem or sequential stenoses.   
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10.6 Table 
Table 10.1  Patient demographic data.   
Values are n, n (%) or mean±SD.  Cx=circumflex artery; EF = ejection fraction; LAD = left 
anterior descending artery; LV = left ventricular; RCA = right coronary artery; MI = 
myocardial infarction; QCA = quantitative coronary angiography 
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10.7 Pullback Figures 
 
Figure 10.1 Process of making pullback measurements and analysis 
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Figure 10.2 Identification of iFR intensity changes within a vessel 
 
iFR-Pullback can identify lesions, measure length and integrate with coronary angiography.  
A shows an iFR-Pullback (upper, iFR plotted along the length of wire movement), iFR 
gradient (middle, the transtenotic pressure gradient measured over the wave-free period in 
diastole over which iFR is calculated) and the change in iFR per millimetre moved by the 
pressure wire (lower panel; this also demonstrates the physiological length of the identified 
lesions).  B shows iFR-intensity (!iFR/mm) or pressure loss superimposed upon the 
coronary angiogram.  Areas of intense pressure loss are marked with a red circle.  The 
greater the number, the greater the pressure loss per millimetre observed at that location.  
This case shows a diffusely diseased LAD with two distinct focal lesions that cause the 
majority of pressure loss; a proximal short lesion causing 0.07 iFR unit drop and another 
11mm lesion causing 0.05 iFR unit drop.  
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Figure 10.3 Process of predicting post-PCI iFR results 
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Figure 10.4 Predicting the result of PCI 
 
 
iFR Pullback can predict the outcome of PCI 
Schematic representation of work-flow and interpretation of iFR-pullback data.  Focal 
discrete disease can be distinguished from diffuse disease and individual physiological 
lesions identified (Upper Panel A).  These can be ‘virtually’ removed by selecting regions of 
interest (Lower Panel B).  The Pullback will calculate the expected post-PCI iFR if that area 
is treated by stenting and demonstrate a predicted Pullback result.  This corroborates 
closely with the observed result. 
 
 411 
Figure 10.5  Alternative PCI strategies could be tested for physiological benefit 
 
 
 
Virtual PCI can be performed on iFR-Pullback to calculate the effect of removing a stenosis. 
A. A resting iFR-Pullback is performed on a RCA with significant disease. iFR-intensity is 
displayed as small red dots representing pressure loss and is integrated onto the 
angiogram. B. Different stenting strategies can be considered. C. On the iFR-pullback 
trace, a stenosis can be selected for removal, and computer algorithms will model the 
impact upon the rest of the vessel. Removing stenosis 1 or 2 alone will not give the vessel 
an iFR above the threshold for treatment; both stenoses are required for an optimal result.  
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Figure 10.6 Diffuse and focal disease within a single vessel 
 
 
Even marked steps in amongst other disease can be mapped.   
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Figure 10.7  Bland-Altman for observed and predicted iFR values 
 
 
 
 Bland-Altman analysis of post coronary intervention iFR: iFR-Pullback predicted iFR 
versus observed measured iFR.  No large systematic bias is found when comparing 
predicted versus observed measured iFR.  
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Figure 10.8 Physiological lesion length may be shorter than anatomical length 
 
 
Angiographic lesion lengths were compared with those derived from iFR pullback, using 2 
distinct approaches. (Middle Panel) The iFR pullback was matched to the anatomic 
findings, and the anatomically chosen lesions were selected for virtual PCI to give a 
predicted iFR value after intervention. (Bottom Panel) The iFR pullback was assessed to 
find the least possible treatment required to achieve a post-PCI iFR value similar to that 
achieved in the actual case.   
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Figure 10.9 Manual iFR pullback compared to hyperemic pullback 
 
 
 
iFR-Pullback can be performed manually and can predict effect of PCI. Diffuse disease 
in the LAD (A) was investigated by performing a manual iFR-Pullback: the pressure wire 
was pulled from distal to ostium over 30 seconds manually at rest (B).  The iFR changes are 
calculate from the raw pressure trace (B).  For a comparison, the resting Pd/Pa ratio 
pullback calculated from the same trace, and a hyperemic FFR pullback taken from a 
pullback during adenosine infusion, are also shown.  Using either iFR or FFR it is possible 
to identify clear steps-up corresponding with individual coronary stenoses.  Using resting 
PdPa such stenosis demarcation is not possible.  
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Figure 10.10 iFR Pullback consoles in clinical practice 
 
 
 
Less information is available on the currently available console.   The operator must 
observe the line while watching the wire position on fluoroscopy.  A novel innovation is the 
inclusion of a dotted raw iFR line, and the sold line which never falls back below the last 
calculated iFR value.  A great deal of information can be observed on the solid blue line 
compared to the raw trace it is acquired from (lower panel). 
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Figure 10.11 iFR Pullback in clinical practice 
 
 
A. Long segment of disease in the LAD with a significant iFR value.  B.  Pullback reveals the 
more proximal stenosis is not likely to be causing ischaemia.  C. Visual estimation on the 
pullback trace enables a prediction of stenting the long segment of disease.  D.  Post-PCI 
iFR check reveals the distal iFR is as predicted.  The proximal iFR remains non-significant, 
therefore the more proximal stenosis can be medically managed. 
 418 
Figure 10.12 iFR Pullback with co-registration 
 
 
 
Ultimately angiographic co-registration will fuse the pullback data (seen as an inset on the 
right) to create attractive maps.  The operator can move a cursor to identify the iFR at any 
given point and choose areas of interest that can be removed from the trace as part of 
‘Virtual PCI’. 
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11 Synthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of this chapter have been published as part of the following paper: 
Nijjer SS, Sen S, Petraco R, Mayet J, Francis DP, Davies JER. The Instantaneous 
wave-Free Ratio (iFR) pullback: a novel innovation using baseline physiology to 
optimise coronary angioplasty in tandem lesions. Cardiovascular 
Revascularization Medicine. 2015;16:167–171. 
 420 
11.1 Synthesis 
This thesis has assessed the use of coronary physiology in relation to coronary 
revascularization with particular focus upon percutaneous stenting.  Coronary physiology 
has the potential to improve outcomes by focusing intervention to coronary vessels with 
greatest ischaemia.  The long-standing paradigm in physiology has been the need for 
hyperemia.  I have explored the novel approach of phasic analysis, specifically the diastolic 
wave-free period, and considered how coronary flow, pressure and resistance change with 
stenosis severity, time and with intervention.  I have then applied these findings to the 
development of a novel physiological tool that maps resting pressure changes and enables 
prediction of the impact of treating a specified stenosis.   
 
11.1.1 The nature of coronary flow 
I have presented the largest known dataset of simultaneous pressure and flow velocity 
recordings in patients undergoing coronary angiography.  The ‘IDEAL’ dataset represents 
an international collaboration and represents a new era in the physiological community.  
Whilst this data cannot replicate what can be done in animals (where a stenosis of any 
severity can be created), it has its own unique advantages.  By averaging across such a 
large dataset with a full spectrum of stenosis severities, including reference vessels, 
remarkably consistent findings are evident.  First, I observe that hyperemic flow is readily 
attenuated by increasing stenosis severity.  The data matches that classically described, 
with a decline in hyperemic flow noted in any stenosis greater than 40-50% diameter 
stenosis (Figure 11.1). In the past, this was the reason to intervene upon these stenosis. 
Importantly, I demonstrate that FFR theory is concordant with measurements of hyperemic 
flow velocity in humans. 
Second, I have shown that resting flow is remarkably stable across stenosis severities, 
regardless of how stenoses are defined and whether there if diffuse or focal disease and 
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whether the stenosis is proximal, mid or distal within a vessel.  This remarkable stability 
demonstrates auto-regulation occurring to maintain a basal state.  I demonstrated that to 
maintain flow microvascular resistance falls under resting conditions and this occurs at the 
expense of distal pressure.  Total vessel resistance is remarkably preserved across all 
stenosis severities, truly demonstrating the capacity for auto-regulation. 
 
11.1.2 Coronary pressure gradients enable assessment of stenoses at rest 
The ideal dataset demonstrates that the wave-free period provides a great deal of 
sensitivity to detect important stenoses by measuring trans-stenotic pressure gradients in 
diastole.  I reveal that the change in gradient with worsening stenosis severity is curvi-
linear.  The presence of any gradient at rest suggests the stenosis is causing 
microcirculatory compensation.  When there is no or trivial gradient at rest, the pressure-
flow relationships are consistent with reference vessels – that is, a vessel without any 
meaningful obstruction.   
 
11.1.3 Reference vessels in humans have a CFR of 2.64 
A commonly re-iterated statement has been that CFR values of 3 may represent relative 
ischaemia if that vessel was truly supposed to have a CFR of 6.  I have presented the  
findings of the largest reference vessel dataset published to date:  the mean CFR in 
patients referred for angiography is 2.64.  We did not observe large CFRs suggesting that 
such arguments are typically made as a straw-man to distract from concerns that in truly 
non-obstructive disease with high CFRs as seen in young patients, a falsely positive FFR 
can be generated. 
A further interesting observation is that in our large dataset, on average, vessels with an 
FFR>0.90 have pressure-flow curves that are identical to those from reference vessels.  
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Therefore, one could suggest that although adenosine is given to increase the spread of 
measurable trans-stenotic gradients, a meaningful increase in gradient is not experienced 
until FFR values are <0.90.  This may partly explain the 0.10 unit difference in the thresholds 
between iFR and FFR. 
 
11.1.4 Stenosis classification  
The IDEAL dataset also enables a detailed assessment of pressure-only based indices such 
as iFR and FFR and enable comparison with a wealth of flow-based indices such as HSR, 
BSR and CFR.  Across a full spectrum of disease, I demonstrate the iFR and FFR have 
equivalent capacity to detect ischaemia.  These findings support the studies described in 
the Introduction, including the smaller ADVISE and CLARIFY studies.  The data provided 
here is also more meaningful than that from the RESOLVE study, because it is possible to 
use a third parameter to balance disagreements.   
 
11.1.5 Flow measurements are preserved over time 
An often repeated concern regarding resting state measurements is whether a resting state 
is possible within the catheter laboratory.  To assess this flow velocity recordings were 
made separated in time .  Recordings made 6 and 12 months apart revealed a remarkable 
consistency in the presence of predominantly non-obstructive disease.  This is strongly 
supportive of clinical decisions made using flow-based indices as were observe the 
findings continue to consistent for a clinically meaningful time. 
 
11.1.6 Coronary pressure is altered by coronary intervention 
I demonstrate that changes in the coronary pressure over the wave-free period after PCI 
are concordant and consistent with changes observed during hyperemia.  There has been 
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concern that a resting index would be unreliable post-PCI to make an assessment of 
interventional success.  We found that the change observed in IFR was consistent with the 
change observed in the accepted reference standard, FFR.  In addition, the change 
induced by intervention is significantly greater than change that may be occurring due to 
inherent limits of test re-test reproducibility. 
 
11.1.7 Hyperemic coronary flow is altered by intervention 
A major finding, that is strongly supportive of the current paradigm of ‘FFR-theory’ in 
coronary physiology, is that hyperemic flow velocity only increases significantly in stenoses 
classed as physiologically important.  Not only does this support guidelines, but it provides 
a mechanistic link to the outcome studies such as FAME-II and meta-regression that 
suggests that hard-outcomes only change when FFR values are <0.66.  Negative and 
borderline stenoses infer no meaningful increase in flow velocity.  Furthermore, I have been 
able to compute the ‘true’ FFR or flow reserve in humans utilizing the flow velocity 
measured before and after PCI.  There is remarkable consistency between what was 
observed in animal experiments and what can be measured in humans undergoing a 
complex and imperfect intracoronary procedure. 
 
11.1.8 Resting flow velocity is unchanged by intervention 
An equally important finding is that resting flow is unchanged by intervention in the vast 
majority of moderate stenoses.  Across the cohort, very little change in resting flow is 
observed.  Not only is resting flow not changed by the severity of a stenosis, with 
measurement along the length of the vessel but it is also not changed by stenting.  This 
makes the resting state an ideal state to assessment diffuse and tandem disease.  Since 
resting flow does not alter, all stenoses within the vessel observe the same trans-stenotic 
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flow and the resultant pressure gradient is a true reflection of the impact that stenosis has 
upon the vessel. 
 
11.1.9 Stable PCI does not adversely alter the microcirculation  
Stable PCI does not lead to significant micro-embolisation or impairment of the 
microcirculation.  Whilst changes are known to occur in the context of NSTEMI and STEMI, 
in stable conditions we observe a relative vasoconstriction from a vasodilated state pre-PCI 
but together with preserved vasodilator reserve.  I note that these changes are detectible 
within minutes of performing PCI and demonstrate the speed of vascular response to 
removal of the stenosis.  This further confirms the capacity of the resting circulation to 
auto-regulate.  These findings also suggest if collaterals are present pre-PCI, they must 
close rapidly after PCI. 
 
11.1.10 Unmet needs in physiologically guided coronary intervention 
Currently used physiological indices have limited ability to isolate individual lesion 
significance in vessels with multiple lesions. The prevalence of such diffuse coronary 
disease is increasing and accurate assessment to guide appropriate therapy is paramount.  
Current physiological assessment in such vessels does not automatically indicate the 
haemodynamic improvement that would be expected post stenting.  The clinical utility of an 
index would be enhanced if it could inform the clinician of the likely effect of any 
intervention.  
 
A tool that can inform the clinician of the haemodynamic benefit of inserting a stent at a 
particular point in the vessel, over a specific length would help clinicians rationalise their 
revascularisation procedure.  However, predicting the haemodynamic response to stenting 
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has been difficult and up to now complex and time consuming.  Overcoming these barriers, 
and amalgamating pressure wire and imaging technology to aid in decision making is the 
next frontier for an interventional cardiology community that is being confronted by an 
increasing prevalence of diffuse coronary artery disease.  
 
I have discussed the difficulties posed by stenosis interaction under conditions of 
hyperemia.  The presence of distal disease will underestimate the importance of the 
proximal lesion if a pressure wire is placed between the two lesions.  A wire placed more 
distally will then overestimate the importance of the distal lesion.  Complex work-flows 
involving repeated FFR-pullbacks mean that in the majority of circumstances physicians are 
more likely to skip physiological assessment in diffuse and tandem disease.  This may 
mean eminently treatable disease is inappropriately deferred.  Furthermore, even if 
performed they do not predict the severity of the non-targeted disease as increases in 
hyperemic flow after PCI renders the original physiological result inaccurate such that pre-
PCI hyperemic gradients cannot predict hyperemic coronary haemodynamics post-PCI.  
These difficulties imposed by hyperemia has hindered the development of predictive 
systems that can model the physiological result of stenting in the presence of multiple 
lesions.30,120 As a result this is currently not possible in clinical practice. A modality that can 
facilitate stenosis specific assessment would add significant value in the management of 
these patients.  Potentially it may permit tailoring of the stenting strategy to optimise 
physiologic outcome.  
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11.1.11 Baseline physiology provides a potential solution to tandem lesion 
assessment 
While resting flow velocity is maintained across stenosis severities, we have shown that 
resting pressure gradients and indices can demonstrate the significance of a stenosis and 
will change appropriately when a stenosis is removed.  Since the pressure loss across a 
stenosis is determined by the degree of flow, it is helpful that flow velocity be stable and 
unchanging when multiple stenoses are present or if another stenosis is removed (Figure 
11.2).  Therefore, if a resting pressure gradient is known at a particular location, then the 
degree of trans-lesional pressure drop for that given location can be expected to be 
unchanged if intervention is performed elsewhere in the vessel.  To maximise the sensitivity  
to detect important stenoses, the flow velocity should be the highest available at rest, 
which will then give the highest pressure gradients at rest also.  All of these points are well 
served by the resting wave-free period. 
It is expected some resting flow interaction will still occur – particularly when there are 
critical stenoses such that there is some increase in resting flow after intervention.  
However, even if there is some interaction, it is expected to be very small and several fold 
smaller than that observed under hyperemia.   
 
These findings allows several assessments of the coronary artery that are clinically useful 
under resting conditions, such as: 
 
1. Evaluation of the stenosis burden of the complete vessel; providing a cumulative 
assessment of all stenoses in that territory. This is also currently possible with hyperaemic 
measures. 
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2. Quantification of the impact of individual stenoses within a diffusely diseased vessel 
or a vessel with tandem stenoses; permitting the differentiation of stenoses according to 
their magnitude of contribution to the overall disease burden of the vessel – impossible with 
current hyperaemic measures. 
3. Prediction of the physiological effect of treating a particular stenosis within the 
vessel; permitting intervention according to the likely physiological gain. This is not possible 
with current hyperaemic measures but is particularly advantageous for diffusely diseased 
vessels as it may prevent the clinician from embarking on a revascularisation strategy that 
may improve the appearance of the vessel but not improve the blood flow to the subtended 
territory.   
 
Resting flow therefore offers unique properties that may overcome the difficulties seen 
during hyperaemia.  A pressure wire pullback under basal conditions may therefore offer an 
innovation to improve physiological assessment in vessels with diffuse or tandem coronary 
disease by providing stenosis specific information.  For such an innovation to be readily 
applicable to day-to-day practice, the approach must be simple, glean the most information 
from the basal haemodynamics, easy to perform and be done using routinely available 
pressure wires. 
 
11.1.12 Development of iFR Pullback 
The final application of the findings in this thesis is the development of iFR-Pullback.  Beat-
to-beat iFR or iFR-gradient measurements enable maps to be generated from a given 
vessel.  Not only can individual stenoses by identified as a focal change in pressure but it is 
possible to predict the iFR if a particular stenosis is removed.  Not only are the results 
promising, but the clinical tool made available for clinicians to use in patients appears to 
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work remarkably well.   The delivery of a simple, rapid and easy to understand tool to 
delineate complex disease and plan revascularization has the potential to alter how 
coronary intervention in selected cases. 
Future work should randomize patients with complex diffuse and tandem disease to either 
routine angiographic intervention or iFR-Pullback guided intervention.  One may expect a 
reduction in the number and the total length of stent deployed, which may reduce 
restenosis rates and stent-related complications. 
 
 
11.2 Conclusion 
Human coronary physiology behaves in a manner consistent with previous animal models 
and smaller studies.  Phasic analysis reveals that the resting wave-free period provides 
ideal circumstances to not only diagnose ischaemia, but also to determine the stenosis-
specific contribution to pressure loss in the vessel.  Consistent behaviour of flow velocity 
over the wave-free period together with predictable changes in pressure enable models 
that can accurately predict the haemodynamic outcome of coronary stenting.  This 
warrants further investigation, firstly in studies to determine its impact upon clinical 
outcomes but also ultimately as an integrated clinical tool for routine practice in the 
management of diffuse and tandem disease.    
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11.3 Figures 
Figure 11.1  Summary of flow and physiological changes during intervention 
 
A summary of the key findings - hyperaemic flow velocity falls with worsening stenosis 
severity and is restored by PCI but to a variable degree.  Hyperaemia alone causes 
pressure gradients meaning that post-PCI residual gradients are partly due to the residual 
stenosis and partly due to the increased pressure gradient.  Resting flow is unchanged 
despite worsening stenosis severity; when stenoses undergo PCI, the pressure-flow curves 
have a change in pressure but not flow velocity.  The change in pressure is predictable if 
the pressure gradient proximal to the stenosis is known. 
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Figure 11.2 The expected behaviour of hyperemic and resting flow after 
removal of stenosis. 
 
 
The expected behaviour of hyperemic and resting flow after removal of stenosis. Upper 
panel. Pioneering studies demonstrated that resting flow is preserved until stenoses are 
critical or sub-totally occluded. Hyperemic flow falls in the presence of any stenosis but 
does so significantly as stenoses exceed 40-50%. Lower panel. In Tandem stenoses (A), a 
measurement of flow at the black marker (() will elicit a flow value as denoted by the black 
dot on the upper panel. In (B), the distal stenosis has been stented. Under hyperemic 
conditions, flow will have increased significantly (red dot); however, under resting 
conditions, there is minimal change expected. 
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13 Appendix 
13.1 Study Entry Criteria for centres contributing to IDEAL Study 
All patients were scheduled for elective coronary angiography with physiological lesion 
assessment by FFR and consented to acquisition of additional physiological data for study 
purposes. 
 
13.1.1 Imperial College London, London, United Kingdom 
Data from ADVISE Family of studies(1), including the CLARIFY(2) and JUSTIFY(3) sub-
studies. 
Eligible for study:   
• Aged over 18 and under 90 years of age 
• Both genders eligible for study 
• Sampling method: non-probability sample 
 
Inclusion criteria: 
• Patient with coronary artery stenosis 
 
Exclusion criteria: 
• Unable to consent 
• Acute myocardial infarction 
• Patent surgical grafts 
• Cardiac pacemaker 
• Significant valvular heart disease 
• Chronic renal failure prohibiting coronary angiography 
• Contraindications to adenosine 
• Contraindications to cardiac MRI 
• Weight > 200 kilograms 
 
 
13.1.2 Academic Medical Center, Amsterdam, The Netherlands 
Eligible for study:    
• No age restriction 
• Both genders eligible for study 
• Sampling method: non-probability sample 
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Inclusion criteria: 
• One or more coronary stenoses (40-70% diameter stenosis at visual assessment). 
 
Exclusion criteria 
• Ostial stenoses  
• Significant left main stenosis 
• Serial stenoses 
• Severe renal function impairment (GFR <30mL/min per 1.73m2) 
• Atrial fibrillation 
• Recent myocardial infarction within 6 weeks 
• Prior coronary artery bypass surgery 
• Visible collateral development to the perfusion territory of interest 
• Significant valvular abnormalities 
 
 
13.1.3 VU University Medical Center, Amsterdam, The Netherlands 
Eligible for study:    
• Aged over 40 years of age 
• Both genders eligible for study 
• Sampling method: non-probability sample 
 
Inclusion criteria: 
• First presentation to cardiologist with suspected coronary artery disease 
• No documented prior history of coronary artery disease 
• Clinically referred for invasive coronary angiography 
 
Exclusion criteria: 
• History of severe chronic obstructive pulmonary disease (COPD) or chronic asthma 
• Pregnancy 
• Renal failure ( i.e. estimated glomerular filtration rate < 45 mL/min) 
• Allergic reaction to iodized contrast 
• Concurrent or prior (within last 30 days) participation in other research studies using 
investigational drugs 
• Significant co-morbidities 
• Atrial fibrillation, second or third degree atrioventricular block 
• Tachycardia 
• Acute myocardial infarction 
• Heart failure 
• Left ventricle ejection fraction estimated < 50% 
• Cardiomyopathies 
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• No informed consent 
 
13.1.4 Hospital Clinical San Carlos Madrid, Spain 
Eligible for study:    
• No age restriction 
• Both genders eligible for study 
• Sampling method: non-probability sample 
 
Inclusion criteria: 
• Non-probability, non-consecutive sampling of patients (both genders) with a clinical 
indication for FFR assessment in one or more stenosed coronary arteries. 
 
Exclusion criteria 
• Patients with myocardial infarction <5 days 
• Contraindications to adenosine or pharmacological hyperemia 
• Left ventricle ejection fraction <30% 
• Left main disease 
• Significant valvular pathology 
• Vessels supplying previously known infarcted territories 
• Serial stenoses 
• Marked diffuse narrowings 
• Patent surgical grafts 
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14 Prizes arising from this thesis 
!
TCT-AP Best Abstract Prize 2015   Winner, oral presentation 
CRT 2015 Young Leader    Recognition for international role 
BCS BHF Prize 2015     Best Abstract in Intervention 
BCIS ACI Young Investigator 2015   Runner-up 
Royal Society of Medicine President’s Prize Second-prize 2014, oral presentation 
NHLI Postgraduate Research Day 2013  Highly commended poster presentation 
TCT-AP Best Oral Presentation 2013  Awarded for three oral abstract 
presentations 
TCT-AP Best Poster Presentations 2013  Best poster presentations 
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